Characterization of Cellular and Viral MicroRNAs in Kaposi’s Sarcoma-associated Herpesvirus Malignancies by O'Hara, Andrea Jayne
  
 
 
 
 
 
Characterization of Cellular and Viral MicroRNAs in Kaposi’s Sarcoma-associated 
Herpesvirus Malignancies 
 
 
 
 
Andrea J. O’Hara 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in 
the Curriculum in Genetics and Molecular Biology. 
 
 
 
 
Chapel Hill 
2008 
 
 
 
 
 
        Approved By: 
 
        Dirk P. Dittmer 
 
        Shawn Ahmed 
 
        Blossom Damania 
 
        Morgan Giddings 
 
        Ronald I. Swanstrom 
 
        William F. Marzluff 
 
 ii 
   
 
 
 
 
 
Abstract 
 
Andrea O’Hara:  Characterization of Cellular and Viral MicroRNAs in Kaposi’s 
Sarcoma-associated Herpesvirus Malignancies 
(Under the direction of Dirk P. Dittmer) 
 
 
 MicroRNAs (miRNAs) are a class of small non-coding functional RNAs that 
mediate post-transcriptional regulation of target mRNAs in a sequence-specific 
manner.  They affect a wide variety of cellular processes, ranging from cellular 
differentiation, proliferation, apoptosis, metabolism, infection and cancer. MicroRNAs 
are regulated by gene copy number alteration, transcription, and processing. Over 
the past few years, miRNAs have also been shown to be encoded in a number of 
viruses, including herpesviruses. The viral-encoded miRNAs are important 
regulators in both the viral life cycle and virus-host interaction, specifically viral 
oncogenesis.   Kaposi’s Sarcoma-associated Herpesvirus encodes 12 viral miRNA 
genes.  It is the causative agent of primary effusion lymphoma (PEL), a non-Hodgkin 
lymphoma (NHL) of B cell lineage, and Kaposi’s sarcoma (KS), a highly vascular 
AIDS-defining cancer of endothelial cell lineage. 
 Using real-time quantitative polymerase chain reaction (QPCR)–based 
arrays, changes were determined in miRNA gene copy number, pre-miRNA, and 
mature cellular miRNA levels for the largest set of PEL examined to date. This 
defined the miRNA signature of PEL, which differs from that of other NHL. 
Furthermore it showed that transcriptional regulation of pre-miRNA as well as 
 iii 
   
mature miRNA levels contribute nonredundant information that can be used for the 
classification of human tumors. Not only the induction, but also the absence of 
specific cellular miRNAs can be used to determine tumor origin and proliferation 
state.  Tumor suppressor miRNAs were significantly down regulated in PEL as well 
as in KS.  These represent tumor-specific, rather than virus-specific miRNAs. Since 
many known tumor suppressor proteins are wild type in KS and PEL, down 
regulation of multiple tumor suppressor miRNAs, provides a novel, alternative 
mechanism of transformation. Finally, using precursor microRNA profiling by a novel 
real-time QPCR method progressive stages of endothelial cell transformation 
cumulating in KS was defined; and particular miRNAs that serve as biomarkers for 
tumor progression were identified. For the first time, comprehensive comparisons 
were possible between primary patient biopsies, well-established culture and mouse 
tumor models.  All together, these results can be used to characterize the cellular 
miRNA signature in KSHV-associated malignancies, namely PEL and KS. 
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CHAPTER I: HERPESVIRUS MICRORNAS IN INFECTION AND CANCER 
 
Andrea J. O’Hara and Dirk P. Dittmer 
 
Department of Microbiology and Immunology, Lineberger Comprehensive Cancer 
Center, Center for AIDS Research, and Curriculum in Genetics and the University of 
North Carolina at Chapel Hill 
 
 
Introduction 
MiRNAs are generally transcribed by RNA polymerase II (figure 1) [Lee, 
2004].  The capped, polyadenylated RNA transcript is known as the primary miRNA 
(pri-miRNA), which may contain one or several miRNAs [Cai, 2004].  Within the pri-
miRNA transcript, the miRNA forms a ~80 bp hairpin stem-loop structure, known as 
the pre-miRNA [Cullen, 2004].  The pre-miRNA hairpin stem-loop structure is 
recognized and cleaved from the pri-miRNA transcript by Drosha and DGCR8 [Lee, 
2003; Denli, 2004; Gregory, 2004; Tomari, 2005].  The pre-miRNA is then exported 
from the nucleus into the cytoplasm by Exportin 5 and its cofactor Ran [Yi, 2003; 
Lund, 2004; Zeng, 2004].  The remainder of the pri-miRNA transcript remains in the 
nucleus and is degraded [Cai, 2005].  The pre-miRNA is then bound by the RNase 
III enzyme Dicer, which cleaves the terminal loop of the pre-miRNA yielding the 21-
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23 bp miRNA duplex product [Bartel, 2004; Cullen, 2004; Chendrimada, 2005; 
Elbashir, 2001a; Elbashir, 2001b; Hutvagner, 2001].  Dicer subsequently facilitates 
the assembly of one of the miRNA strands into the RNA-induced silencing complex 
(RISC) [Chendrimada, 2005; Hammond, 2000; Maniataki, 2005; Tomari, 2004].  The 
unincorporated strand of the mature miRNA is released and degraded.  The RISC 
complex containing the miRNA strand is now ready to function on its target mRNA.   
The miRNA within the RISC complex directs RISC to a complementary 
mRNA species [Schwarz, 2002; Brown, 2005]. The 5’ 2-8 residues of the miRNA, or 
“seed sequence”, engages in Watson-Crick base pairing with its target mRNA 
[Lewis, 2005]. If a perfect match is encountered, Argonaute-2 within the RISC 
complex can function to cleave the mRNA, which will then be degraded [Liu, 2004; 
Meister, 2004; Liu, 2005; Zeng, 2003; Yekta, 2004; Hutvagner, 2002; Bagga, 2005].  
More commonly, imperfect binding will occur, which results in translational 
repression of the target mRNA [Olsen, 1999; Zeng, 2002; Doench, 2004].  This 
typically requires several RISC complexes bound to the target mRNA [Doench, 
2004]. 
MiRNAs require limited homology beyond the seed sequence to act on a 
target mRNA, which reduces the need for conservation.  Therefore, there is an 
expected lack of miRNA sequence homology in viruses, attributable in part to a 
higher rate of mutation and the potentially faster evolution of viruses, as compared to 
eukaryotes. The human gamma herpesvirus Epstein-Barr Virus (EBV), a 
lymphocryptovirus, and Kaposi sarcoma-associated herpesvirus (KSHV), a 
rhadinovirus, for instance are separated by 60-80 million years. In this case, the lack 
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of conservation of miRNAs between genomes is not surprising.  Genomes that are 
not as far divided, such as EBV and rhesus lymphocryptovirus (rLCV), within the 
lymphocryptovirus subfamily, contain several similar miRNAs, suggesting some level 
of conservation and therefore a possible selective advantage [Cai, 2006a]. 
Conversely, KSHV and rhesus rhadinovirus (RRV), within the rhadinovirus 
subfamily, do not contain sequence homologous miRNAs, though in both cases the 
viral miRNA clusters are positional homologs.  
Currently, miRNAs have been confirmed in 12 herpesviruses: herpes simplex 
virus-1 and -2, human, mouse and chimpanzee cytomegalovirus, Epstein-Barr virus, 
rhesus lymphocryptovirus, mouse gammaherpesvirus-68, Kaposi’s sarcoma-
associated herpesvirus, rhesus rhadinovirus and Marek’s disease virus-1 and -2. 
Table 1 gives a summary of each herpesvirus, including the number of viral miRNAs, 
names of viral miRNAs and references of the papers originally describing the 
discovery of the miRNAs. 
 
Herpes Simplex Virus – 1 (HSV-1, HHV-1) 
HSV-1 is an alpha herpesvirus.  Like most alpha herpesviruses, it has a 
relatively short reproductive cycle, spreads rapidly in culture and establishes latent 
infections primarily in sensory ganglia.  HSV-1, which typically causes oro-facial 
infection, can eventually establish latency in trigeminal ganglia in humans.  
Interestingly, growing numbers of genital herpes (over 50% of primary episodes) 
have been attributed to HSV-1 [Xu, 2002].  As is commonly true with latent infection, 
viral reactivation and reoccurrence of infection can occur.  Though the disease is 
  
   
4 
generally mild in most individuals, HSV infection can cause life-threatening illness, 
namely Herpes simplex encephalitis.   
The HSV genome is over 150 kbp in length and encodes nearly 80 gene 
products.  Computational analysis predicted several HSV-1 viral miRNAs [Pfeffer, 
2005].  Northern blot analysis and cloning eventually identified a single miRNA gene 
[Cui, 2006].  Time course analysis indicated HSV1-miR-H1 expression kinetics 
resembled that of a late gene product, detectable starting 4 hours post infection and 
remaining high after 8 hours post infection [Cui, 2006].  Subsequent cDNA 
sequencing recovered an additional 7 mature miRNAs from 5 additional miRNA 
gene loci [Umbach, 2008].  These viral miRNAs were transcribed in both infected 
cell culture models and in the trigeminal ganglia of latently infected mice. Four of the 
viral miRNAs derive from the second exon of the spliced ~6.3kb latency associated 
transcript (LAT) locus of the HSV-1 genome, with LAT able to fold into the expected 
precursor stem-loop structure for each miRNA.  Folding of the resulting pri-miRNA 
into a structure containing multiple hairpins may offer added stability, which may 
explain the high level of stability of the LAT transcript.  The LAT transcript is the only 
viral gene product expressed at abundant levels during latency [Stevens, 1987], 
suggesting viral miRNA expression is highly important in maintaining HSV-1 latency.   
HSV1-miR-H2, -H3, -H4, and -H6 all have predicted viral targets.  HSV1-miR-
H2 is antisense to the immediate-early infected cell protein 0 (ICP0) transcript.  Co-
transfection experiments indicated that ICP0 protein levels were reduced upon 
HSV1-miR-H2 expression, though this is due to a translational repression and not 
mRNA degradation, despite perfect target homology [Umbach, 2008].  ICP0 is not 
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essential for viral replication but promotes lytic infection [Hagglund, 2004]. ICP0 null 
mutant viruses are defective for progression through a productive lytic life cycle 
[Stow, 1986]. The effect of decreased ICP0 protein, an immediate early HSV-1 
transcriptional activator, is a push towards latency of the virus.  Thus, HSV1-miR-H2 
expression may promote or maintain viral latency.  HSV1-miR-H3 and -H4 were 
found to be complementary to ICP34.5 though it was not directly examined as a 
target.  Finally, HSV1-miR-H6 is predicted to target ICP4, an immediate early 
protein.   ICP4 is required for maximal levels of all early and late gene expression 
[Clements, 1977; Knipe, 1978; Preston, 1979; Watson, 1980].  It is involved in both 
specific and nonspecific DNA binding and interacts with transcription factors [Kristie, 
1986; Michael, 1988].  ICP4 mutants are unable to express early, and therefore late, 
lytic genes without exposure to sodium butyrate [Poon, 2006].  Thus, ICP4 is 
required for lytic replication and its down regulation would result in a shift towards 
latency.  Finally, loss of the LAT transcript, which would include loss of all HSV-1 
viral miRNAs, results in a loss of cell protection and increased levels of apoptosis 
[Inman, 2001].  It is therefore likely that all these viral miRNAs may be working in 
part to start or maintain viral latency.  Consequently, a viral miRNA deletion virus 
would preferentially enter the lytic rather than the latent phase of the viral life cycle. 
 
Herpes Simplex Virus – 2 (HSV-2, HHV-2) 
HSV-2 is also an alpha herpesvirus.  HSV-2 infection typically causes genital herpes 
and can establish latency in dorsal root ganglia in humans.  Neonatal HSV infection, 
acquired intrapartum, is highly symptomatic and often lethal.  As with HSV-1, HSV-2 
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recurrent infection can be either symptomatic or asymptomatic [Roizman, 2001].  In 
general, HSV-2 infection recurs more frequently than HSV-1 infection [Benedetti, 
1994; Lafferty, 1987].  
 The HSV-2 genome is 154 kb and encodes nearly 80 gene products.  
Extensive conservation between HSV-1 and HSV-2 genomes exists, with average 
sequence identity of approximately 83% [Dolan, 1998].  Computational analysis had 
previously indicated putative miRNA genes in the LAT region of the HSV-2 genome 
[Pfeffer, 2005].  Sequencing of small RNAs eventually revealed one such miRNA, 
HSV2-miR-I [Tang, 2008].  This sequence was conserved among multiple HSV-2 
strains.  HSV2-miR-I is located in LAT exon 2 and is antisense to ICP34.5, a key 
viral neurovirulence factor. HSV2-miR-I is detectable in infected cell culture, in active 
and latently infected guinea pig dorsal root ganglia and in human latently infected 
sacral dorsal root ganglia. Because HSV2-miR-I is located antisense to ICP34.5, 
ICP34.5 was considered a likely target of HSV2-miR-I.  Further experiments 
revealed that HSV2-miR-I does in fact regulate ICP34.5 protein expression by RISC-
mediated mRNA degradation.  ICP34.5 is a late gene involved in active virus 
replication.  Specifically, ICP34.5 is involved in a pathway to which final effect is to 
shut off PKR activation and induction of interferon (IFN) [Williams, 2001].  This 
pathway is normally activated in HSV infection due the presence of double-stranded 
RNA produced during active infection.  A loss of ICP34.5 expression would result in 
an increase in IFN, which is generally not a desirable effect for the virus.  However, 
during latency, these ds-RNAs are not produced.  Therefore, down regulation of 
ICP34.5 would result in the establishment and maintenance of viral latency. 
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Marek’s Disease Virus – 1 (MDV-1) 
 MDV-1, an alpha herpesvirus, infects epithelial cells, T lymphocytes and B 
lymphocytes in chickens.  However, fully productive infection occurs only in feather 
follicle epithelium.  MDV-1 causes Marek’s disease, a lymphoid cell infiltration or 
lymphomatuous tumor in the peripheral nerves and gonads [Witter, 1997].   
 The MDV-1 genome is nearly 178 kbp long and encodes 87 genes.  MDV-1 
has 14 miRNA genes encoding 23 mature miRNAs in two clusters [Burnside, 2006; 
Yao, 2008; Burnside, 2007].  The first cluster consists of MDV1-miR-M1 to -M5, -M9, 
-M11, -M12, and -M31, which flank the meq oncogene.  The meq gene is the 
strongest candidate for an oncogene in MDV-1; its expression is important for 
transformation of lymphoblastoid cells [Xie, 1996], Rat-2 cells [Liu, 1998], Df-1 cells 
[Himly, 1998; Levy, 2005] and the formation of MDV oncogenesis [Lupiani, 2004].  
Because MDV1-miRs-M1 to -M5 are oriented around the meq locus, with MDV1-
miR-M2 through -M5 in the same orientation, it is possible that these miRNAs are 
contributing to meq–induced oncogenesis.  MDV1-miR-M6 to -M8, -M10 and -M13 
are clustered in a large intron of the latency-associated transcript MSR.  Because 
both the meq locus and latency-associated transcript are expressed during latency, 
these miRNAs may also function to establish or maintain latency. 
 Deep sequencing analysis of multiple MDV-1 strains indicated high levels of 
sequence homology.   Analysis of miRNA expression indicated MDV-1 miRNAs 
were differentially expressed between different strains, with MDV1-miR-M6 to -M8 
showing no change in expression, while MDV1-miR-M2, -M4, -M5, and -M12 were 
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expressed on varying levels in tumors depending on infection strain. Genomic 
clustering of the miRNAs would suggest common pri-miRNA transcripts.  However, 
differential expression indicates a level of regulation beyond transcription, most like 
via miRNA processing.  MDV1-miR-m4 had the highest level of miRNA expression in 
MDV-1, accounting for nearly 72% of all MDV-1 miRNAs. Many targets were 
suggested for the MDV-1 miRNAs, but none has yet been confirmed.  Nonetheless, 
given the extremely high expression of MDV1-miR-m4, it is likely to play an 
important role in MDV-1 pathogenesis. 
 
Marek’s Disease Virus – 2 (MDV-2) 
 MDV-1 and MDV-2 diverged about 26 million years ago. Like MDV-1, MDV-2 
is also an alpha herpesvirus, with the genome about 164 kbp long, encoding 76 
genes.  While genes within the UL and US regions of the two viruses are highly 
conserved, many open reading frames are unique to MDV-1. Moreover, while MDV-
1 causes T-cell lymphomas in chickens, MDV-2 is non-oncogenic.   
 With the discovery of MDV-1 miRNAs, the search began for MDV-2 miRNAs.  
17 miRNA MDV-2 genes were found, which encode 27 mature miRNAs [Yao, 2007].  
These 17 miRNA genes are clustered in two regions of the genome, with 16 
clustered in the same orientation in a 4.2 kb TRL/IRL region.  Four putative ORFs 
exist in this cluster and eight miRNA genes were located in the coding regions of 
these genes.  The clustering of these miRNAs in one region with the same 
orientation suggests a common precursor mRNA transcript.  The only miRNA not in 
this cluster, MDV2-miR-M17, is located in the IRs/RTs region, oriented opposite 
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ICP4.    This suggests ICP4 as a possible MDV2-miR-M17 target, though this has 
not yet been confirmed.  No other targets are known for the remaining MDV-2 
miRNAs. 
 
Human Cytomegalovirus (HCMV, HHV-5) 
The beta herpesvirus HCMV is associated with congenital diseases and post-
transplant complications [Pass, 2001].  It is the only herpesvirus that exhibits natural 
transplacental transmission.  CMV infection in the US among individuals over 6 
years of age is above 58% [Staras, 2006].  Following initial infection, infectious virus 
is found in virtually all bodily fluids for months to years post infection [Mocarski, 
2001].  Like most beta herpesviruses, HCMV has a long reproductive cycle and 
exhibits slow viral spread in culture.  Cytomegalia, or enlarged infected cells, are a 
hallmark of this herpesvirus family.  HCMV specifically infects human fibroblast, 
endothelial, epithelial and astrocyte cells.  Unlike some other herpesviruses, it is not 
significantly associated with any cancers.  At 230 kb with over 150 unique ORFs, 
HCMV has the largest genome of all herpesviruses.   
While viral miRNAs are typically clustered in the latency region of the 
genome, 16 HCMV miRNAs are located in 10 positions across the genome [Pfeffer, 
2005; Grey, 2005; Dunn, 2005]. These miRNA genes are clustered (6 genes) and 
unclustered (4 genes) and transcribed from strands opposite to described ORFs, in 
intergenic regions or within introns [Pfeffer, 2005; Grey, 2005; Dunn, 2005].  These 
miRNAs were also highly expressed during the lytic stage of the viral life cycle.   
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Multiple experiments determined several targets of the viral miRNAs.  HCMV-
miR-UL112-1 targets the viral immediate early gene-72 (IE72) product, an 
immediate early trans-activator.  Repression of IE72 results in attenuation of acute 
replication and therefore a switch to latency [Grey, 2008; Grey, 2007].  When 
HCVM-miR-UL112-1 is expressed, a decrease in protein expression is observed, 
indicating mRNA cleavage and degradation mediated by the miRNA.  HCMV-miR-
UL112-1 specifically binds cellular major histocompatibility complex class I-related 
chain B (MICB), which upsets binding with natural killer cell activating receptor 
NKG2D, resulting in evasion from natural killer cell attack [Stern-Ginossar, 2007].  
This is an example of a viral miRNA directly down-regulating a host immune defense 
gene, providing a means of evading host immune response.  Finally, HCMV-miR-
UL112-1 also suppresses protein levels of viral gene IE1 by transcriptional 
repression [Murphy, 2008].  IE1 is required to execute the virus transcriptional 
program, the regulation of which would influence the choice between latency and 
lytic replication.  Though IE1 is not required for viral replication at high multiplicities 
of infection (MOI), at MOI below 1 PFU/cell IE1 mutant viruses show replication 
attenuation.  At MOI below 0.1 PFU/cell there is a complete failure to replicate 
[Gawn, 2002].    Overall, HCMV-miR-UL112-1 is involved in host immune evasion 
and down regulation of lytic proteins, resulting in the establishment of viral latency.  
To date, no targets have been confirmed for the other HCMV miRNAs.  Chimpanzee 
cytomegalovirus (CCMV) is highly related with many conserved miRNAs, however 
few experiments have been done with this virus so very little is confirmed. 
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Mouse Cytomegalovirus (MCMV) 
 Given the findings of viral miRNAs in HCMV, further research was done to 
determine the presence of viral miRNAs in its murine homolog, MCMV.  Like HCMV, 
MCMV is a beta herpesvirus.  However, HCMV and MCMV share no detectable 
DNA sequence homology.  MCMV has a large tissue tropism and grows to high titer 
in the salivary glands, liver and spleen of immunocompromised mice.   
 The MCMV genome is about 230 kbp long and contains over 165 genes. 
Computational analysis revealed the presence of multiple miRNA genes.   Cloning of 
small miRNA pools and northern blotting confirmed the presence of 18 miRNA 
genes encoding for 28 mature miRNAs [Buck, 2007; Dolken, 2007].  As in HCMV, 
the MCMV miRNAs are spread out throughout the genome, some in clusters, on 
both DNA strands.  Furthermore, the miRNA genes are intergenic, intronic and 
occasionally within or opposite an ORF. Kinetic experiments indicate that the viral 
miRNAs are expressed during the lytic portion of the viral life cycle, consistent with 
immediate-early and early expression [Buck, 2007; Dolken, 2007]. At late infection 
time points, MCMV miRNAs become highly abundant, surpassing expression levels 
of highly abundant cellular miRNAs, suggesting a level of competition between the 
two types of miRNAs [Dolken, 2007].  No conservation of sequence or location was 
observed between MCMV and HCMV, suggesting the miRNAs may function on host 
targets as opposed to viral ones.  
 
Epstein-Barr Virus (EBV, HHV-4) 
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Like many gamma herpesviruses, EBV replicates in lymphoblastoid cells but 
can infect other cell types.  EBV primarily infects human B cells but can infect T cells 
and epithelial cells as well.  A gamma herpesvirus and a lymphocryptovirus, its 
genome is about 170 kbp in length and contains approximately 82 genes.  Following 
B cell infection, the virus goes latent and typically forms a nuclear DNA episome, 
which can later be reactivated. EBV DNA can also integrate into chromosomal DNA.  
EBV infection is generally benign but can cause B- and T-cell lymphomas, as well as 
EBV-associated gastric carcinoma [Kieff, 2001; Kim do, 2007].  EBV infection is 
widespread in the human population, with over 90% of adults positive for antibodies 
to the viral capsid [Henle, 1969].  
The first reported cloning and detection of small RNAs was found in a 
Burkitt’s Lymphoma cell line latently infected with EBV [Pfeffer, 2004].  4% of the 
recovered cDNAs were viral sequences.  The 23 miRNA genes found in EBV are 
distributed into two distinct clusters.  One cluster contains 3 miRNA genes, EBV-
miR-BHRF1-1, -2 and -3, which encode for 4 mature miRNAs, and is located 
proximal to the BHRF1 open-reading frame [Pfeffer, 2004; Cai, 2006a; Grundhoff, 
2006].  The other cluster contains 20 miRNA genes encoding 35 mature miRNAs.  2 
miRNAs, EBV-miR-BART-1 and -2, are located with the BART gene, while an 
additional set of 13 EBV BART miRNAs map to a ~12 kb intronic region within the 
BART gene [Pfeffer, 2004; Cai, 2006a; Grundhoff, 2006].  These miRNA clusters are 
differentially expressed with the 3 member BHRF-1 cluster expressed exclusively in 
stage III latency, while all of the 20 member BART cluster are predominantly 
  
   
13 
expressed during stage II latency.  However, an induction of the miRNA expression 
is seen during lytic reactivation [Cai, 2006a]. 
The transcriptional origin of the miRNA clusters was determined.  The 
expression of the 13 miRNA genes located within the intronic region of the BART 
gene directly coincides with BART expression, indicating the BART mRNA as the 
pri-miRNA transcript for these miRNAs [Cai, 2006a] and the P1 promoter [de Jesus, 
2003; Sadler, 1995; Chen, 2005].  Several stable intermediates containing BART 
miRNAs are detectable, indicating splice variants and preferential processing to 
mature miRNAs [Edwards, 2008].  The BHRF1 miRNAs have differential splicing 
according to latency stage, in association with BHRF1 mRNA.  This includes 
expression of a 1.3 kb transcript of miR-BHRF-1, BHRF1 open reading frame and 
EBV-miR-BHRF-2 during latency III, and expression of a 1.4 kb transcript of BHRF1 
mRNA, EBV-miR-BHRF-2 and EBV-miR-BHRF-3 during induction of EBV replication 
in latency I [Xing, 2007]. 
Several targets are known for the EBV miRNAs. The BART cluster 1 miRNAs 
are reported to target the expression of viral LMP1 protein [Lo, 2007].  The BART 
cluster 1 regulates LMP1 translation, as mRNA levels are not consistent with protein 
levels. LMP1 is required for transformation of primary B-lymphocytes to long-term 
lymphoblastoid cell lines (LCL) [Dirmeier, 2003; Dirmeier, 2005; Kaye, 1999; Kaye, 
1995; Kaye, 1993; Kilger, 1998]. LMP1 also activates NF-KB, the inactivation of 
which results in rapid apoptosis [Cahir-McFarland, 2002; Cahir-McFarland, 2000; 
Cahir-McFarland].  However, elevated expression of LMP1 can result in growth 
inhibition [Eliopoulos, 1996].  MiRNA regulation indicates the importance of tightly 
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controlled LMP1 expression for EBV pathogenesis. One known target of the EBV-
miR-BART2 is the viral mRNA BALF5, which encodes EBV DNA polymerase 
[Pfeffer, 2004; Barth, 2008].  This target mRNA is transcribed from the opposite 
strand as EBV-miR-BART-2 and is cleaved in the area of homology, reducing the 
full-length 5.0 kb mRNA to 3.7 kb [Furnari, 1993].  The purpose of this function is not 
entirely understood, but could be involved in the establishment of latency or 
inhibition of lytic EBV replication. EBV-miR-BART5 is targets the cellular mRNA “p53 
Up-regulated Modulator of Apoptosis”, or PUMA [Choy, 2008].  Reduction of EBV-
miR-BART5 or induction of PUMA can trigger apoptosis in EBV infected cells.  Thus, 
EBV-miR-BART5 expression reduces PUMA levels, which aids in cell survival.  
EBV-miR-BHRF1-3 is known to target CXCL-11, an IFN-inducible T-cell attracting 
chemokine [Xia, 2008].  CXCL-11 has potent anti-tumor activity in laboratory 
animals, thus its down-regulation promotes EBV-related transformation 
[Hensbergen, 2005].  All together, the EBV miRNAs function to establish and 
maintain latency and eventually oncogenesis. 
 
Rhesus Lymphocryptovirus (rLCV) 
RLCV and EBV are primate lymphocryptoviruses that have diverged in 
sequence in parallel to the evolution of their primate host species.  RLCV and EBV 
evolutionarily diverged between 13 and 23 million years ago [Gerner, 2004].  The 
rLCV genome is 171 kb and contains nearly 80 genes.  Sequence analysis indicates 
a 65% shared homology between EBV and rLCV, with the structural proteins being 
most highly conserved and latent proteins being less conserved [Rivailler, 2002].   
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cDNA cloning of latently infected rhesus B cells identified 16 miRNA genes in 
two distinct clusters, expressing a total of 22 mature miRNAs [Cai, 2006a].  One 
miRNA, rLCV-miR-rL1-1 is located adjacent to the rLCV BHRF1 gene.  The other 14 
miRNA genes, expressing the remaining 20 mature miRNAs, are located adjacent to 
the rLCV BART locus.  Eight of the mature miRNAs, derived from six miRNA genes, 
are conserved to EBV, especially in the seed sequence region of the mature miRNA 
[Cai, 2006a].  Additionally, the genomic order and orientation of the conserved 
miRNAs is also maintained.   
To determine the level of conservation of the viral miRNAs, sequence 
homology of different regions of the miRNA gene were compared between EBV and 
rLCV [Cai, 2006a].  While the mature miRNA sequence and base of the hairpin 
stem-loop are important in the processing and function of the miRNA gene, the 
sequence of the terminal loop is relatively irrelevant, as long as an open structure is 
maintained.  Comparison of each of these regions in the conserved miRNAs 
revealed the mature miRNA and base sequence were 89% and 84% conserved, 
respectively, compared to 68% of the terminal loop [Cai, 2006a].  As the overall 
genome sequence homology is 65% conserved, this indicates conservation is 
specific to the functional portions of the miRNA gene [Rivailler, 2002].  The extensive 
level of conservation between EBV and rLCV miRNAs, despite significant sequence 
divergence in other viral latent genes, indicates the targets for these miRNAs are 
also probably conserved.  Currently no rLCV miRNA targets have been confirmed. 
 
Mouse Gammaherpesvirus – 68 (MHV-68) 
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MHV-68 is evolutionarily related to the human gamma herpesviruses EBV and 
KSHV [Speck, 1999].  Its genome is approximately 119 kbp long and encodes 81 
genes.  MHV-68 infection in mice causes acute productive infection in the lungs and 
splenic lymphoproliferation due to viral latency in splenic B cells [Weck, 1996; 
Usherwood, 1996b; Usherwood, 1996a; Sunil-Chandra, 1992b; Sunil-Chandra, 
1992a].   
 Along with computational predictions, nine MHV-68 miRNAs were cloned 
from latently infected mouse B lymphoma S11 cells [Pfeffer, 2005].  All nine of the 
viral miRNAs map to a 6 kbp region near ORF M1, immediately downstream of 
predicted viral tRNA genes. Sequence analysis identified 5 additional miRNA genes, 
though expression of these genes has not been confirmed.  Like EBV and KSHV, 
the viral miRNAs are expressed during latency.  However, unlike most miRNAs, the 
MHV-68 miRNAs are transcribed by RNA pol-III [Pfeffer, 2005].  Each of these 
transcripts contains a tRNA and one to two pre-miRNAs, as confirmed by northern 
blot analysis.  RNA pol-III promoters are generally unregulated in any cell type.  This 
explains previous reports of viral tRNA-like sequences expressed in the germinal 
centers of mice latently infected by MHV68 [Bowden, 1997].  These tRNA-like 
molecules are most likely nonfunctional remnants from the expressed promoter 
region of the miRNA genes and not true tRNAs.  Aside from different transcription, 
the structure of MHV-68 pre-miRNAs is also unusual, with a short hairpin structure 
[Pfeffer, 2005].  This may indicate that the processing and export is distinct from 
other herpesvirus and cellular miRNA maturation.  Loss of the miRNA region was 
shown to result in defects in the establishment of splenic latency though not 
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peritoneal cells, indicating viral miRNAs function to establish latency though miRNA 
targets may be tissue specific [Clambey, 2002].   
 
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV, HHV-8) 
KSHV is a human gamma herpesvirus that primarily infects B-cell and 
endothelial cells. It is the etiological agent of Kaposi’s Sarcoma, a highly vascular 
endothelial tumor found in immunocompromised patients.  KSHV is also associated 
with pleural effusion lymphoma (PEL), a highly aggressive body cavity-based 
lymphoma, and multicentric Castleman’s disease [Chang, 1994]. Its genome is 
approximately 137 kbp in length and encodes 83 genes.  Upon entry of the linear 
viral DNA into the nucleus, the DNA is rapidly circularized to form a nuclear 
episome.  Once episomal, the viral DNA can attach to the cellular DNA via viral 
scaffolding protein LANA.  In vitro models suggest that cells typically switch to a 
latent life cycle 24-48 hours post infection, with approximately 1-3% of cells 
undergoing spontaneous lytic reactivation [Ganem, 2001]. 
 To date, 12 miRNA genes encoding 14 mature miRNAs have been identified 
from latently infected PEL cell lines [Cai, 2005; Pfeffer, 2005; Samols, 2005; 
Grundhoff, 2006]. All 12 miRNAs encoded by KSHV are expressed in latently 
infected cells [Cai, 2006b; Samols, 2005]. These are all found within the latency 
region of the genome, with 10 of the 12 miRNAs located in an intergenic region 
between latency gene K12 (kaposin) and orf71 (v-flip) [Cai, 2005; Pfeffer, 2005; 
Samols, 2005; Grundhoff, 2006]. MiRNA expression occurs via promoters located 5’ 
to orf72 and orf73 and requires read-through of a leaky poly-(A) site at orf71.  This 
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results in several different mRNA products that encode viral miRNAs [Cai, 2006b; 
Pearce, 2005]. KSHV-miR-K12-2 is located in the 3’ UTR of the K12 gene while 
KSHV miRNA miR-K10 is located in the middle of the viral K12 open reading frame.  
Both miRNAs can use the upstream promoters that produce the alternatively spliced 
K12 mRNA.  As a result, K12 translation and miR-k10 production are mutually 
exclusive [Pfeffer, 2005; Cai, 2005; Samols, 2005].  K12 products kaposin A, B and 
C have important functions in cell growth and cytokine production [McCormick, 2005; 
Kliche, 2001].  Because over-expression of these products can be deleterious to the 
cell, KSHV-miR-K12-10 and KSHV-miR-K12-12 production may be tightly regulated 
to ensure that sufficient levels of both miRNAs, as well as kaposin mRNAs, are 
maintained.   
 Sequence analysis of the viral miRNA genes indicates a high level of 
conservation in both mature miRNA sequence and terminal loop sequence in KS, 
MCD and PEL [Marshall, 2007; O’Hara and Chugh, unpublished].  This suggests a 
tight level of selection on the KSHV miRNAs, presumably due to the importance of 
mRNA targeting in all KSHV malignancies.  To date, few KSHV miRNA targets have 
been found.  Expression profiling from the ectopic expression of the viral miRNA 
cluster in 293 cells indicated several possible miRNA targets.  QRT-PCR and 
northern blotting confirmed that thrombospondin 1 (THBS1) protein is the target of 
several KSHV miRNAs: KSHV-miR-K12-1, KSHV-miR-K12-3-3p, KSHV-miR-K12-6-
3p and KSHV-miR-K12-11 [Samols, 2007].  THBS1 is a matricellular glycoprotein 
that regulates proliferation and angiogenesis by activating latent TGF-B through 
direct binding [Bornstein, 2001; Lawler, 2002; Schultz-Cherry, 1995; de Fraipont, 
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2001].  Further analysis of KSHV miRNAs has indicated seed sequence homology of 
KSHV-miR-K12-11 with cellular miR-155 [Skalsky, 2007; Gottwein, 2007].  Indeed, 
expression of cellular miR-155 is low when KSHV-miR-K12-11 is expressed.   This 
indicates both miRNAs probably regulate a common set of targets, and given miR-
155’s known role in B-cell transformation, KSHV-miR-K12-11 is probably 
contributing to B-cell tumorigenesis in KSHV infection [Clurman, 1989; Costinean, 
2006; Eis, 2005]. 
  
Rhesus Monkey Rhadinovirus (RRV) 
RRV is a simian rhadinovirus closely related to KSHV that infects B-cells and 
endothelial cells of immunocompromised rhesus macaques.  Its genome is about 
133 kbp in length and encodes 89 genes.  Given the high level of similarity between 
KSHV and RRV, several studies were carried out to determine if viral miRNAs were 
also present in RRV.  Upon latent infection of RRV in rhesus monkey vascular 
endothelial cell cultures (MVECs), cDNA cloning revealed the presence of 11 mature 
viral miRNAs [Schafer, 2007].  Computer analysis identified 7 viral miRNA genes, 6 
of which were readily folded into the characteristic hairpin stem-loop structure of pre-
miRNAs. The presence of all 11 mature miRNAs was confirmed by primer extension 
analysis, including the miRNA that computational analysis could not structurally 
confirm.  Importantly, all 7 miRNA genes are clustered in a conserved intergenic 
region.  In KSHV, the viral miRNAs are located between K12/kaposin and orf71 
(vFLIP) [Cai, 2005; Pfeffer, 2005; Samols, 2005; Grundhoff, 2006].  RRV lacks a 
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kaposin gene and therefore all the viral miRNAs are located between orf69 and 
orf71.   
As in KSHV, all RRV viral miRNAs are located in the same orientation.  In 
KSHV, this allows for miRNA expression through promoters located 5’ to orf72 and 
orf73 and requires read-through of a leaky poly-(A) site at orf71 [Cai, 2006b; Pearce, 
2005].  Lytic and latent promoters have been identified 5’ of orf73 in RRV and a 
consensus poly-(A) site is present in orf71, suggesting a similar mechanism of 
processing may occur [DeWire, 2005].  Unlike KSHV, viral miRNA expression 
increases dramatically during lytic reactivation of RRV [Schafer, 2007].  This is likely 
due to a strong lytic promoter located immediately 5’ of the orf73 gene which is 
lacking in KSHV [DeWire, 2005].   Though none of the 11 mature RRV miRNAs bore 
any sequence homology to the KSHV miRNAs, genomic location and orientation 
suggest that these miRNAs are generally conserved between genomes.  Differences 
in sequence are likely due to sequence divergence between the two genomes.  
Despite differences in sequence, it is possible that RRV viral miRNAs may have 
similar targets and functions as the KSHV viral miRNAs.  
 
Conclusion 
 There are several popular theories for why viruses encode miRNAs.  Given 
that miRNAs act on the mRNA level and not the protein level, any effects the miRNA 
may have will take hours or even days to develop.  This suggests that viruses most 
likely encode miRNAs to establish long-term or latent infections.  As targeting 
experiments have shown, a number of viral miRNAs target viral mRNAs, with the 
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result being establishment or maintenance of latency.  In HSV-1, HSV1-miR-H2 
targets ICP0, a protein required for progression through the lytic life cycle [Umbach, 
2008].  HSV1-miR-H6 targets ICP4, also required for lytic progression [Umbach, 
2008]. HCMV-miR-UL112-1 targets IE72, the repression of which results in 
attenuation of acute replication [Grey, 2007; Grey, 2008]. Expression of any of these 
viral miRNAs results in reduced expression of a viral mRNA required for lytic 
replication.  All of these are examples of viral miRNAs regulating viral mRNAs in an 
attempt to establish and maintain viral latency. 
 Alternatively, viral miRNAs may function to overwhelm host miRNA 
machinery, out-competing or diverting the host from its normal cellular functions.  In 
KSHV miRNA cloning experiments, the viral miRNAs made up one fourth of all 
cloned miRNAs in the latently infected BCBL cell line [Pfeffer, 2005]. Given 
constraints on viral genome size, the small size of the miRNA gene (<200 bp) is 
certainly appealing [Cullen, 2004].  This is especially true when a miRNA gene can 
regulate hundreds of target mRNAs [Lim, 2005].   
Because many herpesviruses are known to cause cancer, miRNA 
involvement in oncogenesis is probable. Viral miRNAs may be acting as potential 
oncogenes or may be facilitating oncogenesis in target tissues.  As oncogenes, viral 
miRNAs could have direct effects on the induction of oncogenesis.  On the other 
hand, miRNAs may act indirectly to modulate oncogenesis driven by other viral or 
cellular factors.  Evidence of this is already found in cellular miRNAs.  The 
expression of the miR-17-92 cluster significantly accelerated lymphogenesis in mice 
with the c-myc oncogene driven by the immunoglobulin heavy-chain enhancer Eµ 
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[He, 2005].  These tumors were also able to evade apoptosis.   Among viral 
miRNAs, EBV-miR-BART5 targets PUMA, decreasing levels of this pro-apoptotic 
factor, resulting in increased cell survival [Choy, 2008].  And in MDV-1, a number of 
miRNAs cluster around the meq oncogene [Burnside, 2006; Burnside, 2007; Yao, 
2008].  With viral miRNAs clustered around the meq locus, in the same orientation, 
these miRNAs may be aiding in meq oncogenesis.  
Another possibility is that viral miRNAs facilitate oncogenesis by aiding in the 
evasion of innate and adaptive immune responses.  This is especially likely 
considering the need to evade immune responses in order to establish latency, a 
requirement for oncogenesis in herpesviruses. In MHV, a variant of the virus that 
was unable to avoid inflammation, a common immune response, was rapidly cleared 
by the immune system and was found to lack a region of the genome that 
encompassed all 9 MHV68 miRNAs [Macrae, 2001]. In HCMV, HCMV-miR-UL112-1 
targets MICB, resulting in evasion from nature killer cell attack as a means of 
evading the host immune response [Stern-Ginossar, 2007].  This is an example of a 
viral miRNA targeting a cellular mRNA, resulting in evasion of host immune 
response.  Evasion of host immune response can promote oncogenesis. 
Given the number of miRNAs encoded by each virus and the number of 
targets each miRNA may act upon, the viral miRNAs may work on each and every 
one of these functions.  None of these possible functions are mutually exclusive.  
Evidence to this idea is seen in HCMV.  HCMV-miR-UL112-1 has been shown to 
target viral and cellular mRNAs.  The resulting effect of viral targeting includes 
attenuation of acute viral replication resulting in a viral switch to latency.  Meanwhile, 
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cellular targeting results in down regulation of MICB, resulting in host immune 
evasion.  The miRNA is able to target all of these mRNAs simultaneously, despite 
the wide range of effects.  MiRNAs allow a highly specific way of simultaneously 
regulating a wide variety of virus and host cell functions and are therefore important 
regulators in viral life cycle, virus-host interaction and viral oncogenesis. 
 
Notes 
This review was accepted on November 20, 2008.  This is to appear in 
Herpesviridae: Viral Structure, Life Cycle and Infections, edited by Frank Columbus 
and published by Nova Science Publishers. 
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Figure I.1 MiRNA Processing 
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Table I.1 Herpesvirus miRNAs 
Virus  (Host) miRNA Gene 
Acession 
Number Mature miRNA Sequence Reference 
HSV-1 HSV1-miR-H1 MI0004730 HSV1-miR-H1 uggaaggacgggaaguggaag 7 
(Human) HSV1-miR-H2 MI0008937 HSV1-miR-H2-5p ucgcacgcgcccggcacagacu 18 
   HSV1-miR-H2-3p ccugagccagggacgagugcgacu 18 
 HSV1-miR-H3 MI0008938 HSV1-miR-H3 cugggacugugcgguuggga 18 
 HSV1-miR-H4 MI0008939 HSV1-miR-H4-5p gguagaguuugacaggcaagca 18 
   HSV1-miR-H4-3p cuugccugucuaacucgcuagu 18 
 HSV1-miR-H5 MI0008940 HSV1-miR-H5 gucagagauccaaacccuccgg 18 
 HSV1-miR-H6 MI0008941 HSV1-miR-H6 cacuucccguccuuccauccc 18 
      
HSV-2 HSV2-miR-I  HSV2-miR-I uagugcuugccugucuaacuc 17 
(Human)      
      
HCMV HCMV-miR-UL22A MI0001678 HCMV-miR-UL22A uaacuagccuucccgugaga   9,12,14 
(Human)   HCMV-miR-UL22A* ucaccagaaugcuaguuuguag 9,12,14 
 HCMV-miR-UL36 MI0001679 HCMV-miR-UL36 ucguugaagacaccuggaaaga 10,12,14 
   HCMV-miR-UL36* uuuccagguguuuucaacgugc 10,12,14 
 HCMV-miR-UL70 MI0003688 HCMV-miR-UL70-5p ugcgucucggccucguccaga 10 
   HCMV-miR-UL70-3p ggggaugggcuggcgcgcgg 10 
 HCMV-miR-UL112 MI0001680 HCMV-miR-UL112 aagugacggugagauccaggcu 12,14 
 HCMV-miR-US4 MI0003687 HCMV-miR-US4 cgacauggacgugcagggggau 10 
 HCMV-miR-US5-1 MI0001682 HCMV-miR-US5-1 ugacaagccugacgagagcgu 10,12,14 
 HCMV-miR-US5-2 MI0001683 HCMV-miR-US5-2 uuaugauaggugugacgauguc 10,12,14 
 HCMV-miR-US25-1 MI0001684 HCMV-miR-US25-1 aaccgcucaguggcucggacc 9,12,14 
   HCMV-miR-US25-1* uccgaacgcuaggucgguucuc 9,12,14 
 HCMV-miR-US25-2 MI0001685 HCMV-miR-US25-2-5p agcggucuguucagguggauga 12,14 
   HCMV-miR-US25-2-3p auccacuuggagagcucccgcgg 12,14 
 HCMV-miR-US33 MI0001686 HCMV-miR-US33-5p gauugugcccggaccgugggcg 12,14 
   HCMV-miR-US33-3p ucacgguccgagcacaucca 12,14 
      
mCMV mCMV-miR-M23-1 MI0006252 mCMV-miR-M23-1-5p cucgguacggacggggaaccgu 1,8 
(Mouse)   mCMV-miR-M23-1-3p cuccugcgucggcccgaggcc 1,8 
 mCMV-miR-M23-2 MI0006253 mCMV-miR-M23-2 augggggccucggucaagcgg 1,8 
   mCMV-miR-M23-2* ugaacguguccccuaucggugg 1,8 
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Virus  (Host) miRNA Gene 
Acession 
Number Mature miRNA Sequence Reference 
mCMV mCMV-miR-M55-1 MI0006255 mCMV-miR-M55-1 uggugaucggcgugcuagccgu 8 
(Mouse) mCMV-miR-M87-1 MI0006258 mCMV-miR-M87-1 aggcagccgucggcagcggcagc 8 
 mCMV-miR-M95-1 MI0006260 mCMV-miR-M95-1-5p ggucgugggcuugugucgcuug 1,8 
   mCMV-miR-M95-1-3p agcgacgucggaccgcgacggc 1,8 
 mCMV-miR-m01-1 MI0006246 mCMV-miR-M1-1 agaggagaauaacgucgaacgg 8 
 mCMV-miR-m01-2 MI0006247 mCMV-miR-M1-2 gaagagaaucggguuggaacggu 1,8 
   mCMV-miR-M1-2* cguucgacacgguuuccuucga 1,8 
 mCMV-miR-m01-3 MI0006248 mCMV-miR-M1-3 cggugaagcgacuguugccucga 1,8 
   mCMV-miR-M1-3* cgaggaacgcucgcuucacggc 1,8 
 mCMV-miR-m01-4 MI0006249 mCMV-miR-M1-4 uccuaugcuaacacgugcgcgug 1,8 
   mCMV-miR-M1-4* cgccgcgugguagcauuagaac 1,8 
 mCMV-miR-m21-1 MI0006250 mCMV-miR-M21-1 auaggggacacguucaagccg 1,8 
 mCMV-miR-m22-1 MI0006251 mCMV-miR-M22-1 uuccccguccguaccgaggcca 1,8 
 mCMV-miR-m59-1 MI0006256 mCMV-miR-M59-1 uuagcagugccucgaccgucag 8 
 mCMV-miR-m59-2 MI0006257 mCMV-miR-M59-2 cccgaagagcccucacagagcc 8 
 mCMV-miR-m88-1 MI0006259 mCMV-miR-M88-1 cagaagucgaugucggggucu 1,8 
   mCMV-miR-M88-1* augaccgacccccugacaucgg 1,8 
 mCMV-miR-m107-1 MI0006261 mCMV-miR-M107-1-5p cggucacucgucucgagucacc 1,8 
   mCMV-miR-M107-1-3p ugcucgcgucgagugaccgcuc 1,8 
 mCMV-miR-m108-1 MI0006262 mCMV-miR-M108-1 uuucugacgguggcucgugucg 1,8 
   mCMV-miR-M108-1* ucacgagcaaccgcccgaaaug 1,8 
 mCMV-miR-m108-2 MI0006263 mCMV-miR-M108-2-5p.2 ucacucgucgcgagcggucac 1,8 
   mCMV-miR-M108-2-5p.1 gcggucacucgacgcgagcaccg 1,8 
      
EBV EBV-miR-BART1 MI0001067 EBV-miR-BART1-3p uagcaccgcuauccacuauguc 5,12,13 
(Human)   EBV-miR-BART1-5p ucuuaguggaagugacgugcugug 5,12,13 
 EBV-miR-BART2 MI0001068 EBV-miR-BART2-5p uauuuucugcauucgcccuugc 12,13 
   EBV-miR-BART2-3p aaggagcgauuuggagaaaauaaa 12,13 
 EBV-miR-BART3 MI0003725 EBV-miR-BART3 cgcaccacuagucaccaggugu 5,11,12 
   EBV-miR-BART3*  accuaguguuaguguugugcu 5,11,12 
 EBV-miR-BART4 MI0003726 EBV-miR-BART4  gaccugaugcugcuggugugcu 5,11,12 
 EBV-miR-BART6 MI0003728 EBV-miR-BART6-3p  cggggaucggacuagccuuaga 5,11,12 
   EBV-miR-BART6-5p  uaagguugguccaauccauagg 5,11,12 
 EBV-miR-BART7 MI0003729 EBV-miR-BART7  caucauaguccaguguccaggg 5,11,12 
   EBV-miR-BART7*  ccuggaccuugacuaugaaaca 5,11,12 
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Virus  (Host) miRNA Gene 
Acession 
Number Mature miRNA Sequence Reference 
EBV   EBV-miR-BART8*  gucacaaucuauggggucguaga 5,11,12 
(Human) EBV-miR-BART9 MI0003731 EBV-miR-BART9  uaacacuucaugggucccguagu 5,11,12 
   EBV-miR-BART9*  uacuggacccugaauuggaaac 5,11,12 
 EBV-miR-BART10 MI0003732 EBV-miR-BART10 uacauaaccauggaguuggcugu 5,11,12 
   EBV-miR-BART10*  gccaccucuuugguucuguaca 5,11,12 
 EBV-miR-BART11 MI0003733 EBV-miR-BART11-5p ucagacaguuuggugcgcuaguug 5,11,12 
   EBV-miR-BART11-3p  acgcacaccaggcugacugcc 5,11,12 
 EBV-miR-BART12 MI0003734 EBV-miR-BART12  uccugugguguuuggugugguu 5,11,12 
 EBV-miR-BART13 MI0003735 EBV-miR-BART13*  aaccggcucguggcucguacag 5,11,12 
   EBV-miR-BART13 uguaacuugccagggacggcuga 5,11,12 
 EBV-miR-BART14 MI0003736 EBV-miR-BART14  uaaaugcugcaguaguagggau 5,11,12 
   EBV-miR-BART14*  uacccuacgcugccgauuuaca 5,11,12 
 EBV-miR-BART15 MI0004988 EBV-miR-BART15  gucagugguuuuguuuccuuga 11,12 
 EBV-miR-BART16 MI0004989 EBV-miR-BART16  uuagauagagugggugugugcucu 11,12 
 EBV-miR-BART17 MI0004990 EBV-miR-BART17-5p  uaagaggacgcaggcauacaag 11,12 
   EBV-miR-BART17-3p uguaugccugguguccccuuagu 11,12 
 EBV-miR-BART18 MI0004991 EBV-miR-BART18-3p uaucggaaguuugggcuucguc 11,12 
   EBV-miR-BART18-5p  ucaaguucgcacuuccuauaca 11,12 
 EBV-miR-BART19 MI0004992 EBV-miR-BART19-5p acauuccccgcaaacaugacaug 11,12 
   EBV-miR-BART19-3p  uuuuguuugcuugggaaugcu 11,12 
 EBV-miR-BART20 MI0004993 EBV-miR-BART20-5p  uagcaggcaugucuucauucc 11,12 
   EBV-miR-BART20-3p  caugaaggcacagccuguuacc 11,12 
 EBV-miR-BHRF1-1 MI0001064 EBV-miR-BHRF1-1  uaaccugaucagccccggaguu 12,13 
 EBV-miR-BHRF1-2 MI0001065 EBV-miR-BHRF1-2*  aaauucuguugcagcagauagc 12,13 
   EBV-miR-BHRF1-2  uaucuuuugcggcagaaauuga 12,13 
 EBV-miR-BHRF1-3 MI0001066 EBV-miR-BHRF1-3  uaacgggaaguguguaagcaca  
      
rLCV rLCV-miR-rL1-1 MI0003737 rLCV-miR-rL1-1 uaaccugaucagccccgggguu 5 
(Simian) rLCV-miR-rL1-10 MI0003746 rLCV-miR-rL1-10  uagugcgccggugaccugauag 5 
 rLCV-miR-rL1-11 MI0003747 rLCV-miR-rL1-11  ugacacucgauaggauacgggg 5 
 rLCV-miR-rL1-12 MI0003748 rLCV-miR-rL1-12-5p agaccagaccaugcacaguggg 5 
   rLCV-miR-rL1-12-3p  aacggugcauggacuggcuaga 5 
 rLCV-miR-rL1-13 MI0003749 rLCV-miR-rL1-13  gaucauagccaguguccaggga 5 
 rLCV-miR-rL1-14 MI0003750 rLCV-miR-rL1-14-5p  ucggacggucuggugcgcuugau 5 
   rLCV-miR-rL1-14-3p  ucgcacaucaggcugaacgac 5 
      
28 
Virus  (Host) miRNA Gene 
Acession 
Number Mature miRNA Sequence Reference 
rLCV rLCV-miR-rL1-15 MI0003751 rLCV-miR-rL1-15  uccuguagaguaugggugugguuu 5 
(Simian) rLCV-miR-rL1-16 MI0003752 rLCV-miR-rL1-16-5p agcaggcaugucuucauucc 5 
   rLCV-miR-rL1-16-3p  caugaaacacauggccuguucc 5 
 rLCV-miR-rL1-2 MI0003738 rLCV-miR-rL1-2  uaucuuuugcgggggaauuucca 5 
 rLCV-miR-rL1-3 MI0003739 rLCV-miR-rL1-3  cgcaccucgccgucucuacugcu 5 
 rLCV-miR-rL1-4 MI0003740 rLCV-miR-rL1-4-3p caccacacgauccacuaggucu 5 
   rLCV-miR-rL1-4-5p  accuaguaauugugcgguguu 5 
 rLCV-miR-rL1-5 MI0003741 rLCV-miR-rL1-5-3p cgcaccacuuuucacuaggugu 5 
   rLCV-miR-rL1-5-5p aaccuagugccggugaugugcu 5 
 rLCV-miR-rL1-6 MI0003742 rLCV-miR-rL1-6-5p uuuaguggaagugacgugcugug 5,12 
   rLCV-miR-rL1-6 uagcaccgcuauccacuauguc 5,12 
 rLCV-miR-rL1-7 MI0003743 rLCV-miR-rL1-7  cgagguaaacaucggcuuacug 5 
 rLCV-miR-rL1-8 MI0003744 rLCV-miR-rL1-8  uaaggugaauauagcugcccauug 5,12 
 rLCV-miR-rL1-9 MI0003745 rLCV-miR-rL1-9  ucgaugcaugguccccccuuagu 5 
      
MHV-68 MGHV-miR-M1-1 MI0001669 MGHV-miR-M1-1 uagaaauggccguacuuccuuu 12,15 
(Mouse) MGHV-miR-M1-2 MI0001670 MGHV-miR-M1-2  cagacccccucucccccucuuu 12,15 
 MGHV-miR-M1-3 MI0001671 MGHV-miR-M1-3 gaggugagcaggaguugcgcuu 12,15 
 MGHV-miR-M1-4 MI0001672 MGHV-miR-M1-4  ucgaggagcacguguuauucua 12,15 
 MGHV-miR-M1-5 MI0001673 MGHV-miR-M1-5  agaguugagaucgggucgucuc 12,15 
 MGHV-miR-M1-6 MI0001674 MGHV-miR-M1-6  ugaaacugugugaggugguuuu 12,15 
 MGHV-miR-M1-7 MI0001675 MGHV-miR-M1-7-5p  aaagguggaggugcgguaaccu 12,15 
   MGHV-miR-M1-7-3p  gauaucgcgcccaccuuuauu 12,15 
 MGHV-miR-M1-8 MI0001676 MGHV-miR-M1-8 agcacucacuggggguuugguc 12,15 
 MGHV-miR-M1-9 MI0001677 MGHV-miR-M1-9  ucacauuugccuggaccuuuuu 12,15 
      
KSHV KSHV-miR-K12-2 MI0002476 KSHV-miR-K12-2 aacuguaguccgggucgaucug 4,6 
(Human) KSHV-miR-K12-1 MI0002475 KSHV-miR-K12-1 auuacaggaaacuggguguaagc 4,6,12,14,15 
 KSHV-miR-K12-11 MI0002474 KSHV-miR-K12-11  uuaaugcuuagccuguguccga 6,12,14,15 
 KSHV-miR-K12-12 MI0004987 KSHV-miR-K12-4-3p  uagaauacugaggccuagcuga 11 
    KSHV-miR-K12-12  accaggccaccauuccucuccg 11 
 KSHV-miR-K12-3 MI0002483 KSHV-miR-K12-3  ucacauucugaggacggcagcga 4,6,12,14,15 
    KSHV-miR-K12-3*  ucgcggucacagaaugugaca 4,6,12,14,15 
 KSHV-miR-K12-4 MI0002482 KSHV-miR-K12-4-5p agcuaaaccgcaguacucuagg 4,6,12,14,15 
 KSHV-miR-K12-5 MI0002481 KSHV-miR-K12-5  uaggaugccuggaacuugccgg 4,6,12,14,15 
      
29 
Virus  (Host) miRNA Gene 
Acession 
Number Mature miRNA Sequence Reference 
KSHV KSHV-miR-K12-6 MI0002480 KSHV-miR-K12-6-3p  ugaugguuuucgggcuguugag 4,6,12,14,15 
(Human)    KSHV-miR-K12-6-5p  ccagcagcaccuaauccaucgg 4,6,12,14,15 
 KSHV-miR-K12-8 MI0002478 KSHV-miR-K12-8  uaggcgcgacugagagagcacg 4,6,12,14,15 
 KSHV-miR-K12-9 MI0002477 KSHV-miR-K12-9  cuggguauacgcagcugcguaa 4,6,12,14,15 
   KSHV-miR-K12-9*  acccagcugcguaaaccccgcu 4,6,12,14,15 
      
RRV RRV-miR-rR1-1 MI0005718 RRV-miR-rR1-1  cgaucgcaccuuuggccggccgg 16 
(Simian)   RRV-miR-rR1-1*  ggccaccgaggaugcgguc 16 
 RRV-miR-rR1-2 MI0005719 RRV-miR-rR1-2  auacggcgcugcacgguugga 16 
 RRV-miR-rR1-3 MI0005720 RRV-miR-rR1-3  cccgaugagcaguuagucc 16 
 RRV-miR-rR1-4 MI0005721 RRV-miR-rR1-4*  cucguuaaccgcccucccgaga 16 
   RRV-miR-rR1-4  uggggagggcggucagcgcgcg 16 
 RRV-miR-rR1-5 MI0005722 RRV-miR-rR1-5  ccggaacccaaagacacgugcccg 16 
 RRV-miR-rR1-6 MI0005723 RRV-miR-rR1-6*  cgauguacgcccuuucgcagu 16 
   RRV-miR-rR1-6  cgcggaaaggugugcacaucgua 16 
 RRV-miR-rR1-7 MI0005724 RRV-miR-rR1-7-5p  uggagagcaguuaacgugcguuc 16 
   RRV-miR-rR1-7-3p  cgcacgucgauugcucucuag 16 
      
MDV-1 MDV1-miR-M31 MI0008337 MDV1-miR-M31  ugcuacagucgugagcagaucaa 3 
(Chicken) MDV1-miR-M1 MI0005093 MDV1-miR-M1*  ugcugcgcaugaaagagcga 2,3,20 
    MDV1-miR-M1  ugcuuguucacugugcggca 2,3,20 
 MDV1-miR-M10 MI0006988 MDV1-miR-M10-5p  gcguugucucguagagguccag 3,20 
    MDV1-miR-M10-3p  ucgaaaucucuacgagauaaca 3,20 
 MDV1-miR-M11 MI0006989 MDV1-miR-M11-3p  ugaguuacauggucaggggauu 20 
    MDV1-miR-M11-5p  uuuuccuuaccguguagcuuaga 20 
 MDV1-miR-M12 MI0006990 MDV1-miR-M12  ugcauaauacggaggguucu 2,3,20 
 MDV1-miR-M13 MI0006991 MDV1-miR-M13  gcauggaaacguccugggaaa 20 
    MDV1-miR-M2  guuguauucugcccgguaguccg 2,3,20 
 MDV1-miR-M3 MI0005095 MDV1-miR-M3  augaaaaugugaaaccucucccgc 2,3,20 
 MDV1-miR-M4 MI0005096 MDV1-miR-M4  uuaaugcuguaucggaacccuuc 2,3,20 
    MDV1-miR-M4*  aaugguucugacagcaugacc 2,3,20 
 MDV1-miR-M5 MI0005097 MDV1-miR-M5*  aaccguaugcgaucacauugac 2,3,20 
    MDV1-miR-M5  uguguaucguggucgucuacugu 2,3,20 
 MDV1-miR-M6 MI0005098 MDV1-miR-M6-5p  ucuguuguuccguaguguucuc 2,3,20 
    MDV1-miR-M6-3p  gagaucccugcgaaaugacagu 2,3,20 
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MDV-1 MDV1-miR-M7 MI0005099 MDV1-miR-M7  uguuaucucggggagaucccgau 2,3,20 
(Chicken)    MDV1-miR-M7*  ucgagaucucuacgagauuacag 2,3,20 
 MDV1-miR-M8 MI0005100 MDV1-miR-M8-5p  uauuguucugugguugguuucg 2,3,20 
    MDV1-miR-M8-3p  gugaccucuacggaacaauagu 2,3,20 
 MDV1-miR-M9 MI0006987 MDV1-miR-M9*  aaacuccgagggcaggaaaaag 20 
   MDV1-miR-M9  uuuucuccuuccccccggaguu 20 
      
MDV-2 MDV2-miR-M14 MI0005882 MDV2-miR-M14-3p  ucaggaaguuccgugcccgaa 19 
(Chicken)   MDV2-miR-M14-5p  gugugguacggugcacccugaga 19 
 MDV2-miR-M15 MI0005883 MDV2-miR-M15*  uggaagggaaaggcaaaccgga 19 
   MDV2-miR-M15  ugguguguuuuucccuuccaucgca 19 
 MDV2-miR-M16 MI0005884 MDV2-miR-M16  cauccagucuguuuuggcaucuga 19 
 MDV2-miR-M17 MI0005885 MDV2-miR-M17*  aguccuucccggguccccuaga 19 
   MDV2-miR-M17  uaggacaaccgggacggacagg 19 
 MDV2-miR-M18 MI0005886 MDV2-miR-M18-3p  caaugccugcggagagaaaga 19 
   MDV2-miR-M18-5p  uguuuucucucaggcuggcauugc 19 
 MDV2-miR-M19 MI0005887 MDV2-miR-M19  caugccccccuccgaggguagc 19 
 MDV2-miR-M20 MI0005888 MDV2-miR-M20*  uccuuagcguggugccugaga 19 
   MDV2-miR-M20  ucaaguacugcgcgcaaggaccg 19 
 MDV2-miR-M21 MI0005889 MDV2-miR-M21*  uccuccuucgcggggugcuuga 19 
   MDV2-miR-M21  gagcaccacgccgauggacggaga 19 
 MDV2-miR-M22 MI0005890 MDV2-miR-M22*  uaguggcuugcuuguaggcugu 19 
   MDV2-miR-M22  ucuuacacgcacgucacucugguc 19 
 MDV2-miR-M23 MI0005891 MDV2-miR-M23  augguccgugguacgguguccu 19 
 MDV2-miR-M24 MI0005892 MDV2-miR-M24  uuagaugccgucagggaaagau 19 
 MDV2-miR-M25 MI0005893 MDV2-miR-M25-3p  caugcacuacuccggggguaggac 19 
   MDV2-miR-M25-5p  ccuccuucggacgagugcuugccg 19 
 MDV2-miR-M26 MI0005894 MDV2-miR-M26  uccuuugugcugugugugaga 19 
 MDV2-miR-M27 MI0005895 MDV2-miR-M27-3p  gcgucgagcaccgugcuggaggaa 19 
   MDV2-miR-M27-5p  cuucguccgguguucgaggcgu 19 
 MDV2-miR-M28 MI0005896 MDV2-miR-M28*  cgaggguaggcgcagaggaaaucg 19 
   MDV2-miR-M28  uuuucucgacgccuacccucggcg 19 
 MDV2-miR-M29 MI0005897 MDV2-miR-M29  ucuucacguaccucucuauggcu 19 
 MDV2-miR-M30 MI0005898 MDV2-miR-M30  caacacucccucggacgcagca 19 
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Abstract 
 MicroRNAs are regulated by gene alteration, transcription, and processing. 
Thus far, few studies have simultaneously assessed all 3 levels of regulation. Using 
real-time quantitative polymerase chain reaction (QPCR)–based arrays, we 
determined changes in gene copy number, pre-miRNA, and mature miRNA levels 
for the largest set of primary effusion lymphomas (PELs) to date. We detected PEL-
specific miRNA gene amplifications, and concordant changes in pre-miRNA and 
mature miRNA. We identified 68 PEL-specific miRNAs. This defines the miRNA 
signature of PEL and shows that transcriptional regulation of pre-miRNA as well as 
mature miRNA levels contribute nonredundant information that can be used for the 
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classification of human tumors. 
 
Introduction 
 MicroRNAs (miRNAs) are approximately 22-nt–long noncoding RNAs, which 
are found in all metazoans.  Approximately 500 miRNAs have been identified in 
humans [Sanger Institute]. Many miRNAs are evolutionarily conserved.  MiRNA 
homologs have been identified in Drosophila, humans, and plants.  Each miRNA can 
regulate the expression of multiple target messenger RNAs (mRNAs).  MiRNAs 
regulate many processes including developmental stages, cellular responses such 
as inflammation, the differentiation of hematopoietic stem cells into lymphocytes, 
and the transformation of normal cells into cancer cells [Calin, 2006].  MiRNAs 
themselves are transcriptionally regulated and often show stringent tissue specificity.   
 Most miRNA gene loci are interspersed between coding regions or located 
within introns, though some can be embedded within an open reading frame.  Thirty-
seven percent of human miRNAs are organized in multi-miRNA clusters [Altuvia, 
2005], many of which can be found around fragile sites[Calin, 2004; Zhang, 2006]. 
Clustered miRNAs are regulated by a common promoter and processed from a 
single primary transcript (pri-miRNA) that may contain several miRNAs, as well as 
coding exons.  Hence, miRNAs are subject to (1) genomic alterations at the DNA 
level, (2) transcriptional regulation at the pre-miRNA level, and (3) processing control 
at the mature miRNA level.  Thus far, few studies have evaluated these 3 modes of 
regulation simultaneously.   
 In the nucleus, Drosha initiates miRNA processing (Figure II.1A) by cleaving 
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the primary miRNA (pri-miRNA) to release the approximately 60-nt-long precursor 
miRNAs (pre-miRNAs) [Lee, 2003].  After export to the cytoplasm, the pre-miRNAs 
are further processed by Dicer to yield an approximately 22-bp miRNA duplex 
[Hutvagner, 2001; Grishok, 2001]. One strand of this duplex is then incorporated into 
the RNA-induced silencing complex (RISC), where it guides the RISC to mRNAs 
bearing complementary sequences [Hammond, 2000; Meister, 2004]. If the mRNA 
contains a perfectly complementary sequence, the RISC component Ago2 cleaves 
the target leading to mRNA degradation [Meister, 2004; Zeng, 2003].  In the case of 
an imperfect complementary target, RISC binding can induce translational inhibition 
[Zeng, 2003]. Translation inhibition is highly cooperative and requires several RISCs, 
potentially each with a different miRNA [Doench, 2004; Doench, 2003]. 
 We hypothesized that cancer-specific miRNA profiles are determined by a 
combination of changes at the level of the gene locus, that is, mutations, deletions, 
or amplifications, changes at the level of transcriptional regulation, and changes at 
the level of miRNA processing.  Hence, comprehensive miRNA profiling should 
query genomic loci, precursor miRNAs, as well as mature miRNAs.  We 
hypothesized further that this information can be used for the differential diagnosis of 
lymphomas, specifically of primary effusion lymphoma (PEL).   
 PELs are a unique type of post-germinal center diffuse large B-cell lymphoma 
(DLBCL) [Cesarman, 1995; Klein, 2003]. Clinically PELs are defined by their effusion 
phenotype.  Furthermore, all PEL tumors carry Kaposi sarcoma–associated 
herpesvirus (KSHV).  KSHV also encodes viral miRNAs [Cai, 2005; Samols, 2005]. 
These are highly conserved among KSHV isolates [Marshall, 2007]. We assembled 
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the largest group of PEL samples to date, which allowed us to generate the first 
miRNA signature for PEL.  Using a novel real-time quantitative polymerase chain 
reaction (QPCR)–based assay, we identified miRNAs, which are concordantly 
transcribed in most PELs and are present at the pre-miRNA and mature miRNA 
level.  The more abundant of these miRNAs were previously cloned, which 
independently confirms our data.  However, high-throughput QPCR-based profiling 
uncovered twice as many PEL-specific miRNAs as found by cloning methods.  We 
found a second group of miRNAs, which are uniformly present in nontransformed 
tonsil tissue, but down-regulated in PEL as well as a third group of miRNAs that 
were uniquely up- or down-regulated in individual PEL cell lines.  These data can be 
used to molecularly classify PEL.  Based on the known and predicted targets of 
miRNAs, which are present in PEL, we propose that PEL-specific miRNAs define the 
biologic phenotype of PEL.   
 
Methods 
Cell lines and tissue samples 
 All cells were cultured in RPMI containing 25 mM HEPES, 10% fetal bovine 
serum, 0.05mM 2-mercaptoethanol, 1mM sodium pyruvate, 2mM L-glutamine, 0.05  
g penicillin/mL, and 50 U streptomycin/mL at 37°C and in 5% CO2.  Deidentified 
frozen tonsil tissue biopsies were obtained from the cooperative human tissue 
network (CHTN).  Use of human cell lines and tissue was deemed “exempt” by the 
UNC IRB and does not require IRB approval.  The PEL cell lines are described in 
Table 2.S3.   
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DNA and RNA isolation 
 DNA was isolated using WizardSV kit (Promega, Madison, WI).  Total RNA 
was isolated using Triazol (Sigma-Aldrich, St Louis, MO) as described [Papin, 2005]. 
RNA was quantitated on a Nanodrop, and equal amounts of RNA were subjected to 
DNase I treatment (Ambion, Austin, TX).  RNA was reverse transcribed using cDNA 
archive kit (Applied Biosystems, Foster City, CA).  RNA integrity was evaluated 
using a 2100 Bioanalyzer Series C (Agilent, Santa Clara, CA).  Total RNA was 
measured using the RNA 6000 Series II Nano Kit, and small RNA was measured 
using the Small RNA Kit according to the manufacturer’s recommendations (Agilent).  
All chips were analyzed using 2100 Expert software version B.02.04 (Agilent).   
 
Real-time QPCR 
 We used two 96-well plates containing a total of 372 different primers 
representing 168 cellular and 12 viral pre-miRNA targets, and 6 cellular and viral 
control mRNA targets.  All primers conform to universal real-time PCR conditions 
[Papin, 2005; Fakhari, 2002; Hilscher, 2005], with a predicted Tm of 60 (±1)°C 
(mean ± standard deviation [SD]) and 100-bp or smaller amplicon length.  Real-time 
QPCR was conducted under universal cycling conditions (40 cycles) with SYBR as 
the method of detection following our previously validated methods [Papin, 2005]. 
A36- L reaction mix was made and distributed in triplicate into a 384-well plate using 
a CAS-1200 robot that uses filtered carbon-graphite pipette tips (Tecan, Durham, 
NC) for liquid level sensing, allowing for a pipetting accuracy of 0.1 µL.  The final 
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primer concentration was 250 nM in total of 9.0 µL reaction volume.  Real-time 
QPCR was conducted using a Roche LC420 unit (Roche, Indianapolis, IN).  The 
combined pipetting and instrument error was less than 6% (data not shown).  All 
reactions were done in technical as well as experimental triplicates.  As pre-miRNA–
specific primers also detect the corresponding gene, we used these primers for DNA 
gene profiling.  For DNA QPCR, each reaction contained 1.67 ng DNA/µL.  For RNA 
QPCR, 40 µL of the 100-µL RT reaction was used for each 384-well plate, yielding a 
final amount of 0.1 µL cDNA per each 9-µL reaction.  Real-time QPCR primers 
against 165 mature miRNAs were used according to the manufacturer’s protocol 
(Applied Biosystems).  Of note we were able to quantify miR-K5 from BC-1 cells and 
miR-K4 from VG-1 cells, even though the corresponding pre-miRNAs contain a 
single nucleotide polymorphism (SNP) [Gottwein, 2006; A.J.O. and D.P.D., 
unpublished observations, July 2007], which is located within the primer binding site.  
This underscores the robustness of a SYBR-based pre-miRNA QPCR assay, which 
tolerates up to 2 SNPs in each primer binding site as opposed to TaqMan-based 
mature miRNA QPCR assays, which do not tolerate SNPs [Papin, 2004]. 
 
Calculations 
 CT represents a logarithmic measure of the underlying target concentration.  
CT values of technical replicates were averaged to yield a single CT for each primer 
pair.  In case of triplicates, if one and only one replicate yielded CT ≥ 40, the 
average of the remaining 2 CTs was used.  Each experiment was repeated an 
additional 2 times (biologically replicated).  The mean CT values were normalized to 
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the CT of U6 as reference to yield dCTU6.  For DNA copy number determination and 
miRNA profiling, dCTU6 were standardized (Z-transformation [Troyanskaya, 2002]) to 
the median of each array.  The standard deviation (SD) of U6 was less than 1 CT 
unit, evidencing that we can discern 2-fold changes in gene copy number (data not 
shown).  Unsupervised clustering was conducted using ArrayMiner (Optimal Design, 
Brussels, Belgium) and a correlation metric.  Clustering using self-organizing maps 
was conducted using cluster [Eisen, 1998]. Additional statistical tests were 
conducted using SPSS v11.0 (SPSS Science, Chicago, IL) and R version 2.5.0 
(www.r-project.org/). 
 
Results 
Viral miRNA gene profile in PEL 
 All PELs are virally infected.  They contain 2 classes of miRNAs: those 
encoded by cellular genes and those encoded by either KSHV or Epstein-Barr virus 
(EBV).  Whereas nothing is known about the cellular miRNAs in PEL, the viral 
miRNAs have been intensely studied [Cai, 2005; Samols, 2005; Gottwein, 2006; 
Pfeffer, 2005]. This afforded us an internal positive control.  First, we determined 
relative miRNA gene copy numbers (Figure II.1B).  Total DNA was isolated and 
subjected to real-time QPCR.  All PELs encode the genes for the KSHV miRNAs 
[Cai, 2005; Samols, 2005], whereas only EBV coinfected PELs contain the genes for 
the EBV miRNAs (Figure II.1B).  Except for VG-1 cells, we detected all KSHV 
miRNA genome loci at equivalent levels in all PELs.  The 95% confidence interval 
(95%CI) was 0.45 to 1.15 dCTU6 units (n = 5).  dCTU6 represents the log2 difference 
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between the U6 and the target miRNA gene copy number.  One CT unit represents 
a 2-fold difference.  This experiment established the limit of our assay based on 
combined technical and biologic variation.  Using triplicates we were able to 
distinguish 5-fold, or twice the 95%CI, differences in gene copy number.  The reason 
for the decreased signal for miR-K4 in VG-1 cells is due to a single nucleotide 
polymorphism in the gene encoding miR-K4 (A.J.O. and D.P.D., unpublished 
observation, July 2007).  The EBV miRNA loci could be detected only in the 2 EBV 
genome–positive cell lines BC-1 and JSC-1.  The relative abundance of the EBV 
miRNA genes was lower than those compared with the KSHV miRNA genes (Table 
2.S1), evidencing that on average, fewer EBV genomes than KSHV genomes are 
present in PEL. 
 
Genomic miRNA gene profile in PEL 
 Next, we designed primers for all cellular pre-miRNAs and used these to 
determine the gene copy number of the cellular miRNA loci.   We conducted 
comparative genomic profiling for 168 miRNA loci.  DNA was isolated and adjusted 
for DNA concentration based on A260 absorption, and real-time QPCR was 
performed in triplicate (Figure II.2A).  Most miRNA genes showed little variation 
across cell lines with dCTU6 95%CI: 6.15 to 6.80.  Genomic profiling of miRNAs in 
PELs is not trivial, since PELs exhibit severe aneuploidy [Nair, 2006; Mullaney, 
2000] and genome coverage based on 168 miRNAs loci was sparse.  Nevertheless, 
we gained important insights.  KSHV miRNA loci were easily detected since in PELs 
the KSHV genome is present in more than 20 copies in all but the virus-negative, 
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non-PEL lymphoma cell lines.  Their 5% trimmed mean dCTU6 values were lower 
that those of most cellular miRNAs (Figure II.2A open circles), indicating that on 
average fewer PCR cycles were needed to yield a significant signal.  Lower dCT 
values correspond to higher copy number.  The trimmed mean is computed based 
on only 100 - 5 = 95% of all observations.  It is less susceptible to outliers than a 
regular arithmetic mean.  EBV miRNA gene loci likewise stood out, since they were 
absent in all but 3 EBV-positive cell lines (Figure II.2A closed circles).  A large range 
(dCTU6   8 units) in copy number variation represents miRNAs that were deleted in at 
least one PEL.  For instance, miR-34a was deleted in JSC-1 cells (Figure II.2A, 
arrow indicates triplicate measurements).  Additional miRNA genes that had 
sustained deletions or amplifications were identified by pairwise scatter plots (Figure 
II.S1): hsa-miR- 153-1 (Chr 2), 218-1 (Chr 4), 107 (Chr 10), 188 (Chr X), and 125a 
(Chr 19) were amplified in more than 50% of PELs.  In sum, while miRNA genome 
loci typing clearly identified miRNA genes that were missing in individual cell lines, 
no one miRNA locus in our collection was consistently lost or amplified in all PELs.  
This suggests that the PEL-specific miRNA signature is derived primarily from 
transcriptional reprogramming rather than a specific mutation in a miRNA gene 
locus. 
 
Pre-miRNA profile of PEL 
 We used our array to identify pre-miRNAs that were transcribed in PEL.  Total 
RNA was isolated, DNAse I–treated, reverse transcribed, and subjected to real-time 
QPCR (see Figure II.S2 for detailed experimental data for a representative set of 
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miRNAs).  Overall the KSHV miRNAs were present at much higher levels than the 
cellular miRNAs (see also Figure II.S4), probably due to the high genome copy 
number (20-30 copies) of KSHV in PEL [Staudt, 2004].  In contrast, in EBV+ PEL, 
the EBV miRNAs were present at approximately equal level of cellular miRNAs.  To 
gain a complete picture, we performed unsupervised clustering.  This method of 
analysis orders miRNAs based solely upon their relative levels of expression without 
making any a priori assumptions.  This is in contrast to classifications schemes that 
incorporate information upfront, for example, about the tumor cell lineage (PEL or 
not PEL) and then ask whether a given miRNA is overrepresented in one or the 
other group.  Four distinct clusters of pre-miRNAs were evident (Figure II.2B).  A 
detailed picture can be gleaned from the heatmap representation (Figure II.3).  Here 
the relative levels of all miRNAs in the array are preserved, such that miRNAs that 
were not detectable are coded in blue and the most highly abundant miRNAs in the 
entire array are coded in red.  The KSHV miRNAs were abundant in PEL and absent 
in tonsil or the virus-negative lymphoma lines BJAB, DG75, BL-8, Jurkat (T cell), and 
CEM (T cell) (Figure II.3C).   
 Hsa-miR-125b, -181b-2, -27b-1, and -31–1 clustered with the KSHV miRNAs, 
although their degree of overexpression in PEL was lower than for the KSHV pre-
miRNAs (Figure II.3C).  The mature hsa-miR-125b, -181b, and -27b miRNAs could 
also be detected by TaqMan QPCR (below).  A second cluster of pre-miRNAs was 
uniformly expressed in B cell–rich tonsil as well as PEL (Figure II.3E).  For many of 
those abundant pre-miRNAs, we were also able to detect the corresponding mature 
miRNAs (below).  Many of those were lymphoid lineage– specific miRNAs, 
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suggesting that the PEL tumor miRNA profile reflects the tissue of origin.   
 A third cluster represents pre-miRNAs that were down-regulated in PEL, as 
well as the virus-negative B-cell lymphomas compared with tonsil tissue (Figure 
II.3B).  This included mir-155, the recently identified cellular ortholog to KSHV mir-
K12-11 [Skalsky, 2007], as well as let-7a-2 and let-7a3 among others.  Furthermore, 
we identified pre-miRNAs that were uniquely up-regulated in individual cell lines.  As 
expected, the EBV pre-miRNAs were detected only in the EBV-positive BC1, BC5, 
and JSC-1 PEL cell lines (Figure II.3C).   
 
miRNA profile of PEL 
 We used a TaqMan-based miRNA array to profile mature miRNAs in PEL.  
This assay format yielded excellent reproducibility (Figure II.4A).  We defined the 
PEL signature as all miRNAs that (a) were detectable in fewer than 38 cycles and 
(b) exhibited limited variation, as evidenced by a standard deviation (SD) of less 
than 4-fold, across multiple PEL cell lines (Figure II.4B shaded box).  This yielded 68 
miRNAs, which are listed in Table 2.S2.  Alternatively, a stricter definition required 
that all signature miRNAs were present in every PEL cell line tested.  This yielded 26 
miRNAs (Figure II.4C), namely hsa-miR-9, -16, -17–3p, -17–5p, -19a, -20, -23b, -
26a, -29b, -30e, -34a, -103, -106a, -140, -142–3p, -148a, -152, -181b, -182, -186, -
191, -194, -210, -301, -320, and -331.   
 One hundred eight (61%) of the mature miRNA arrays were also represented 
in our pre-miRNA array.  This allowed us to establish a correspondence between 
pre-miRNA and miRNA levels.  Real-time QPCR for mature miRNA detected 11 
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(10%) miRNAs, which were not detected at the pre-miRNA level, and pre-miRNA 
profiling detected 45 (42%) of pre-miRNAs for which we could not detect the 
corresponding miRNA.  The majority of miRNAs were detectable as mature as well 
as pre-miRNAs.  Hence, consensus information as well as nonredundant information 
can be gained from combining mature miRNA and pre-miRNA profiling.   
 MiRNA cloning previously reported a few cellular miRNAs for the BCBL-1 and 
BC-1 cell lines [Cai, 2005; Samols, 2005]. As these experiments were designed to 
identify KSHV viral miRNAs, the cloning approach was not saturating.  It 
preferentially identified abundant cellular miRNAs such as hsa-miR-16 (Figure II.4C, 
miRNAs marked with an * or **).  Cloning also identified some miRNAs for which we 
could detect the pre-miRNA, but not the mature miRNA by real-time QPCR (see 
Table 2.S2 for a summary of all data).  Importantly, half of the miRNAs uncovered 
herein by real-time QPCR were novel and not identified in prior cloning attempts.   
 
Discussion 
 MiRNA profiling has emerged as a powerful new approach to stratify human 
cancer and to identify novel pathogenesis determinants [Calin, 2006].  Some 
miRNAs are considered bona fide oncogenes based upon their strong transforming 
properties in animal models [He, 2005]. To date, cellular miRNAs have not been 
profiled in PEL.  Here we report the miRNA profile of PEL.  Multiple layers of 
regulation control miRNA abundance, and our study for the first time combined 
querying them all.  First, we evaluated miRNA gene locus deletions, amplifications, 
and mutations using DNA QPCR.  This identified cell line–specific deletions of 
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individual miRNA loci; however, no miRNA loci were lost in all PELs.  Hsa-miR-218–
1, -107, -153–1, -188, and -125a were amplified in multiple PELs and await 
confirmation by genotyping.   
 The nascent transcript (pri-miRNA) is regulated at the level of promoter 
activity.  Pri-miRNAs are processed into pre-miRNAs depending on Drosha levels 
and specificity (Figure II.1A).  Upon nuclear export, Dicer generates mature miRNAs.  
We found a high concordance between pre-miRNAs and mature miRNAs.  Our 
results are in agreement with those of Schmittgen and colleagues [Jiang, 2005; 
Schmittgen, 2004], who likewise profiled pre-miRNA levels and found them to be 
good predictors of mature miRNA abundance.  This suggests that transcriptional 
control of miRNAs plays an important role in miRNA regulation.   
 There exists an additional justification to profile pre-miRNAs, because mature 
miRNAs of identical sequence can be derived from different pre-miRNAs, each 
located at a different genomic location and each under control of a different 
promoter.  Thus, profiling pre-miRNA levels provides a stepping-stone toward the 
identification of miRNA regulatory elements. 
 The real-time QPCR assays for miRNAs and pre-miRNAs revealed a 
remarkable robustness and sensitivity.  On average replicates showed less than 3-
fold variation over a linear range of 5 orders of magnitude.  This outperformed 
hybridization or radio-activity-based assays, for which we were not able to establish 
statistically significant differences of less than 10-fold (data not shown).  Equally 
remarkable was the robustness of the miRNA profile between PEL cell lines.  Even 
though each individual PEL had some pre-miRNAs and miRNAs (≤ 5%) that were 
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unique to a particular cell line, the signature miRNAs were highly up-regulated in 
most PELs to almost the exact level (SD ≤ 4-fold).  This implies that the PEL 
signature miRNAs are important for and unique to this class of lymphomas. 
 We feel that integrating multiple approaches of miRNA profiling yielded an 
accurate picture, as each method is subject to technical limitations and necessarily 
subjective cutoff limits.  Figure II.4C shows the minimal set of PEL-specific miRNAs.  
We could detect each of these miRNAs in every PEL cell line tested.  Table 2.S2 
shows a slightly larger set allowing for some variation within PELs.  As our miRNA 
profiling included cell lines that were previously analyzed by miRNA cloning 
approaches, we could establish a concordance between profiling by cloning and 
profiling by real-time QPCR arrays.  Real-time QPCR-based profiling identified many 
more miRNAs in PEL than cloning, though that may simply be a function of the 
number of clones sequenced for the particular cell line [Landgraf, 2007; Lim, 2007]. 
 Several miRNAs were identified by multiple methods in PEL cell lines.  They 
fit the biology of PEL.  Hsa-miR-181b is B-lymphoid specific and can drive B 
lymphopoiesis upon ectopic expression in bone marrow progenitor cells [Chen, 
2004]. Hsa-miR-181 and hsa-miR29b are markers for B-cell chronic lymphocytic 
leukemia (B-CLL), although they are down-regulated in the most aggressive forms.  
Recently it was shown that hsa-miR-181 and hsa-miR29b target the mRNA for TCL-
1 [Pekarsky, 2006]. Hsa-miR-15a was easily detectable in PELs, whereas it is 
commonly down-regulated in B-CLL.  In B-CLL, hsa-miR-15a expression was 
inversely correlated with its target, BCL-2, mRNA levels [Cimmino, 2005]. Since 
KSHV encodes a viral BCL-2 homolog [Sarid, 1997], there is no selection pressure 
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to induce human BCL-2.  As a result, BCL-2 mRNA is low in PELs by comparison 
with other DLBCLs (Figure II.S3).  Hsa-miR-34a has been ascribed tumor-
suppressor activity in neuroblastomas by targeting E2F3 mRNA [Welch, 2007], but 
no data have been reported with regard to human lymphoma.  Hsa-miR-222 was 
shown to target c-kit in endothelial cells and other cancers [Poliseno, 2006; Lee, 
2007], and c-kit is induced in KS and KSHV-infected endothelial cells.  However, c-
kit is neither significantly up- nor down-regulated in PEL [Klein, 2003], suggesting 
that in lymphoid cancer, hsa-miR-222 has other targets.  Interestingly, hsa-miR-
222/221 are encoded in close proximity to each other on Xp11.3; but while hsa-mir-
222 was easily detectable by pre-miRNA (see Figure II.S3C for details) and mature 
miRNA profiling and cloning, hsa-mir-221 was not detected by either of these 
methods, demonstrating that these 2 adjacent miRNAs are differentially regulated. 
 Hsa-miR-155 has been studied extensively in the context of human 
lymphoma, but was underrepresented in PELs.  This corroborates the recent 
observation that Hsa-miR-155 is an ortholog of KSHV miR-K12-1131 and inversely 
correlated with KSHV miRNA levels (although BC2, BC3, and JSC1 were 
exceptions).  The miR-155 gene locus is embedded within exon 3 of the BIC mRNA, 
which was initially identified as a viral integration site in avian lymphoma.  BIC and 
miR-155 are highly expressed in HD, DLBCL, and other lymphomas, but 
interestingly not in BL [Eis, 2005]. While BIC mRNA was induced by phorbol ester in 
EBV-Ramos BL cells, neither the mature hsa-miR-155 miRNA nor the hsa-miR- 155 
pre-miRNA was detectable [Kluiver, 2007]. This provides another example of 
discordant regulation between the nascent pri-RNAs comprising both protein and 
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miRNA coding regions, and pre-miRNA/miRNA levels.  It supports our contention 
that combined pre-miRNA and miRNA profiling provides novel information for the 
classification of human tumors that is independent of messenger RNA profiling.   
 In summary, PELs express B-cell lineage– and B-cell lymphoma–specific 
miRNAs, despite the absence of most B-cell CD surface antigens.  This study thus 
contributes to the definition of common and differential miRNA markers for human B-
cell lymphoma.  We show that pre-miRNA profiling yields corroborative as well as 
novel, nonredundant information to mature miRNA profiling, which can be used for 
the stratification of human cancer. 
 
Note added in proof: Gottwein et al [Gottwein, 2007] also recently reported on the 
inverse correlation between KSHV infection and hsa-mir-155 levels and common 
targets for the cellular and viral orthologs. 
 
Notes 
 This manuscript was submitted August 7, 2007; accepted December 5, 2007 
and published in Blood Journal, 15 February 2008, volume 111, number 4, pages 
2347-2353. 
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Figure II.1: Genomic profiling of KSHV and EBV miRNAs 
 (A) Outline of miRNA maturation and the species that can be detected using 
pre-miRNA–specific primers and SYBR-based real-time QPCR or miRNA-specific 
primers and TaqMan-based real-time QPCR. (B) Plot of relative copy number of viral 
miRNA gene loci. Variations in input DNA were adjusted using U6. This yielded 
dCTU6, which represents a logarithmic measure of relative gene copy number. 
Primers are indicated on the horizontal axis. Positive dCTU6 indicate lower copy 
number. Colors indicate different cell lines. The JSC-1 and BC-1 cell lines are EBV 
positive.  
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Figure II.2: Comparative genomic profiling for cellular miRNA loci in PEL 
 (A) Variation in miRNA gene copy number. Plotted is the range of dCTU6 on 
the vertical and the 5% trimmed mean dCTU6 on the horizontal axis. The 5% trimmed 
mean is the arithmetic mean excluding the top and/or bottom 5% of the data. 
Crosses indicate the values for each cellular miRNA. KSHV miRNAs are shown by 
open circles; EBV miRNA gene loci, by closed circles; and hsa-miR-34a, by the 
arrow. Range indicates the difference between the lowest and highest value for each 
miRNA across all PEL cell lines. If a particular miRNA gene is present in every 
single cell line at 2 copies per cell, the range is 0 or close to 0, since it reflects only 
the measurement error. A high range indicates that one or more of the cell lines 
have more than 2 copies per cell (amplification) or have no copy per cell (deletion). 
This indicates that one or more cell lines in the sample have sustained amplifications 
or deletions. These were identified by analyzing the individual scatterplots in Figure 
S1. (B) Representation of individual clusters of pre-miRNAs as obtained after 
unsupervised clustering. The axes represent the first 3 principal components of the 
dataset. The objective of principal component analysis is to test whether all the data 
are correlated, or if indeed significant patterns or groups of data exist and how 
many. It serves as a quality control tool for our analysis. As can be seen here, 4, no 
more and no less, well-separated clusters emerged. These are further analyzed in 
Figure 3. Individual pre-miRNAs are represented by dots. Cluster membership is 
indicated by lines and semitransparent hulls. 
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Figure II.3: Pre-miRNA profile of PEL 
 (A) Unsupervised cluster analysis of standardized dCTU6 for pre-miRNAs 
using a correlation metric. Standardization was achieved by calculating Z scores 
across each individual array of dCTU6. This technique eliminates variation in assay 
performance between individual samples. Red indicates higher abundance; blue, 
lower than median abundance; white, the median. (B,C) Enlarged view. (B) Cluster 
of pre-miRNAs with decreased abundance in PEL vis-a` -vis tonsil. (C) Cluster of 
pre-miRNAs with increased abundance in PEL vis-a` -vis tonsil. (D) Cluster of pre-
miRNAs equal abundance in PEL vis-a` -vis tonsil. (E) Cluster of pre-miRNAs with 
high abundance in PEL as well as in nonvirus-associated lymphoma lines. The 
cluster of absent pre-miRNAs is not shown separately. 
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Figure II.4: Mature miRNA profiles of PEL  
 (A) Scatterplot analysis of 2 cell lines JSC-1 (vertical axis) and BC-1 
(horizontal axis). Plotted are mean CT values of technical triplicates. Lines indicate 
the SD. Dots correspond to individual miRNAs. CT = 40 indicates absence of a 
miRNA signal. (B) Variation of mature miRNA levels in PEL. Plotted is the SD across 
multiple cell lines on the vertical axis against the mean CT on the horizontal axis (n = 
10). Open circles indicate mature miRNAs as detected by TaqMan assay. Dark 
circles indicate that the corresponding pre-miRNA was also overexpressed. Crossed 
circles indicate miRNAs that were cloned from PEL (data from Cai et al [Cai, 2005] 
and Samols et al [Samols, 2005]). Shaded area indicates the cutoff used to derive 
the PEL miRNA signature shown in Table 2.S2. (C) Fraction of total (165) probes on 
the vertical axis, for which every PEL sample yielded a CT lower than indicated on 
the horizontal axis. All miRNAs with CT of 38 or less (i.e., those that were uniformly 
detectable in all PEL lines) are tabulated on the right. The # indicates miRNAs that 
were also cloned once; ##, miRNAs that were cloned independently by 2 groups 
[Cai, 2005; Samols, 2005]. 
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Figure II.S1: Individual correlations reveal miRNA deletions  
 Shown are individual scatter plots of the relative gene copy number (dCT) for 
a set of PEL cell lines. These were from left to right and top to bottom : BC-1, BC-3, 
BCBL-1, BCP-1, DG75, JSC-1, VG-1. Dots indicate individual miRNA genes and 
lines the regression. Dots that deviated dramatically from the regression line indicate 
a deletion or amplification.   
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Figure II.S2: Exemplary data  
  (A) Picture of the amplification curves. (B) picture of an agarose gel of the 
products. (C) Quantitation for selected miRNAs (bottom) for a set of PEL cell lines 
indicated by the different colors.   
 
  54 
   
 
Figure II.S3: Analysis of hsa-mir-222 and hsa-mir-15a target BCL-2 in PEL  
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Figure II.S4: Summary data and Euklidian-metric based clustering of dCTU6. 
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Table II.S1: Summary statistics for Figure II.1B 
Primer KSHV+EBV+ 
(n=2) 
SD KSHV+EBV- 
(n=4) 
SD KSHV-
EBV- 
(n=1) 
Diff. 
to 
EBV-  
(in x 
SD) 
Diff. 
to 
KSHV- 
(in x 
SD) 
 
BART-1 7.37 0.71 19.67 0.40 18.59 17.43 15.91 
BART-2 4.42 0.51 20.63 1.89 18.59 8.57 7.49 
BHRF-1 6.50 0.12 21.98 1.16 18.59 13.40 10.46 
        
vFlip (mRNA) 1.01 0.65 1.55 0.90 15.05 0.60 15.56 
miR-K1 -1.18 0.26 -0.08 1.60 8.33 0.68 5.93 
miR-K2 -2.21 0.12 -1.26 1.31 7.08 0.73 7.07 
miR-K4 -1.08 0.29 1.66 4.59 18.59 0.60 4.28 
miR-K5 -1.04 0.10 0.38 1.66 14.97 0.86 9.64 
miR-K6 1.54 0.69 2.96 1.66 18.15 0.85 9.98 
miR-K8 -0.15 0.49 0.96 1.35 13.19 0.82 9.86 
miR-K10 0.20 0.85 0.54 1.93 14.13 0.18 7.23 
kaposin (mRNA) -0.05 0.34 2.64 5.86 16.67 0.46 2.85 
        
mean KSHV miR -0.56  0.74  13.49 0.67 7.71 
SD KSHV miR 1.21  1.33  4.44 0.24 2.20 
count KSHV miR 7  7  7 7 7 
SEM KSHV miR 0.46  0.50  1.68 0.09 0.83 
pos.CI KSHV miR 0.33  1.72  16.78 0.85 9.34 
neg.CI KSHV miR -1.46  -0.25  10.20 0.50 6.08 
 
Abbreviations are standard deviation (SD), standard error of mean (SEM), 95% 
confidence interval (CI). Differences are explained in fold standard deviation (x 
SD).  
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Table II.S2: miRNA signature of PEL in decreasing order of abundance  
 
mature miRNA(1)      cloned(2)  
--------------------------------------------------------------------------------------------------------- 
miR-16       y y    
miR-17-5p        y    
miR-21       y y    
miR-142-3p       y y 
miR-181b       y  
miR-15b       y 
miR-92        y 
miR-181a       y y 
miR-29c  
miR-19a 
miR-29a       y  
miR-103       y 
miR-25       y 
miR-210       y y  
miR-30b  
miR-26b  
miR-191 
let-7a 
miR-15a       y 
miR-30c 
miR-20        y y 
miR-34a   (3) BC-3     y    
let-7a 
miR-320       y 
miR-17-3p       y    
miR-182 
miR-106a 
miR-186 
miR-29b        y y 
let-7a 
miR-26a  
miR-30d       y 
let-7g 
miR-140       y 
let-7d 
miR-195 
miR-9 
miR-152  (3) BC-3 
miR-146   (3) JSC-1     y 
miR-301       y y 
miR-148a  
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Table II.S2 (continued):  
mature miRNA(1)      cloned(2)  
--------------------------------------------------------------------------------------------------------- 
let-7a 
miR-142-5p       y 
miR-331 
miR-23b  
miR-23a 
miR-342 (3) BCBL-1 
miR-324-5p 
miR-27b  
miR-194 
miR-30e 
miR-130b (3) BC-1     y y 
miR-150 (5) BC-1 
miR-339 
miR-374 
miR-132 
miR-205 (3) BC-1, BC-3 
miR-213 
let-7i  
miR-182* (3) BC-1, BC-3 
miR-125a 
miR-107 
miR-100 (3) only BC-1     y 
miR-181c 
miR-197 
miR-303p 
miR-125b (3) BC-3, JSC-1 
miR-296 
miR-99a       y 
 
 
(1) mature miRNA refers to miRNAs with mean CT ≤ 38 and SD ≤ 2 for (n=10) 
arrays from cell lines BC-1, JSC-1, BC-3 and BCBL-1 as determined by 
TaqMan™  assay. 
(2) Cloned refers to miRNAs that were previously cloned from BC-1 or BCBL-1 cells 
or both (yy). 
(3) miRNAs with SD>2 and the cell line that was negative. 
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Table II.S3: Cell lines 
Cell Lines:          
  
 Status: Reference   
 KSHV EBV  
    
   
BC-1 + +  5,6 
BC-2 + +  6 
BC-5 + +  8   
JSC-1 + +  4   
       
BC-3 + -  1 
BCBL-1 + -  9 
BCLM + -  7 
BCP-1 + -  2   
VG-1 + -  3   
 
BJAB - -  
DG-75 - -  
 
Tonsil 5* - - 
Tonsil 6* - - 
Tonsil 9* - - 
 
*Number refers to age of individual 
1. Arvanitakis, L., et al., Establishment and characterization of a primary effusion (body cavity-
based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus 
(KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood, 1996. 88(7): p. 2648-54. 
2. Boshoff, C., et al., Establishing a KSHV+ cell line (BCP-1) from peripheral blood and 
characterizing its growth in Nod/SCID mice. Blood, 1998. 91(5): p. 1671-9. 
3. Brander, C., et al., Definition of an optimal cytotoxic T lymphocyte epitope in the latently 
expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis, 2001. 
184(2): p. 119-26. 
4. Cannon, J.S., et al., A new primary effusion lymphoma-derived cell line yields a highly 
infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol, 2000. 74(21): p. 
10187-93. 
5. Cesarman, E., et al., Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-
related body-cavity-based lymphomas. N Engl J Med, 1995. 332(18): p. 1186-91. 
6. Cesarman, E., et al., In vitro establishment and characterization of two acquired 
immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing 
Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood, 1995. 86(7): 
p. 2708-14. 
7. Ghosh, S.K., et al., Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma 
through azidothymidine-mediated inhibition of NF-kappa B. Blood, 2003. 101(6): p. 2321-7. 
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Abstract 
 The elevation of tumor specific microRNAs reflects tissue of origin and tumor 
stage. (a) We show that the absence of specific miRNAs likewise can be used to 
determine tumor origin (miR-155) and proliferation state, since tumor suppressor 
miRNAs (miR-222/221, let-7 family) were significantly downregulated in primary 
effusion lymphoma (PEL) as well as in Kaposi sarcoma (KS). PEL and KS are 
associated with KSHV infection. (b) We identified fifteen KSHV-regulated miRNAs in 
latently infected, non-tumorigenic endothelial cells (EC). By contrast, miR-143/145 
were elevated only in KS tumors, not KSHV infected EC. These represent tumor-
specific, rather than virus-specific miRNAs. Since tumor suppressor proteins are 
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wild-type in KS and PEL, downregulation of multiple tumor suppressor miRNAs, 
provides a novel, alternative mechanism of transformation.  
 
Introduction 
MicroRNAs (miRNA) are a new class of genes that function as inhibitory RNA 
molecules that are incorporated into the RISC complex. The RISC complex can 
degrade the miRNA-targeted mRNAs or can inhibit protein translation of the target 
mRNA. Because the biochemical function of miRNAs is to inhibit protein expression, 
it is not surprising that miRNAs can exhibit tumor suppressor phenotypes.  
Conversely, miRNAs have also been associated with growth promoting 
phenotypes, if their targets include tumor suppressor proteins or proteins that are 
required for cell maturation and differentiation.  Many miRNAs are cell lineage 
associated whereas others are found in many tissues, albeit at different levels 
[Landgraf, 2007]. Hence, miRNAs like mRNAs can be subjected to microarray 
profiling. Tumor signatures based on miRNA profiles have clinical predictive power, 
analogous to profiles based on mRNA [Yanaihara, 2006]. We have used real-time 
QPCR based arrays to profile mRNAs in two AIDS-defining cancers: primary 
effusion lymphoma (PEL) and Kaposi sarcoma (KS). 
PEL is a monoclonal CD138+, post germinal center non-Hodgkin B cell 
lymphoma [Nador, 1996]. PEL express CD71+, CD38+ activation markers and are 
invariably infected with Kaposi sarcoma associated herpesvirus (KSHV). They can 
be dually infected with Epstein-Barr virus (EBV). EBV-positive and EBV negative 
PEL can be differentiated based on their mRNA transcription pattern [Fan, 2005], but 
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do not differ appreciably in culture, or in animal models [Staudt, 2004; Petre, 2007].  
KS is also associated with KSHV infection [Chang, 1994].  KS is a malignancy of 
endothelial lineage cells and thought to be at the border between infection-induced 
vascular hyperplasia and clonal neoplasia. 
We find that many previously identified tumor suppressor miRNAs were 
downregulated in PEL and KS. These include miR-155, miR-220/221 as well as 
miR-let7 family members. These miRNAs were more downregulated in the 
monoclonal, fully transformed PEL than in endothelial lineage KS biopsies or KSHV-
infected non-tumorigenic endothelial cells.  This reinforces the importance of tumor 
suppressor miRNAs in oncogenic transformation and underscores their clinical utility 
for tumor classification. 
 
Materials and Methods 
 PEL cell lines listed in supplemental table 1. KS biopsies were obtained with 
informed consent and used de-identified. RNA was isolated as per our prior 
procedures [O'Hara, 2008] and miRNA levels quantified using a commercial assay 
according to manufactures recommendations (Applied Biosystems Inc.). Data were 
normalized to U6 and clustered using Arrayminer™ (Optimal Design Inc., Nivelles, 
Belgium). ANOVA, t-test and analysis of residuals (|residual| >10) after robust 
regression were conducted in R (www.r-project.org) [Rousseeuw, 2003].  
 
Results and Discussion 
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To identify miRNAs that are downregulated in KSHV associated cancers we 
profiled PEL, normal tonsil tissue, KSHV-infected and uninfected endothelial cells 
(EC), and—for the first time—patient KS biopsies. We had previously used a smaller 
collection of PEL to catalog miRNAs that were detectable in all PEL [O'Hara, 2008]. 
At the time though we did not have the statistical power to also identify mature 
miRNAs that were specifically downregulated in PEL compared to controls.  
Using a TaqMan™ real-time quantitative PCR based miRNA array we 
determined the levels of 84 mature miRNAs. Based on the large number of samples 
(n=21), low false positive signal of the non-template reactions (4.6% of n= 588), and 
low mean replicate variability (95%CI of the SD over all samples: 1.63 … 2.62 CT 
units), we consider 1.82.62 = 4.7 fold differences in miRNA levels to be biologically 
significant. All miRNAs were measured in duplicate or triplicate (n= 6,265 individual 
reactions). Principal component analysis identified seven clusters, as well as 
miRNAs that could not be uniquely partitioned into any one cluster (Figure III.1A). 
The clusters were (i) miRNAs that were highest in PEL (Figure III.1C, cluster PEL); 
(ii) miRNAs that were present at higher levels in KS tumors compared to EC, 
regardless of KSHV infection, or in PEL, most significantly miR-143 and -145  
(arrows in Figure III.1B, cluster KS, and Figure III.2A, III.2B); and (iii) miRNAs that 
were downregulated in PEL compared to tonsil, KS or endothelial cells (Figure 
III.1C, cluster “not PEL”, “EC”). These included miR-155, which is required for 
differentiation of germinal center (GC) B cells into plasmablasts [Vigorito, 2007]. Low 
levels of miR-155 are associated with GC-type diffused large B cell lymphoma 
(DLBCL) and genetic instability [Dorsett, 2008; Lawrie, 2007]. KSHV encodes a viral 
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ortholog to miR-155 [Gottwein, 2007; Skalsky, 2007], which could compensate for 
some of the miR-155 functions. 
MiR-221 and miR-222 were downregulated in PEL (Figure III.1C). This was 
verified by ANOVA (Figure III.2C, III.2D). MiR-221 and miR-222 exhibit tumor 
suppressor phenotypes [le Sage, 2007; Galardi, 2007; Medina, 2008]. Both miRNAs 
were also downregulated in KS compared to KSHV-infected EC. This unifies earlier 
observations, which identified c-Kit as a target for miR-221/222 in endothelial cells 
[Poliseno, 2006], and which observed c-Kit overexpression in KS and KS models 
[Moses, 2002; Koon, 2005]. 
MiR-125a, -27a,b and let7 family members were also downregulated in PEL 
(Figure III.2E, III.2F). These miRNAs are co-regulated and exhibit tumor suppressor 
phenotypes [Johnson, 2005; Kumar, 2008]. In Burkitt lymphoma, ectopic introduction 
of let-7 family miRNAs decreased c-Myc expression and inhibited cell proliferation 
[Sampson, 2007]. 
 To test the hypothesis that KSHV alone was responsible for the alterations in 
miRNA expression, we employed a pair of KSHV-infected or uninfected isogenic EC 
cell lines [Wang, 2008].  The EC were immortalized with telomerase and 
subsequently infected with KSHV [Wang, 2008]. They mostly express the viral latent 
genes. KSHV-infected EC displayed increased angiogenic potential, enhanced 
survival in low serum, while maintaining EC differentiation markers. They did not 
form tumors in nude mice and have no detectable chromosome rearrangements 
(unpublished) and thus are most likely to reflect changes due to viral infection, rather 
than secondary alterations due to transforming mutations of the host. We used t-test 
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to identify KSHV-induced miRNAs in these cells (Figure III.2G). After adjustment for 
multiple comparisons (q≤0.05 [Storey, 2003]) we identified 14 (16%) KSHV-
regulated miRNAs. These were miR-16, -181b, -19b, -20a, -204, -220, -338, -31, -
15a, -106a, -10b, -126, -376a. MiR-181b was not detectable at all in KSHV negative 
EC; miR-20a, -338, and -220 were not present in KSHV-positive EC. Next in rank 
order, just above the q≤0.05 significance threshold were miR-19a, -let7f, -92 
(supplemental table III.S2).  
Since we expected the majority of miRNAs not to change, we used analysis 
of residuals as an alternative to detect KSHV regulated miRNAs. This identified miR-
181b, -220, -338, -20a, -152, and -10a (Figure III.2H).  The miRNAs 152 and 10a 
were not identified by t-test, because the SD for one of the triplicate measurements 
was >1 CT unit. In case of miR-10a, the entire sample was variable. By contrast, we 
identified a single reaction failure as outlier in case of miR-152. As such miR-152 is 
also KSHV regulated.  
To establish the biological relevance of the KSHV-regulated miRNAs we 
analyzed their levels in KS and PEL by ANOVA. KSHV induced miRNAs were 
elevated in KS biopsies and many were higher in PEL still (Figure III.2A-F). This 
pattern correlated with KSHV latent mRNA and miRNA levels, which are higher in 
KS tumors compared to KSHV-infected EC, and highest in PEL [O'Hara, 2008].  
  In sum, we report that multiple tumor suppressor miRNAs (miR-155, miR-
220/221, let-7 family) are downregulated in KSHV associated cancers including PEL 
and KS. This is also thefirst report of miRNA profiling of primary KS biopsies. We 
identified miR-143/145 as novel KS tumor, as opposed to KSHV-regulated, miRNA 
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biomarkers. As the classical tumor suppressor proteins (p53, Rb, p21/ARF, PTEN) 
are not mutant in KSHV associated malignancies ([Petre, 2007] and unpublished), 
the downregulation of tumor suppressor miRNAs provides an alternative mechanism 
of transformation. 
 
Notes 
 This paper was submitted to Blood Journal September 13, 2008 and 
accepted pending minor revisions October 13, 2008.  
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Figure III.1:  Cluster analysis of mature miRNA levels in KS and PEL 
 Data were first normalized relative to U6 to yield dCT. dCT data were 
clustered using a correlation metric. (A) Principal component analysis (PCA) of the 
data identified 7 clusters as well as miRNAs that did not fall into any of the clusters 
(red crosses). (B) Heatmap depiction of individual (duplicate) miRNAs. Red indicates 
increase and blue decrease relative to all data in this set. Only cluster members are 
shown, not unclassified miRNAs. “PEL” indicates PEL, “T” indicates tonsil, “K” 
indicates KS and “H” indicates endothelial cells. The rightmost lane represents 
KSHV latently infected EC. Bars indicate miRNAs that were significantly changed in 
a pairwise comparison of KSHV and mock-infected EC. Arrows indicate miR-145 
and miR-143, which we identified as KS tumor specific, but not KSHV-regulated 
miRNAs. 
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Figure III.2: Box plot of miRNA levels in EC, KSHV-infected EC, KS and PEL 
 (A-F) Samples classes are shown on the horizontal axis and relative miRNA 
levels (dCT) on the vertical axis. “dCT” indicates the miRNA abundance relative to 
U6 (set to 0). Lower dCT levels correspond to higher mRNA levels on a 2log scale. 
The line indicates the median, boxes approximate the 25% and 75% percentiles and 
whiskers 1.5x the box size. Outliers are indicated by a circle. The p values are for 
miR-143 p≤10-7, for miR-145 p≤10-10, for miR-221 p≤10-12, for miR-222 p≤10-14, for 
miR-125a p≤10-6, for miR-let7b p≤10-6 (G) Change in miRNA levels in KSHV latently 
infected EC. The horizontal axis shows mean relative levels dCT over n=6 replicates 
(3 for uninfected and 3 for KSHV-infected EC). Lower dCT levels correspond to 
higher mRNA levels on a 2log scale. The vertical axis shows the p value of the 
pairwise t-test. MiRNAs that were significant after adjustment for multiple 
comparisons are labeled. (H) Analysis of residuals for the same data set. Shown on 
the vertical axis are the residuals and on the horizontal axis the fitted values as 
predicted by linear regression analysis of KSHV-infected vs. uninfected EC. 
Significantly altered genes with |residual| >10 are labeled. Additional changed genes 
are shown in supplemental table 2. 
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Table III.S1:  PEL Cell Lines Profiled 
Cell Lines:            
  Status:   Original Description    
  KSHV  EBV         
BC-1   +  + Cesarman, E., et al., Blood, 1995. 86(7): 
       p. 2708-14. 
BC-2   +  + Cesarman, E., et al., Blood, 1995. 86(7): 
       p. 2708-14.  
BC-5   +  + Guasparri, I., et al. J Exp Med, 2004.  
       199(7): p. 993-1003  
CRO-AP2  +  + Carbone, A., et al., Int J Cancer, 1997.  
       73(4): p. 562-9. 
CRO-AP5  +  + Carbone, A., et al., Br J Haematol,  
       1998. 102(4): p. 1081  
BC-3   +  - Arvanitakis, L., et al., Blood, 1996.  
       88(7): p. 2648-54.   
BCBL-1  +  - Komanduri, K.V., et al., J AIDS Hum  
       Retro, 1996. 13(3):  p.215-26. 
BCLM   +  - Ghosh, S.K., et al., Blood, 2003. 101(6): 
       p. 2321-7.   
BCP-1  +  - Boshoff, C., et al., Blood, 1998. 91(5): p. 
       1671-9.   
HHB-2  +   Gradoville, L., et al., J Virol, 2000.  
       74(13): p. 6207-12. 
TY1   +  - Katano, H., et al.. J Med Virol, 1999.  
       58(4): p. 394-401. 
VG-1   +  - Brander, C., et al., J Infect Dis, 2001.  
       184(2): p. 119-26. 
HUVEC+KSHV +  - Wang, L., and Damania, B. Cancer Res. 
        2008;68(12):4640-8.  
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Table III.S2: Statistically significant KSHV-regulated miRNAs 
MiRNA 
dCT 
Huvec 
KSHV 
dCT 
Huvec 
Mock T-test Median 
Fold 
Change Bonf. Residual Fitted 
mir-31 -6.69 -8.48 0 -7.21 3.28 0.36 0.25 -6.94 
mir-16 -8.19 -10.25 0 -9.04 4.16 0.03 0.16 -8.35 
mir-19b -5.83 -8.36 0 -7.03 5.22 0.07 1.01 -6.84 
mir-220 15.09 6.1 0 11.27 510.23 0.37 10.37 4.72 
mir-338 15.09 6.58 0 10.42 1309.68 0.13 9.99 5.1 
mir-204 -0.15 2.07 0.01 0.72 0.2 0.46 -1.65 1.5 
mir-10b -3.86 -4.49 0.01 -4.27 1.54 1.24 -0.11 -3.75 
mir-126 -6.89 -8.38 0.01 -8.11 4.18 1.31 -0.03 -6.86 
mir-106a -3.71 -5.53 0.01 -4.25 4.42 1.05 0.87 -4.58 
mir-15a 0 -2.69 0.01 -0.64 6.52 1.05 2.31 -2.31 
mir-20a 15.09 -7.31 0.01 2.02 2335014 0.46 21.09 -6 
mir-376a -4.23 -2.14 0.02 -3.76 0.25 1.41 -2.36 -1.87 
mir-92 -5.02 -6.82 0.02 -6.22 2.58 2.18 0.59 -5.61 
let-7f -5.66 -7 0.02 -5.84 3.69 2.2 0.09 -5.75 
mir-19a -6.28 -8.14 0.02 -6.59 4.13 1.94 0.39 -6.67 
mir-142-3p 0.22 3.68 0.03 1.25 0.25 2.44 -2.56 2.78 
mir-9 1.88 3.96 0.04 3.34 0.22 3.93 -1.13 3.01 
mir-323 -2.13 -1.07 0.04 -1.44 0.51 3.53 -1.12 -1.01 
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Abstract 
 MicroRNAs have emerged as key regulators of cell lineage differentiation and 
cancer. We used precursor microRNA profiling by a novel real-time QPCR method 
(i) to define progressive stages of endothelial cell transformation cumulating in 
Kaposi sarcoma (KS) and (ii) to identify particular miRNAs that server as biomarker 
for tumor progression. KS is an AIDS-defining cancer of endothelial cell lineage. We 
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were able to compare primary patient biopsies to well-established culture and mouse 
tumor models. Loss of mir-221 and gain of mir-15 expression demarked the 
transition from merely immortalized to fully tumorigenic endothelial cells. Mir-140 and 
Kaposi sarcoma-associated herpesvirusviral microRNA increased linearly with the 
degree of transformation. Mir-24 emerged  as a biomarker for specific for KS.  
  
Introduction 
Kaposi’s sarcoma (KS) and hemangioma are the only two human cancers of 
endothelial lineage. KS remains the most frequent AIDS-associated malignancy 
even in populations with ready access to highly anti-retroviral therapy (HAART)[El 
Amari et al., 2008; Franceschi et al., 2008]. Today, approximately one third of AIDS-
KS tumors develop in patients on successful long-term HAART, i.e. with near normal 
T lymphocyte counts and undetectable HIV viral loads [Krown et al., 2008]. In sub-
Saharan Africa, KS ranks among the most common cancers overall since HIV turned 
the endemic form of this disease into an epidemic. By comparison to epithelial 
cancers, endothelial-lineage cancers are less common still, and most study 
endothelial cells because of their ancillary role in tumor angiogenesis rather than 
their role as the driving force of tumor formation. In KS, endothelial lineage cells 
drive tumor growth. Recent data suggest that tumor-associated stromal cells, 
including endothelial cells can acquire epigenetic or perhaps even genetic features 
of transformation, which in turn support tumor growth [Ghosh et al., 2008; Hu et al., 
2005; Qiu et al., 2008].  KS offers the opportunity to study endothelial cell 
transformation and tumorigenesis in detail, and microRNAs provide one possible 
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means of large-scale, stable epigenetic reprogramming. To test the hypothesis that 
microRNA signatures delineate progressive stages of endothelial cell transformation 
resulting in metastatic KS, we used high throughput, quantitative real-time PCR-
based micro RNA profiling. 
KS is tightly associated with Kaposi’s sarcoma associated herpesvirus 
(KSHV) [Chang et al., 1994; Gao et al., 1996; Martin et al., 1998]. Every tumor cell 
carries the virus and expresses at least the viral latent proteins [Dittmer et al., 1998; 
Dupin et al., 1999]. Here, we show for the first time using primary patient biopsies 
that every KS tumor transcribed the latent viral microRNAs (miRNA) as well.   
KSHV is also the etiological agent of the B cell lineage tumor primary effusion 
lymphoma (PEL), as well as the B cell lineage hyperplasia, plasmablastic variant of 
multicentric Castleman disease (MCD) [Cesarman et al., 1995; Soulier et al., 1995]. 
This dichotomous phenotype allows testing of the hypotheses that the miRNA profile 
for these two cancers reflect (a) their tissue of origin,  (b) progressive cancer 
signatures, (c) a signature induced by latent viral infection or (d) a combination of all. 
The miRNAs have emerged as master regulators of cell lineage differentiation 
and key modulators of cancer (reviewed in [Calin and Croce, 2006]).  They are 
small, 22 nucleotide non-coding RNA molecules that, upon incorporation into the 
cytoplasmic RISC complex, can inhibit translation of target messenger RNAs and 
ultimately target them for degradation (Figure 1A). At present, the Sanger database 
has recorded 678 human miRNAs [Griffiths-Jones et al., 2008] each capable of 
targeting up to several hundred different mRNAs. KSHV encodes multiple viral 
miRNAs [Cai et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005; Samols et al., 
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2005], including a viral ortholog to miR-155 [Gottwein et al., 2007; Skalsky et al., 
2007]. Even though some targets for these viral miRNAs have been identified 
[Samols et al., 2007], exactly how they function in KS tumorigenesis is unresolved.   
MiRNA profiling has provided invaluable insights into tissue development and 
cancer. Many tumor-specific and cell lineage-specific signatures have been 
compiled [Landgraf et al., 2007; Volinia et al., 2006; Yanaihara et al., 2006] and 
many others]. We previously established the miRNA signature for PEL [O'Hara et al., 
2008] using real-time quantitative PCR. We developed a comprehensive approach, 
which quantified miRNA gene copy number, pre-miRNA levels and mature miRNA 
levels using the same assay format. Here, we use this novel technology to discern 
pre-miRNAs that identify KS, KSHV infection and distinct, progressive stages of 
endothelial cell transformation. 
KSHV transforms primary human endothelial cells in culture [Flore et al., 
1998], though this is a rare event. KSHV infection consistently only leads to 
morphological alterations (“spindling”) and reduced growth factor dependence [Ciufo 
et al., 2001; Grossmann et al., 2006; Grundhoff and Ganem, 2004; Lagunoff et al., 
2002]. KSHV infection of immortalized human endothelial cells leads to extended 
survival, growth factor independence [Carroll et al., 2004; Moses et al., 1999; Wang 
and Damania, 2008] but not complete transformation, as defined by the ability to 
form tumors in nude mice. Importantly, during latent viral infection, lymphatic 
endothelial cell differentiation markers remain expressed, and if not already of 
lymphatic endothelial origin, KSHV is capable of inducing this phenotype in human 
endothelial cell preparations derived from tissues such as the vasculature [Carroll et 
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al., 2004; Hong et al., 2004; Wang et al., 2004]. KSHV infection per se does not 
induce dedifferentiation of lineage-committed lymphatic endothelial cells. A study by 
An et al succeeded in deriving two fully tumorigenic clones of lymphatic endothelial 
cells (TIVE E1 and TIVE L1) that maintain KSHV in the absence of selection [An et 
al., 2006]. Introduction of KSHV into murine endothelial progenitor cell preparations 
also resulted in the clonal outgrowth of at least one fully transformed cell line [Mutlu 
et al., 2007]. By contrast, attempts to culture tumor cells directly from KS lesions 
largely failed. Today, we have only a single KS tumor-derived cell line, SLK, which is 
fully transformed, but has lost the viral genome [Herndier et al., 1994]. Together with 
primary KS biopsies, these culture systems exemplify multiple stages of endothelial 
cell cancer progression (Table 1).  In this study, we used high throughput profiling to 
identify cell lineage and cancer progression stage-specific pre-miRNAs for this 
representative set of KSHV-infected and uninfected immortalized endothelial cells, 
KS biopsies and PEL lymphoma cell lines (Figure 1 B). 
 
Results 
Experimental Approach 
A total of 47 samples were selected for profiling at the DNA and pre-miRNA 
level (supplemental table 1).  These include all presently available PEL cell lines (n = 
14). Four KSHV-negative Burkitt’s lymphoma cell lines were included as controls 
and are expected to contain miRNAs that are common to B lineage lymphomas. The 
miRNA difference between these samples and PEL defines part of the PEL 
signature [O'Hara et al., 2008].  For this study, we added 9 tonsil tissues as a normal 
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tissue control.  These serve to determine which miRNAs are highly abundant in B 
cells, as tonsils consist of over 50% B cells, including germinal center (GC) B cells, 
which many assume to be the normal precursor of PEL [Fan et al., 2005; Klein et al., 
2003; Nador et al., 1996].  Two T-cell lymphoma cell lines were included to 
differentiate T cell miRNAs.  
For the first time, KS primary biopsies were also assessed for pre-miRNA 
transcription. We collected 9 AIDS-KS skin biopsies from the Americas. KS primary 
biopsies can contain multiple cell types due to inflammatory infiltrates, however, the 
majority of cells in a cutaneous KS biopsy are KSHV-infected endothelial cells 
[Dupin et al., 1999; Staskus et al., 1997; Sturzl et al., 1997].  
Two immortalized virus-negative endothelial cell lines were included in the 
arrays, as well as isogenic controls carrying latent KSHV [Wang and Damania, 
2008].  A similar model exists in the E1 TIVE and L1 TIVE cell lines [An et al., 2006].  
These currently represent the best human cell culture tumor model for KS, as these 
two cell lines induce KS-like tumors in nude mice with 100% efficiency.  Also 
included is the only known KS-derived cell line, SLK [Herndier et al., 1994], which 
has lost the KSHV genome, but is tumorigenic in mice. 
 
Tumor-associated genetic abnormalities in miRNA loci.   
To determine whether any of the human miRNA loci sustained genetic insults, 
we used real-time QPCR and primers directed against the pre-miRNA as described 
[O'Hara et al., 2008]. In this assay, a homozygous deletion will result in a loss of 
signal, a heterozygous deletion in a reduction in copy number and a gene 
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amplification in a copy number increase. After adjustments and normalization, the 
data were subjected to unsupervised cluster analysis. This separated KSHV-infected 
samples from uninfected samples based upon the presence of the KSHV miRNA 
gene locus (Figure 2).  Principal component analysis of the clustering confirmed that 
all clusters were non-overlapping (Supplemental Figure 1A) The viral EBV miRNA 
genes were detectable only in the EBV-positive PEL and BL cell lines, but not KS or 
any other samples. EBV miRNA genes were not detectable in normal tonsil tissue. 
Note that this representation emphasizes large differences. All  KSHV miRNAs were 
present in all KSHV-infected cells as determined by gel electrophoresis and 
sequencing; the apparent variation was due to SNPs, which affected the efficiency of 
primer annealing for some samples (O’Hara and Chugh, unpublished observation).  
The relative copy number for the KSHV miRNA genes was significantly lower 
in KSHV carrying endothelial cell lines compared to PEL. This is consistent with 
earlier reports that PEL carry more viral episomes (50 ~ 100 copies/ cell) than KS (~ 
10 copies/ cell) and KSHV-infected endothelial cell cultures [Boshoff et al., 1995; Li 
et al., 1996; Renne et al., 1996; Staskus et al., 1997]. Among the KSHV infected 
endothelial cell models, the HMVEC carried the highest KSHV genome number, 
suggesting that they are most capable of maintaining high levels of the KSHV 
episome. This is consistent with earlier studies showing that not all endothelial cells 
are equally permissive for KSHV infection, which drives reprogramming towards 
lymphatic endothelial cells [Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004]. 
 Whereas individual cell lines showed loss or gain of miRNA gene copy 
numbers as we noticed before [O'Hara et al., 2008], no specific deletions or 
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amplifications in miRNA gene loci that were present in all PEL lines in this sample 
could be identified, suggesting that the clustering was driven primarily by the KSHV 
and EBV DNA signals.  
To detect more subtle alterations, we therefore repeated the clustering 
without the viral-specific probes. Visual inspection yielded trends, but did not detect 
any alterations as obvious as the viral miRNA genes (data not shown). The large 
number of data points allowed us to test directly whether the copy number of any 
one miRNA was significantly altered in KSHV infected tissue (PEL, E1 and L1 TIVE, 
HUVEC+KSHV, HMVEC+KSHV) compared to normal tissue (Tonsil, HUVEC, 
HMVEC). We used the Welch-modified t-test to account for unequal variances 
between the KSHV infected (n= 53) and normal (n=18) dataset. After adjustment for 
multiple comparisons [Storey and Tibshirani, 2003], we identified 30 miRNA genes 
that were significantly altered (q ≤0.0001). We found miRNA genes that were 
increased in copy number, as well as miRNA genes that were decreased in copy 
number. Based on melting curve analysis, some cellular miRNA genes also 
contained SNPs (data not shown). As expected, this set included all KSHV miRNA 
genes, which served as positive controls, but not the EBV miRNA genes. The EBV 
miRNA genes define the limit of detection, since less than half of PEL in our 
collection were EBV positive, and no endothelial cells were EBV positive. Therefore, 
by inference, all cellular miRNA genes in this set of 30 (supplemental table 2) were 
significantly altered in the majority of KSHV infected samples.  
 
Unsupervised clustering reveals the pre-miRNA profile of KS  
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Our pre-miRNA data set, which included 160 primer pairs, representing 145 
cellular miRNAs, 9 viral miRNAs, 2 viral mRNAs and 4 cellular RNAs (U6), and 47 
samples consisted of > 20,000 individual data points.  QPCR measures target 
abundance on a 2log scale with higher CT numbers reflecting lower abundance. For 
the data, the average of the triplicate CT values was taken.  These were normalized 
to U6 levels, to give a normalized dCT value. Note that dCT values represent the 
underlying pre-miRNA levels on a 2log scale thus facilitating robust clustering [Eisen 
et al., 1998; Simon et al., 2003]. Following normalization, each sample set was Z-
standardized to remove any variation between samples [Cheadle et al., 2003; 
Troyanskaya et al., 2003].   
Figure 3 shows the heatmap representation after hierarchical clustering for 
the full panel of samples, with red indicating a higher level of expression and blue 
indicating a lower level of expression compared to the median of all data (white).  6 
distinct groups were identified. These represent the minimal number of non-
overlapping clusters based on principal component analysis (supplemental figure 
1B).  The first two groups represent the miRNAs that are unchanged across all 
samples, those with low levels of expression (I in blue) and the miRNAs with high 
levels of expression in all samples (II in red).  The KSHV miRNAs and mRNAs all 
cluster together in group III. Group IV represents the miRNAs that are 
downregulated in KSHV-positive infection.  20 miRNAs are represented in this 
group. Group V represents 11 cellular miRNAs highly expressed in the HUVEC and 
HMVEC cells, both uninfected and infected.  Interestingly, these cell types highly 
express a set of miRNAs that is distinctive to these untransformed cell lines.  These 
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miRNAs do not appear to be significantly enriched in any of the other endothelial cell 
types (KS or TIVE).  Finally, group VI contains cellular miRNAs that are 
downregulated in all B-cell lymphomas, including PEL.  
To remove the impact lineage-specific determinants [B cell  (PEL and Tonsil) 
vs. endothelial cell] from the analysis, we analyzed the two KSHV-associated cell 
types separately. Our analysis of PEL specific miRNAs was previously published 
[O'Hara et al., 2008] and analysis of the extended data set confirmed this 
observation (data not shown). When the endothelial-derived subset of samples was 
analyzed alone, a clearer picture emerged that highlights similarities and disparities 
between different stages of endothelial cell transformation (Figure 4A).  The groups 
represent the minimal number of non-overlapping clusters based on principal 
component analysis, as shown in supplemental figure 1C.  The first two groups  (I 
and II) represent miRNAs with minimal discernable patterns across all samples—at 
least at the power of our analysis.  Blue indicates low levels while red indicates 
comparable high levels of miRNAs, vis-à-vis the median of all data in this set. This is 
not to say that pre-miRNAs did not exhibit any change between samples classes, 
only that these changes were smaller compared to others and therefore less 
informative from a biomarker perspective. For example, mir-222 clusters in group II 
because it was more highly transcribed in all samples relative to other miRNAs. 
Nevertheless mir-222 was downregulated in KSHV-infected, tumorigenic samples, 
compared to EC. The pattern of mir-222 parallels that of mir-221, which is expected 
because of their known co-regulation [Galardi et al., 2007; Medina et al., 2008].  
However, the range of change was much larger for mir-221. 
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Group III shows the miRNAs that are upregulated upon KSHV infection of EC 
and even more in KS and in the tumorigenic L1/E1 clones.  This group includes the 
KSHV miRNAs along with the cellular miRNAs let-7a-1, let-7a-2, let-7a-3, mir-7-1, 
mir-27a, mir-125b-2, mir-140, mir-152, mir-181c, mir-194-2, and mir-220.  The 
detailed transcription pattern for this group is shown as a bar graph for miRNA let-
7a-3 (Figures 4B, all bar graphs show Z-standardized values of median dCTU6).  
To demark the degree of latent transcription, LANA mRNA levels are shown 
(Figure 4B). LANA is transcribed in all KSHV-positive samples but not the KSHV-
negative SLK, HUVEC or HMVEC cell lines. LANA mRNA levels correlated with 
increasing tumor-forming capability of the infected cells (p≤10-13 by ANOVA of linear 
model). They were lowest in KSHV-infected HUVEC and E1/L1 cells in culture, 
higher in E1 mouse tumors and KS lesions and highest in PEL (data not shown). 
This was mirrored by KSHV mir-K12-2 (Figure 4C). KSHV miRNA transcription 
levels correlated KSHV episome copy number (DNA) as measured by real-time 
QPCR using the same primer sets with DNA as input (data not shown). The positive 
correlation between the level of viral miRNA and the relative tumorigenicity of the 
sample class supports a causal role for miRNA in KS tumorigenesis. It further 
suggests that KSHV miRNAs are required to maintain the KS tumor phenotype. The 
alternative “hit and run” hypothesis that KSHV infection represents only the tumor-
initiating event, which is subsequently superseded by host genome alterations, is not 
supported by our data. 
Group IV is a set of 8 cellular miRNAs with upregulated expression in KS 
tumors only, compared to all other sample types. These include mir-24-2, mir-30c-2, 
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mir-125a, mir-130a, mir-196, mir-215, mir-218-2, and mir-367. The bar graph of mir-
24-2 levels in figure 4E serves as an example for the miRNA expression pattern of 
this group, where expression was highest in KS tumors and low in other samples 
even though they are KSHV-infected.   
Group V compromises a group of 13 cellular miRNAs with highest levels in 
the E1 and L1 TIVE cell lines. These pre-miRNAs were present at higher levels in 
E1/L1 cells even compared to KS biopsies. These are mir-17, mir-22, mir-28, mir-32, 
mir-128b, mir-135b, mir-143, mir-151, mir-181b-2, mir-205, mir-213, mir-216 and 
mir-372. The bar graph of mir-32 expression in figure 4F is an example of the 
miRNA expression pattern for this group.  
Group VI consists of 13 miRNAs with highest levels in the non-tumorigenic 
endothelial HUVEC and HMVEC cell lines, whether KSHV-infected or not. These are 
mir-26b, mir-29a, mir-34b, mir-92-1, mir-93, mir-133a-1, mir-133a-2, mir-193, mir-
221, mir-223, mir-301, mir-323 and mir-346. 11 of these miRNAs are the same as 
those found in the HUVEC/HMVEC upregulated cluster from the full data set (figure 
3).  Additionally, mir-34b and mir-92-1 fell into this group upon clustering of only the 
endothelial cell data. The histogram of mir-29a expression in figure 4G is an 
example of the miRNA transcription pattern for this group, with highest levels in both 
infected and uninfected HUVEC/HMVEC cells and significantly lower levels in all 
other samples.   
Group VII is the inverse of group VI and consists of miRNAs with lowest 
levels in the endothelial HUVEC and HMVEC, whether KSHV-infected or not.  This 
group compromises 11 cellular miRNAs: mir-7-2, mir-9-2, mir-30b, mir-107, mir-
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135a-2, mir-153-1, mir-153-2, mir-181b-2, mir-197, mir-325 and mir-370. The bar 
graph of mir-370 expression in figure 4H is an example of the miRNA transcription 
pattern of this group.  
In sum, unsupervised clustering as a discovery tool identified pre-miRNAs 
that signify distinct stages of endothelial cell transformation. Therefore we next used 
supervised classification methods to derive a minimal set of transformation-stage 
specific biomarkers for KS tumorigenesis. The success of this endeavor depends on 
high quality data from a large set of samples even more so than purely descriptive 
profiling.  
 
Quality Control 
Having obtained a clustering of miRNAs and samples, it is important to 
conduct rigorous technical and experimental controls to assure the validity of these 
results. Various methods of miRNA extraction have been developed, but few have 
been validated with regard to pre-miRNA profiling.  To monitor RNA integrity and 
yield, we used the Agilent bioanalyzer (Figure 5A-D).  The total RNA isolation with 
Triazol™ retained the highest concentration of miRNAs (20.5 pg/µl) while preserving 
overall RNA integrity as measured by RIN value (9.7).  Subsequent high molecular 
weight RNA depletion (HMWD) as required for other profiling approaches (e.g. 
[Thomson et al., 2004]) depleted mRNA and rRNA, as expected, but also decreased 
overall small RNA yield (10.5 pg/µl).  Hence, we used total RNA for all further 
studies (see supplemental table 3 for additional details). 
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We used real-time QPCR to determine individual pre-miRNA levels as per our 
published procedures [O'Hara et al., 2008]. Individual miRNA CT readings were 
normalized to CT of U6 rRNA ( CTU6 ). Hence, it was critical that U6 rRNA levels for 
each sample were comparable, since otherwise the reverse transcription reaction 
may be saturated or, in case of diluted samples, of lower than expected efficiency.  
Figure 5E shows comparable average CTU6 values for each DNA sample, 
aggregated by sample class.  Variation is minimal except for one PEL (AP3).  Two 
tonsils were considered outliers (T 176 and T 200), though given the tight grouping 
of the remaining 3 samples we considered them within usable range.   Figure 5F 
shows average CTU6 values for each cDNA sample, aggregated by sample class.  
Again, variation is minimal except for two outliers (HMVEC and KS 101), for which 
we had only small amounts of RNA available.   
All experimental samples were run in triplicate for RT-positive and DNA 
reactions.  Pooled samples were run in triplicate for RT-negative control reactions.  
Non-template control (NTC) reactions were run to assure that the primers were free 
of contamination and did not yield non-specific products or primer dimers at a 
significant rate. A reaction was considered positive if the corresponding CT was 
greater than 38.00 cycles.  To remove primers with substantial capacity for primer 
dimer formation, any primer pair with mean CT <38.00 in the RT- or NTC reactions 
was omitted from further analysis.  This removed 8 cellular pre-miRNA and 1 viral 
miRNA primer pairs (KSHV-mir-k12-10a) from our original set [O'Hara et al., 2008].  
Conversely, any primer pair that failed to efficiently amplify the corresponding DNA 
target (mean CTDNA >38.00) was also omitted from further analysis. This filtering 
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removed 15 cellular pre-miRNA primer pairs, 1 viral miRNA primer (KSHV-mir-k12-
3). It also removed all no primer controls from the data set.  In all, the final array 
included 160 primer pairs, representing 145 cellular miRNAs, 6 KSHV miRNAs, 3 
EBV miRNAs, 2 KSHV mRNAs and 4 cellular rRNAs (U6).  These were run in 
parallel for each sample. The distribution of all data used in the analysis was as 
follows: for the NTC (Figure 5J), 203 of 5120 reactions (3.96%) of the reactions had 
a CT<38. These were randomly distributed across all samples and all primers.  For 
the RT- reactions (Figure 5G), 286 of 5920 (4.83%) of the reactions had a CT<38. 
Pair-wise comparison of the RT- and NTC results indicated perfect overlap between 
the positive samples indicating these were incidences of shared positivity and should 
therefore only be counted once (data not shown).  Therefore the false positive rate 
was 4.83%.  In the DNA samples (Figure 5I), 12,567 of 13,920 (90.28%) of the 
reactions had CT<38.  Given that less than 5% of the total number of reactions 
represent viral targets, the presence of which is variable from sample to sample, the 
remaining negative values most likely indicate deletions of miRNAs in certain 
samples. The distribution was unimodal and followed a normal distribution (data not 
shown). Finally, the RT-positive (Figure 5H) set contained 8,299 of 20,000 (41.50%) 
positive reactions (CT <38) in total.  These are less than half the positive reactions 
recorded for the corresponding DNA results.  This means that although we could 
detect 86% of all miRNA genes (DNA) in all samples, only 45.54% were actively 
transcribed in our set of samples.   This is likely due to a combination of factors, 
including tissue type and developmental stage. For instance, we would not expect 
liver or brain-specific miRNAs to be present in any of our samples.  
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One of the concerns in profiling cell lines in culture is that the transcription 
signature may be reflective of a particular proliferation state rather than a general 
characteristic of the tumor subtype. Cell cycle dependence is well documented for 
mRNA levels in fibroblasts [Iyer et al., 1999]. For several miRNAs, too, cell cycle and 
miRNA transcription rates are linked [Chang et al., 2007; Hwang et al., 2007; Linsley 
et al., 2007; Liu et al., 2008; Tarasov et al., 2007; Vasudevan and Steitz, 2007; 
Visone et al., 2007]. To guard against this fallacy, we only used RNA derived from 
log-phase cells for our profiling analysis. Nevertheless, to test the hypothesis that 
some miRNA levels were proliferation state dependent, we conducted a time course 
experiment for the E1 and L1 TIVE cell lines. Both cell lines exhibited identical 
growth behavior in culture (Figure 6A), which we divided into a logarithmic (0-48 hrs) 
and stationary (72-120 hrs) phase. Each phase contained 3 time points. Within each 
phase the median SD was < 1 CT unit, i.e. the biological replicates were extremely 
reproducible.  
We then conducted pair-wise comparisons of the two cell lines and the two 
growth phases.  Very few pre-miRNAs were differentially regulated: mir-302b-2, mir-
328 and mir-335 were detectable in stationary L1 cells, but not logarithmic growing 
L1 cells (Figure 6B).   Viral mRNA Kaposin was also seen as differentially regulated 
in this comparison. These were not differentially regulated in E1 cells and therefore 
Kaposin, mir-302b-2 and mir-335 also stand out in the E1 to L1 stationary 
comparison (Figure 6D). In E1 cells, pre-miRNAs KSHV-mir-K8 and mir-133b 
differed significantly between logarithmic and stationary phase (Figure 6C), with mir-
133b standing out in the E1 to L1 logarithmic comparison (Figure 6E).  Mir-27b also 
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was significantly altered between E1 and L1 logarithmic comparisons, however its 
expression was similar enough within cell lines that it was not previously detected as 
differentially regulated. By and large, the L1 cell line showed a wider variation then 
the E1 cell lines. Lastly, we conducted unsupervised clustering (supplemental figure 
2). This revealed some growth stage dependent pre-miRNAs, but they were all at 
the lower limit of detection and thus the biological significance of this pattern is not 
clear. 
 
miRNAs as endothelial cell tumor stage biomarkers.  
Unsupervised comparisons represent the first level of profiling studies. Here, 
they revealed (i) the existence of multiple distinct steps of endothelial cell 
transformation and (ii) pre-miRNAs that were selectively transcribed in one or more 
stages and that therefore may serve as candidate biomarkers.  These will now be 
validated by supervised class prediction methods. Based upon pre-miRNA clustering 
(Figures 3 and 4) and published phenotypic analyses (summarized in table 1), we 
defined and then analyzed the following classes: Endothelial cells (EC), KSHV-
infected endothelial cells (ECK), endothelial cells that have the ability to form tumors 
in nude mice (ECT, which includes the KSHV-positive TIVE- E1, L1 cell lines as well 
as KSHV-negative SLK cells), 5 independent xenograft tumors of TIVE- E1 cells 
(ECTUM), KS patient biopsies (KS), PEL, and as negative controls tonsil (TON) and 
non-KSHV associated lymphomas (TUM).  
 First, we conducted pair-wise comparisons between classes using the median 
dCT for each class (supplemental figure 3). The two TERT-immortalized EC cell 
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lines HUVEC and HMVEC exhibited a nearly identical pre-miRNA transcription 
pattern (r2 = 0.7238).  Infection with KSHV of these immortalized cell lines did result 
in changes (r2 = 0.6798). Of note, this comparison is between median levels for the 
two EC cell lines (HUVEC and HMVEC) and three independent clones of tightly 
latently infected TERT-HUVEC cells. Thus, it exhibited more variability than a pair-
wise comparison of just two cell lines.  
The most drastic change in overall pre-miRNA transcription emerged when 
comparing KSHV-infected, non-tumorigenic EC cell lines to the two KSHV-infected, 
highly tumorigenic E1/L1 cell lines. Here, we failed to detect any linear correlation. 
The two TIVE cell lines E1 and L1, of course, exhibited a strikingly similar pattern of 
pre-miRNA transcription as shown in detail in figure 6 and supplemental figure 3. 
The pair-wise comparison between E1/L1 cells in culture to E1 xenograft tumors 
showed a reasonable linear correlation, but less than between different culture 
models (r2 = 0.5684). Analysis of residuals identified all KSHV miRNAs as well as 
mir-223 to be significantly upregulated in the tumorgraft (data not shown). Since 
there are no human infiltrating lymphocytes in the SCID mouse model, and since the 
tumor vasculature is made of murine endothelial cells, any changes in pre-miRNA 
composition reflect the grafted human tumor cells.  
Importanly, the comparison between E1 xenograft tumor biopsies and patient 
KS biopsies yielded a better correlation (r2 = 0.5846) than between E1/L1 cells in 
culture and E1 tumor grafts. This reinforces the results of the phenotypic 
characterization of E1/L1 cells [An et al., 2006] and demonstrates that the E1/L1 
xenograft model adequately mimics primary KS patient biopsies.  
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 Next, we identified and validated a set of diagnostic pre-miRNA biomarkers 
that signify the different steps of endothelial cell transformation. To give a better 
impression of within class variability, Figure 7 A-D plots individual dCTU6 for cellular 
pre-miRNAs including technical replicates for each class.  
 Mir-221 emerged as a biomarker for the transition from immortalized to 
tumorigenic endothelial cells independent of KSHV infection status (Figure 7A). Mir-
222 was co-regulated with mir-221, but did not change as dramatically (data not 
shown). Since mir-221/222 exhibit tumor suppressor activity in endothelial cell and 
prostate cancer models [Galardi et al., 2007; le Sage et al., 2007; Medina et al., 
2008; Poliseno et al., 2006], this suggests that the down-regulation of the mir-221 
biomarker is of biological significance. 
 Mir-15 exhibited the opposite pattern of transcription as mir-221. It was high in 
tumorigenic KSHV-infected endothelial calls, KS and PEL (Figure 7B). There was 
one significant difference between mir-15 and mir-221 expression: the KSHV-
negative SLK cells transcribed significantly lower levels of Mir-15 (asterisk in Figure 
7B). In a separate analysis of only the endothelial/KS sample and excluding SLK 
cells (data not shown), mir-15 levels correlated closely with KSHV latent mRNA and 
miRNA transcription and can thus be considered KSHV –regulated. 
 Mir-140 levels correlated linearly with tumor status. It was present at 
appreciable levels only in E1 tumors (Figure 7C, class ECTUM) and KS, but not 
E1/L1 cells (Figure 7C, class ECTUM ECT).  By contrast mir-140 levels did not 
distinguish tonsil and PEL, since 50% of PEL lines as well as all KSHV-negative 
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lymphoma lines had only very low levels of mir-140. Hence, the utility of mir-140 as a 
biomarker is limited to the endothelial lineage, but not lymphatic lineage cancers. 
 Mir-24-2 levels were strikingly elevated only in KS biopsies, not E1 xenograft 
tumors or PEL (Figure 7D). It therefore serves as a KS-specific biomarker and not as 
a marker for KSHV-associated transformation. This may have utility for clinical 
diagnosis, but more importantly it represents at least one molecular difference 
between clinical KS lesions and all available tissue culture models. In other words, 
any of the KS-specific mir-24-2 dependent reprogramming of target mRNA and 
protein levels is not captured in our current, laboratory-based understanding of KS 
and KSHV biology. 
 To establish the utility of these four biomarkers for endothelial cell 
tumorigenesis, we calculated cumulative density distributions (cdf) (Figure 7E-H) 
and finally a decision tree. Mir-221, mir-24.2 and mir-15a showed a step curve, 
which allowed for classification into positive and negative samples. Mir-140 showed 
an almost linear cdf consistent with gradual changes among multiple sample 
classes. This is reflected in the minimal decision tree (Figure 7I) that distinguishes 
between all samples based on cut-off levels for just three miRNAs. Mir-15a is not 
present in the tree, since it is redundant to mir-221 and thus does not contribute 
additional classification power. Likewise, similar decision trees can be built using 
other representative miRNAs from each of the clusters identified in figure 4, but were 
not quite as accurate.  
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 In sum, supervised classification established (a) the presence of molecularly 
distinct, progressive steps of endothelial cell transformation and (b) a minimal set of 
biomarkers that distinguishes between these steps. 
 
Discussion 
Pre-miRNA profiling   
 Mature miRNA profiling has previously been used to stratify lineage types and 
disease progression stages. Pre-miRNA profiling likewise has been used 
successfully to stratify human tumors [Jiang et al., 2005; Lee et al., 2008; Lee et al., 
2007]. We previously profiled pre- and mature miRNA for PEL [O'Hara et al., 2008] 
in order to establish a cancer signature. Here we have ascertained the first pre-
miRNA profile of KS, based upon primary patient biopsies and validated pre-clinical 
models.   
At the genomic level, we found a variety of changes between different cell 
lines and tissue types, but no deletions or amplifications common to all KS biopsies 
or KSHV-positive samples.  At the pre-miRNA level, there are groups of cellular 
miRNAs that define distinctive tissue types.  QPCR has been shown to be an 
effective form of miRNA profiling.  Northern blotting has limitations including low 
throughput and poor sensitivity.  Alternative high throughput profiling methods, like 
cDNA micro-arrays require high concentrations of input target, poor sensitivity for 
rare targets and the need for post-array validation, likely through QPCR.  Therefore, 
QPCR appears to be the best method and can be applied easily on a pre-miRNA 
level.  Previous studies have also indicated that, in general, pre-miRNA expression 
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levels can be used to determine mature miRNA expression levels.  In non-cancerous 
and cancerous colorectal tissues, the precursors for 26 cellular miRNAs were 
equally expressed and expression of only 2 of the mature miRNAs were reduced in 
cancerous samples .  Since then, many other groups have published results 
indicating similar expression levels between pre-miRNAs and their corresponding 
mature miRNAs . Thus, pre-miRNA profiling has been validated as both appropriate 
and relevant for tumor classification. 
The miRNA genes are named according to the 60-80 bp sequence of the pre-
miRNA segment.  Each miRNA gene locus produces one pre-miRNA, which in turn 
can produce one or two mature miRNAs depending on whether both strands of the 
mature product are found to be functionally inserted into the RISC complex. While all 
miRNA genes, and therefore all pre-miRNAs, are made of unique sequence, 
different premiRNAs are processed to the identical mature 22 nt miRNA.  For 
instance, there are 3 different let-7a genes: let7-a-1, let-7a-2 and let-7a-3.  Each is 
found in a different location of the genome (chromosome 9, 13, and 22, 
respectively), contains a unique sequence in the base of the hairpin and in the loop 
and has the potential for differential transcriptional regulation.  As a result, each of 
these genes makes a unique pre-miRNA product, which we detected with unique 
QPCR primers.  However, each of these precursors makes the identical mature 
miRNAs, known simply as let-7a and let-7a* (depending on which strand is 
incorporated into the RISC).  Each of the strands of the mature miRNA were found 
to be functional, hence two mature products with different seed sequences stem 
from any one of three different genes.  
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 How well do pre-miRNA levels correlate with mature miRNA levels? This 
seemingly simple question has a non-trivial answer. (i) The majority of studies show 
that pre-miRNA levels correlate well with mature miRNA levels [Jiang et al., 2005; 
Lee et al., 2008; Schmittgen et al., 2004; Schmittgen et al., 2008]. However, there 
are well-documented instances, where SNPs affect Dicer processing [Duan et al., 
2007; Gottwein et al., 2006]. These exceptions are informative in their own right and 
only simultaneous quantification of pre- and mature miRNA levels can identify these. 
(ii) The two assays measure two different events and thus provide non-redundant 
information. The pre-miRNA pool represents an intermediate step and thus responds 
directly and without delay to changes in cellular transcription. Pre-miRNAs are co-
transcriptionally processed [Cai et al., 2004; Morlando et al., 2008]. They have a 
short half-life much like mRNAs and thus provide a sensitive read-out for the 
purpose of tumor profiling. Mature miRNAs are part of the relatively stable RISC 
complex and thus provide a time-delayed read-out of the state of the cell. (iii) The 
two assays have different performance characteristics. Unfortunately, these are 
different for each miRNA (presumably sequence dependent) as exemplified in 
supplemental figure 3. Even though relative levels of pre- and mature miRNAs 
correlate well, the QPCR-based assays for pre- and mature miRNAs have different 
sensitivities and varying ability to distinguish between the presence and absence of 
a particular miRNA. In toto, pre-miRNA profiling provides for an independent tumor 
classification from mature miRNA profiling; it identifies unique target miRNAs as 
biomarkers. Many of these will correspond to results obtained by mature miRNA 
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profiling, but the predictive power and sensitivity may vary for individual miRNA 
species. 
 
Pre-miRNA profiling defines progressive stages of endothelial cell transformation. 
 In the case of KS and its related endothelial infected cell models, each group 
(KS, E1 and L1 TIVE, and the HUVEC/HMVEC group) had a distinctive cellular 
miRNA profile.   
Even though we found some differences in the transcription pattern between 
individual KSHV miRNAs (unpublished), the KSHV miRNA levels as a group 
correlated with increasing tumor-forming capability of the infected cells (p≤10-10 by 
ANOVA of linear model). They were present in KSHV-infected HUVEC clones, high 
in E1/L1 cells in culture, higher in E1 mouse tumors and KS lesions and highest in 
PEL. Of note, the non-tumorigenic EC clones were made with JSC-1 derived KSHV 
[Vieira and O'Hearn, 2004], whereas TIVE E1/L1 clones were made from BCBL-1 
derived KSHV [An et al., 2006]. There are also sequence differences between these 
two cell lines that may affect our pre-miRNA assay [Marshall et al., 2007]. 
In addition to the viral miRNAs, all KSHV-infected cells had high levels of the 
cellular miRNAs let-7a-1, let-7a-2, let-7a-3, mir-7-1, mir-27a, mir-125b-2, mir-140, 
mir-152, mir-181c, mir-194-2, and mir-220. Together these data support a model of 
KSHV disease progression through the model cell lines (Figure 8).   Immortalized 
endothelial cells (tertHUVEC and tertHMVEC) are infected with KSHV.  Both the 
uninfected and infected endothelial cells share common pre-miRNA profiles (Figure 
3 Group V and figure 4A Groups VI and VII), however the infected cells now express 
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low levels of KSHV miRNAs as well as a distinct group of cellular miRNAs (Figure 
4A Group III).  These infected cells are now able to grow in reduced serum, 
indicating the virus has a transformative effect on the cells, however these cells do 
not form tumors in mice and are therefore not oncogenic.   The viral life cycle in 
these cells remains tightly latent. The E1 and L1 TIVE cells are infected cells that 
have undergone a second transformative event.  These cells are capable of forming 
tumors in mice.  The E1/L1 TIVE cells express relatively intermediate levels of KSHV 
miRNAs (Figure 4A Group III) and a distinctive group of pre-miRNAs (Figure 4A 
Group V).   While these cells are highly transformed, similar to KS, the life cycle of 
the virus is still tightly latent.  KS expresses the highest level of KSHV miRNAs, as 
compared to other infected cell types (Figure 4A Group III).  It expresses a third 
distinctive group of pre-miRNAs that are highly upregulated in KS specifically (Figure 
4A Group IV) and continues to express a second set of the same miRNAs that were 
highly induced upon KSHV infection in the HUVEC/HMVEC cells (Figure 4A Group 
III).  Unlike the previous cell culture models, KS has a number of infected cells 
undergoing spontaneous lytic reactivation.  Overall, it is observed that expression of 
KSHV miRNAs increases with disease progression through the model.  Each cell 
type profiled has a unique set of highly expressed cellular miRNAs, independent of 
the presence of virus, and a second set of commonly expressed miRNAs that is 
dependent on the presence of virus.  Given that the cell models are pure cultures of 
cells while primary KS biopsies are a mixture of cells, it is possible that some of 
these miRNA expression differences are due to other infiltrating cell types.  
However, given that the overall input amount of sample is identical in each reaction 
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and the extremely high level of KSHV transcript expression in the KS biopsies, any 
additional cells in the biopsy are likely infected and therefore contributing to the 
tumor microenvironment. 
 
Individual miRNAs emerge as novel tumor-stage specific biomarkers with important 
biological functions.   
Mir-221 is a tumor suppressor for endothelial cell lineage cancers 
independent of KSHV infection. We found the highest levels of Mir-221 in uninfected 
and KSHV latently-infected HUVEC and HMVEC cells.  This corroborates prior 
reports of high mir-221 levels in endothelial cell lines [Kuehbacher et al., 2007; 
Poliseno et al., 2006; Suarez et al., 2007].  High levels of mir-221 exert anti-
angiogenic effects in HUVEC cells, resulting in inhibited tube formation, migration 
and wound healing [Poliseno et al., 2006].  This anti-angiogenic effect correlated 
with downregulation expression of the mir-221 target protein c-kit [Poliseno et al., 
2006]. In Dicer siRNA-transfected cells, mir-221 expression has been shown to 
indirectly downregulate expression of endothelial nitric oxide synthase (eNOS) 
[Suarez et al., 2007].  Nitric oxide is a key regulator of endothelial cell growth, 
migration, vascular remodelling and angiogenesis.  Furthermore, depletion of mir-
221 in HUVEC cells caused secondary changes in other miRNA expression levels 
[Poliseno et al., 2006; Tuccoli et al., 2006]. These downregulated miRNAs included 
many that are also predicted to target c-kit. All in all, mir-221 seems to possess 
endothelial cell lineage-specific differentiation functions as well as general 
tumor/proliferation suppressor functions. These also surface in the other cancers 
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and cell lineages. Disregulation of mir-221 has been found in melanomas due to 
silencing of the promyelocytic leukemia zinc finger (PLZF) transcription factor 
[Felicetti et al., 2008]. C-kit expression was also reduced by mir-221 in 
haematopoietic progenitor cells.  In this system, too, mir-221 inhibited proliferation 
[Felli et al., 2005]. Additional targets for miR-221 include CDKN1B/p27 and 
CDKN1C/p57, which are cell cycle regulators [Fornari et al., 2008; Galardi et al., 
2007; le Sage et al., 2007; Visone et al., 2007].  Dual down-regulation of p27 and c-
kit results in enhanced proliferation and differentiation blockade of the melanoma 
cells [Felicetti et al., 2008].  
Mir-34 is present in endothelial cells, PEL and KS as these tumors retain wild-
type p53.  We found high levels of pre-miR-34 in KS and PEL. The miR-34 promoter 
is p53 responsive [Chang et al., 2007; Corney et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007; Welch et al., 2007] and high levels of miR-
34 are consistent with the biology of PEL and KS, which are unusual among human 
cancers because they almost universally retain fully functional, wild-type p53 
[Katano et al., 2001; Petre et al., 2007]. Three different miR-34 genes are present in 
the human genome.  Mir-34a is located within the second exon of a non-coding 
gene, which contains a predicted p53-binding site.  Genes mir-34b and mir-34c are 
located within a single non-coding precursor with a transcriptional start site adjacent 
to a predicted p53 binding site [He et al., 2007].  All three genes produce mature 
miRNAs with an identical seed sequence; the remaining nucleotides are not 
conserved. Of all three p53 responsive miRNAs, mir-34a appears to be the most 
responsive in terms of fold change [Tarasov et al., 2007]. Upon activation by p53, 
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mir-34a is responsible for post-transcriptional gene silencing of multiple targets, 
including CDK4, CDK6, and CyclinE2.  It will be interesting to determine whether 
mir-34a, similar to p53-responsive mRNAs [Petre et al., 2007], can be even further 
induced upon chemotherapy in PEL and KS. 
We found down-regulation of the let-7 miRNA family. This family had 
previously been assigned a growth suppressive function [Johnson et al., 2005; 
Takamizawa et al., 2004] and is commonly downregulated in human cancer.  Except 
for the let-7a miRNAs, expression of the let-7 miRNA family is downregulated. K-
Ras, N-Ras and H-Ras are known targets of the let-7 miRNAs [Johnson et al., 
2005].  In addition to RAS, the let-7 family also targets cell-cycle regulators CDK6 
and CDC25A [Johnson et al., 2007].  The MYC oncogene has also been found to be 
a target of let-7 [Sampson et al., 2007].  Decreased let-7 expression provides a 
means for increased expression of these oncogenes.  
As noted before, let-7a expression is increased upon KSHV infection.  At this 
point we do not know the precise molecular mechanism.  Methylation status has 
been correlated with altered levels of miRNA expression.  DNA hypomethelation has 
been noted at the let-7a-3 loci resulting in an increase in let-7a expression in lung 
adenocarcinomas [Brueckner et al., 2007].  let-7a miRNA expression is upregulated 
upon IL-6 expression [Meng et al., 2007].  As high human IL-6 levels are a signature 
of PEL and KS [Brockmeyer et al., 1999; Drexler et al., 1999; Foussat et al., 1999; 
Jones et al., 1999; Sin et al., 2007] and since KSHV encoded a viral homolog to 
human IL-6 [Moore et al., 1996; Neipel et al., 1997; Nicholas et al., 1997; Staskus et 
al., 1999], this constitutes a possible autocrine feedback mechanism. 
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Mir-140 is tightly correlated with KSHV latent protein and latent miRNA 
transcription in KS and KS tumor models.  Mir-140 was highly expressed in KS, as 
well as KS tumor models.  Currently, little is known regarding mir-140 expression 
profiles or possible mRNA targets [Tuddenham et al., 2006]. TargetScan miRNA 
target software indicates a number of possible targets for mir-140, including E2F3, a 
member of the E2F family of transcription factors essential for cell cycle regulation.  
This prediction, however, awaits experimental verification. 
Mir-24 emerged as a high specific KS biomarker. Mir-24 has been shown to 
be important in cell-cycle regulation, cell growth and differentiation in a variety of cell 
types [Merkerova et al., 2008; Wang et al., 2008b]. Though these as well as 
functional studies on mir-24 and its targets are still in the early staged. Tantalizing 
connection exists to p16 and dehydrofolate reductase among others [Cheng et al., 
2005; Lal et al., 2008; Mishra et al., 2007; Sun et al., 2008; Wang et al., 2008a]. 
In sum, our pre-miRNA profiling of primary KS tumor biopsies and the 
comparison to well-studied culture and mouse xenograft models of KS yielded a 
progression model for endothelial lineage cancer (Figure 8) akin to the no classical 
model for colorectal cancer progression [Fearon and Vogelstein, 1990]. We hope 
that this will benefit basic and translational studies of KS, which remains the most 
frequent cancer in people living with HIV/AIDS today. We also identified specific 
KSHV and KS-associated miRNA, foremost among them mir-221, mir-140, mir-15a 
and mir-24. Based upon their strength of association with specific stages of 
endothelial cell tumor progression we speculate that these are also functionally 
involved in KS tumorigenesis.   
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Materials and Methods. 
 
Cell Culture and clinical biopsies.  
Cells were grown in continuous culture on a 3T3-like schedule, i.e. passaged 
at subconfluency, and RNA collected in log phase, typically 24 - 48 hrs after 
reseeding. All B and T cells were cultured in RPMI containing 25mM HEPES, 10% 
fetal bovine serum (AP2, AP3, AP5 in 20%), 0.05 mM 2-mercaptoethanol, 1 mM 
sodium pyruvate, 2 mM L-glutamine, 0.05 ug penicillin/mL, and 20 U 
streptomycin/mL at 37° and in 5% CO2.  TIVE cells were cultured in DMEM 
containing 10% fetal bovine serum, 2 mM L-glutamine, 0.05 ug penicillin/mL, and 20 
U streptomycin/mL at 37° and in 5% CO2.  HUVEC-hTERT cells were cultured in 
EGM-2 containing 10% fetal bovine serum, hydrocortisone, hRGF, VEGF, R3-IGF, 
Ascorbic acid, hEGF, GA-1000 and heparin at 37° and in 5% CO2.  HUVEC+KSHV 
cells were cultured in the same media also containing 0.5pM/ul puromycin to 
maintain selection.  De-identified frozen tonsil and melanoma tissue biopsies were 
obtained from the cooperative human tissue network (CHTN).  KS frozen tissue 
biopsies were obtained after informed consent at University of Miami, Prof. Edgard 
Santos University Hospital, Salvador, Brazil and Beth Israel Deaconess Medical 
Center.  All cell lines and references are described in supplemental table 1. 
 
DNA and RNA isolation 
  101 
   
DNA was isolated from cell lines and samples using the Wizard SV Genomic 
kit (Promega, Madison, WI).  Total RNA was isolated using Triazol (Sigma-Aldrich, 
St Louis, MO) as previously described. Total RNA was quantitated on a Nanodrop 
and equal amounts of RNA were subjected to DNase I treatment (Ambion, Austin, 
TX).   RNA was reversed transcribed using the cDNA Archive Kit (Applied 
Biosystems, Foster City, CA), with the addition of RNase Inhibitor and, in pre-miRNA 
screening, the additions of T4 gene protein 32.  RNA integrity was evaluated using a 
2100 Bioanalyzer Series C (Agilent, Santa Clara, CA).  Total RNA was measured 
using the RNA 6000 Series II Nano kit and small RNA was measured using the 
Small RNA kit, according to the manufacturers recommendations.  All Chips were 
analyzed using 2100 Expert software version B.02.04.  The average RNA integrity 
value for total RNA among all samples profiled was 8.00 ± 2.60. 
 
Real-time QPCR 
For DNA and pre-miRNA expression profiling, two 96-well plates containing 
372 different primers were used.  These primers represent 168 cellular and 12 viral 
pre-miRNA targets, as well as 6 cellular and viral control miRNA targets.  All primers 
conform to universal real-time PCR conditions with a predicted Tm of 60 and 100-bp 
or smaller amplicon length.  Real-Time QPCR was conducted under universal 
cycling conditions of 40 cycles with SYBR Green as the method of detection 
following our previously validated methods.  A 36ul reaction mix was made using a 
CAS-1200 robot that uses filtered carbon-graphite pipette tips (Tecan, Durham, NC) 
for liquid level sensing, allowing for a pipetting accuracy of 0.1ul.  The reaction mix 
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was then distributed in triplicate into a 384-well plate using a Matrix repeat pipettor 
(Thermo Inc.).  The final primer concentration was 250nM in total of the 9ul reaction 
volume.  Because pre-miRNA-specific primers also detect the corresponding gene, 
these primers were used for DNA gene profiling as well.  For DNA QPCR, each 
reaction contained 1.67ng DNA/ul.  For pre-miRNA QPCR, 40ul of the 100ul RT 
reaction was used for each 384 well plate, yielding a final amount of 0.1ul cDNA per 
each 9ul reaction.  Real-time QPCR primers against 93 mature miRNAs and 1 
cellular mRNA were used according to the manufacturers protocol (Applied 
Biosystems).  The combined pipetting and instrument error for all of the QPCR 
reactions was less than 6% (data not shown).  All reactions were done in technical 
triplicates. 
 
Statistical Analysis 
Data were collected in triplicate for each RT reaction. Since averaging these 
replicates would mask individual reaction failures, we clustered all replicates 
individually after masking outliers. Each array of 160 primers contained four 
separate reactions for U6 yielding six CTU6. We calculated the mean and median of 
these four reactions to yield ^CTU6.  The maximal difference between mean and 
median was 0.30 CT units. All other CT data were normalized to ^CTU6. This yielded 
dCT for each primer/sample combination. The dCT were normalized to median for 
each array and subjected to unsupervised clustering using a Correlation metric 
[Eisen et al., 1998] and the program Arrayminer. 
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Our exploratory cluster analysis included all primers and all samples. 
However, for statistical analysis we excluded primers, which yielded CT < 38 for the 
non-template and reverse transcriptase negative controls. We also excluded 
primers, which did not yield a signal (CT<38) in at least one of the samples as 
uninformative. We used QQ plots for each sample and Kolgomoroff-Smirnoff 
statistics to test for normal distribution across arrays (data not shown).  
For miRNA gene copy number analysis, data were collected in triplicate (or 
duplicate) for each sample. Since averaging these replicates would mask individual 
reaction failures, we clustered all replicates individually after masking outliers. Each 
set of 160 primer pairs contained four separate reactions for U6 yielding four CTU6. 
We calculated the mean of these four reactions to yield ^CTU6.  In only two samples 
did the median deviate significantly from the mean based on an analysis of residuals 
(data not shown). This suggested individual reaction or pipetting failures. We 
imputed modified ^CTU6 for those singular cases based on the following rule: if <50% 
of replicates differed by >1 CT from the mean of the remainder, they were replaced 
by the mean of the remaining data points. After imputation, the mean ^CTU6 across 
all samples and all technical replicates (n= 348) was 20.94 ± 1.97 with a median of 
21.26. For individual quadruplicate CTU6 measurements, the SDs ranged from 0.03 
to 1.00 CT. 71.26% of SDs for technical replicates were ≤ 0.32 CTs. Hence, this 
array identified 2-fold changes in copy number. All other CT data were normalized to 
^CTU6. This yielded a dCT for each primer/sample combination. The dCT were 
subjected to unsupervised clustering using an Euklidian metric and visualized on a 
log2 scale[Eisen et al., 1998]. 
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For supervised comparisons between two classes, we used the Welch-
modified t-test as implemented in the R statistics program [Maindonald and Braun, 
2007]. This yielded unadjusted, univariate p values for each individual miRRNA 
gene. This particular variant of the t-test allows for unequal variances between the 
two classes. An analysis of variances showed that most miRNA genes had identical 
variances between the KSHV-infected (n= 53) and normal tissue (n=18) data sets. 
We used q-value computation [Storey and Tibshirani, 2003], to assess the false 
discovery rate. Supplemental table DNA only reports the minimal set of miRNA gene 
loci (30 out of 156 or 19.23%), in which we do not expect any false positives. The 
Bonferroni-adjusted p-value was ≤0.01 for each of these 30 genes. 
The statistical methods for supervised comparisons between two classes of 
pre-miRNAs were as described above for miRNA gene loci. We only report the 
minimal set of miRNA genes for which we do not expect any false positives. The 
Bonferroni-adjusted p-value was ≤0.05 for each of the hits. 
 
Notes 
 This paper was submitted to PLoS Pathogens on November 3, 2008. 
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Figure IV.1 Experimental Approach 
  (A) As shown, DNA, primary miRNA (pri-miRNA) transcripts and precursor 
miRNA (pre-miRNA transcripts) are all present in the nucleus of the cell.  Each of 
these species can be detected using a set of traditional primers and SYBR green, 
however detection of the pri-miRNA and pre-miRNA are RT-dependent.   The 
mature product is exported from the nucleus of the cell.  Using a unique commercial 
array from ABI, this species can be detected using Taqman probes, following a 
reverse transcriptase reaction. (B) Profiling of miRNAs follows the diagram as 
shown, with both DNA and pre-miRNAs being screened with an identical set of 160 
primer pairs and mature miRNAs being screened with a subset of miRNAs found to 
be of interest in any results. 
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Figure IV.2: MiRNA gene locus assessment. 
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 Shown is a heatmap, with blue indicating low levels of signal, white 
intermediate, and red high levels of signal when comparing across all primer pairs.  
The horizontal axis indicates samples (shown in replicates): PEL indicates PEL, B 
indicates KSHV-negative B cell lymphoma, T indicates T cell lymphoma, Tonsil 
indicates tonsil and Endothelial indicates all endothelial culture cell models, including 
SLK, E1 and L1 TIVE, and infected and uninfected HUVEC and HMVEC cells.  
Additionally, viral status is shown, with + indicating KSHV-positive and – indicating 
KSHV-negative. The vertical axis indicates genomic miRNA location. Any change in 
relative color across the horizontal axis indicates an amplification or deletion.  Of 
note, the EBV miRNAs and KSHV miRNAs are featured for their obvious changes 
on the genomic level.  MiRNA loci indicated to be amplified or deleted are listed, 
along with genomic location, p-value and Bonferroni transformation in supplemental 
table 2. 
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Figure IV.3: Pre-miRNA profiling of all samples.   
 Shown is a heatmap, with blue indicating low levels of signal, white 
intermediate, and red high levels of signal, when comparing across all primer pairs.  
The horizontal axis indicates samples: PEL indicates PEL, B indicates KSHV-
negative B cell lymphoma, T indicates T cell lymphoma, Tonsil indicates tonsil and 
Endothelial indicates all endothelial culture cell models, including SLK, E1 and L1 
TIVE, and infected and uninfected HUVEC and HMVEC cells.  Additionally, viral 
status is shown, with + indicating KSHV-positive and – indicating KSHV-negative. 
The vertical axis indicates the pre-miRNA.  Groups I and II represent the miRNAs 
that are unchanged across all samples.  Group III indicates cellular and KSHV 
miRNAs induced upon KSHV infection. Group IV represents the miRNAs that are 
downregulated in KSHV-positive infection. Group V represents 11 cellular miRNAs 
highly expressed in the HUVEC and HMVEC cells, both uninfected and infected. 
Group VI contains cellular miRNAs that are downregulated in all B-cell lymphomas, 
including PEL.   The miRNA cluster results are summarized in Table 2. 
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Figure IV.4: Pre-miRNA profiling of primary KS biopsies and endothelial derived cell 
cultures.  
 (A) Shown is a heatmap, with blue indicating low levels of signal, white 
intermediate, and red high levels of signal, when comparing across all primer pairs.  
The horizontal axis indicates samples: KS indicates primary KS biopsies and 
Endothelial indicates all endothelial culture cell models, including SLK, E1 and L1 
TIVE, and infected and uninfected HUVEC and HMVEC cells.  Additionally, viral 
status is shown, with + indicating KSHV-positive and – indicating KSHV-negative. 
The vertical axis indicates the pre-miRNA. Groups I and II represent the miRNAs 
that are unchanged in all samples. Group III shows the cellular and viral miRNAs 
that are upregulated upon KSHV infection.  Group IV indicates viral and cellular 
miRNAs upregulated specifically in KS, group V for E1 and L1 TIVE, and group VI 
for uninfected and infected HUVEC and HMVEC cells.  Group VII are cellular 
miRNAs downregulated in uninfected and infected HUVEC and HMVEC cells.  All 
results are summarized in Table 3. Bar graphs representative of each group 
described are shown on the left (B-H).  All samples are shown in the same order as 
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the clustering, with KS representing primary KS biopsies and Endothelial indicating 
all endothelial  cell culture models profiled.  Again, viral status is also listed.  In the 
bar graphs, each cell type is divided by a black bar.   All bar graphs are dCTU6 
normalized and Z-standardized.  (B) Lana expression is high in all KSHV-positive 
cell lines and not present in KSHV-negative cell lines.  (C) KSHV-mir-K2 is 
upregulated in all KSHV-positive samples, with the highest level of expression in 
primary KS biopsies, intermediate in E1 and L1 TIVE cells and lowest in infected 
HUVEC and HMVEC cells.  (D) Cellular miRNA let-7a-3 shows a similar expression 
pattern of increased expression upon KSHV infection.  (E) Mir-24-2 has increased 
expression in primary KS biopsies, as compared to other cell types. (F) Mir-32 has 
increased expression in E1 and L1 TIVE cells, as compared to other cell types.  (G) 
Mir-29a has increased expression in both infected and uninfected HUVEC and 
HMVEC cells while mir-370 (H) shows reduced expression in this group, as 
compared to other cell types. 
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Figure IV.5: QPCR quality control.  
 Agilent Bioanalyzer RNA chip results are shown for two common extraction 
methods of RNA.  The BC2 cell line was used.  (A) The RNA nano chip on triazol 
extracted total RNA has a calculated concentration of 237.5 ng/ul, using peak 
comparison, and a RNA integrity value of 9.7, while (B) the high molecular weight 
deleted sample (HMWD) is depleted for the rRNA and tRNA necessary for these 
calculations.  (C) The small RNA chip on the total RNA sample has a concentration 
of 20.5 pg/ul, as measured by area between 20-40 nt, while (D) the HMWD depleted 
sample has only 10.5 pg/ul in the same region.  Average U6 values of all samples 
for the DNA (E) and RNA (F) are shown in box and whisker plots.  C indicates 
endothelial cell culture models, both infected and uninfected, KS indicates primary 
KS biopsies, L indicates B and T cell lymphoma cell lines, P indicates PEL, and T 
indicates Tonsil Tissue.  Outliers are shown in open dots.  Histograms of individual 
QPCR reactions are shown for all reaction types, with frequency shown on the y-axis 
and CT value shown on the x-axis.  A CT value ≤38.00 is considered positive.  (G) 
For all RT negative reactions (n=5,920), 4.83% are positive.  (H) For all RT positive 
reactions (n=20,000), 41.50% are positive.  (I) For all DNA (n=13,920), reactions 
90.28% are positive.  (J) For all non-template water control reactions (n=5,120), 
3.96% are positive. 
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Figure IV.6: Pre-miRNA profiling throughout the cell cycle indicates few miRNAs are 
changed.  
 (A) Growth curves for the E1 (red dots) and L1  (blue triangles) cell lines. 
Number of cells per T75 flask is shown on vertical axis and time in hours since 
seeding  on the horizontal axis. Logarithmic indicates the time points that were 
averaged to yield logarithmic phase pre-miRNA levels and Stationary indicates time 
points that were averaged to yield stationary phase pre-miRNA levels. (C-E) Pair-
wise comparisons of average log-pre-miRNA levels (dCTU6) of proliferation phases 
and cell lines. (Only data points with SD ≤ 3 were included in the comparison). 
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Figure IV.7: Validation of 4 individual biomarkers for endothelial cell transformation.  
 (A-C) Shown are relative transcription levels (dCT) on the vertical and sample 
class on the horizontal axis. Red Dots indicate individual data points (>2 for each 
sample) for KSHV-K12-2, hsa-mir-221, XY, XZ. (E-G) Density plots of dCT values 
for these four genes. Relative frequency (in %) is shown on the vertical axis and 
relative levels (dCT) on the horizontal axis. The dotted line indicates the cut-off value 
for class determination. (E) Decision tree of clustering based on just these 4 
markers. 
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Figure IV.8: Model of KSHV-dependent progressive transformation of endothelial 
cells as identified by pre-miRNA clustering.  
 Upon KSHV infection, KSHV miRNAs and cellular miRNAs are induced.  
Through various stages of transformation, additional cellular miRNAs are induced 
and KSHV miRNA expression increases.  EC indicates primary endothelial cells, 
which can grow in reduced serum upon KSHV infection.  E1, L1 indicate E1 and L1 
TIVE cells, which can form tumors in mice.  KS indicates Kaposi’s sarcoma, which is 
the only cell type to experience notable levels of lytic reactivation with KSHV 
infection.  
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Table IV.1: Samples representative of different stages in endothelial cell 
transformation 
 
Samples:  
 Status:   
 KSHV Tumora Reference 
Cell lines: 
tertHUVEC - - b 
tertHMVEC  - - b 
    
tertHUVEC-2 + - b 
tertHUVEC-6 + - b 
tertHMVEC-1 + - b 
    
E1 TIVE + + c 
L1 TIVE + + c 
    
SLK - + d 
    
Tumor biopsies: 
E1 Tumor-1 + ++ this study 
E1 Tumor-2 + ++ this study 
E1 Tumor-3 + ++ this study 
E1 Tumor-4 + ++ this study 
E1 Tumor-5 + ++ this study 
    
KS-1 + +++ this study 
KS-2 + +++ this study 
KS-3 + +++ this study 
KS-4 + +++ this study 
KS-5 + +++ this study 
KS-6 + +++ this study 
KS-7 + +++ this study 
KS-8 (2007) + +++ this study 
KS-8 (2008) + +++ this study 
  
a.    Relative tumor-forming capability 
b. Wang L, Damania B (2008) Kaposi's sarcoma-associated herpesvirus confers a 
survival advantage to endothelial cells. Cancer Res 68: 4640-4648. 
c.  An, F.Q., et al., Long-term-infected telomerase-immortalized endothelial cells: a 
model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. 
J Virol, 2006. 80(10): p. 4833-46. 
d. Herndier BG, et al. (1994) Characterization of a human Kaposi's sarcoma cell 
line that induces angiogenic tumors in animals. Aids 8: 575-581. 
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Figure IV.S1:  Principal component analysis  
 (A) DNA clustering, (B) pre-miRNA clustering of all samples and (C) pre-
miRNA clustering of endothelial-derived samples indicate non-overlapping clusters. 
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Supplemental Figure IV.S2:  Minimal influence of proliferation phase on pre-miRNA 
levels in E1 and L1 cells.  
 (A) Clustering analysis indicates few miRNAs changed in expression pattern 
during growth phases.  (B) Principal component analysis of clustering indicates non-
overlapping clusters. 
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Figure IV.S3:  Pair-wise comparisons of dCT values for pre-miRNAs.  
 (A) HUVEC against HMVEC, (B) KSHV-infected HUVEC against EC, (C) 
E1/L1 against KSHV-infected HUVEC, (D) E1/L1 cells in culture against E1 tumors, 
(E) KS biopsies against E1 tumors, (F) KS tumors against E1/L1 cell lines. Plotted 
are median dCTU6 values. 
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Table IV.S1:  Indicated are the samples profiled, viral status and original cell line 
reference paper or sample source. 
 
Viral Status  Viral Status 
Samples KSHV EBV 
Reference 
   Samples KSHV EBV Reference 
BC1 + + 
(Cesarman, 1995; 
Cesarman, 1995)  
HUVEC 
KSHV C1 + - (Wang, 2008) 
BC2 + + (Cesarman, 1995)  
HUVEC 
KSHV C2 + - (Wang, 2008) 
BC5 + + (Guasparri, 2004)  
HMVEC 
KSHV + - (Wang, 2008) 
CRO-AP2 + + (Carbone, 1997 )       
CRO-AP5 + + (Carbone, 1998)  BJAB - - 
(Menezes, 
1975) 
JSC1 + + (Cannon, 2000)   BL8 - + (Xia, 2008) 
BC3 + - (Arvanitakis, 1996)  BL5 - + (Xia, 2008) 
BCBL + - (Komanduri, 1996)  DG75 - - 
(Ben-Bassat, 
1977) 
BCLM + - (Ghosh, 2003)      
BCP1 + - (Boshoff, 1998)  CEM - - (Foley, 1965) 
VG1 + - (Brander, 2001)  Jurkat - - 
(Schneider, 
1977) 
CRO-AP3 + - (Carbone, 1998)      
HHB2 + - (Gradoville, 2000)  T012 - - a 
TY1 + - (Katano, 1999)  T013  - - a 
     T014  - - a 
BJAB+ 
KSHV + - (Nun, 2007)  T127 - - a 
     T176  - - a 
SLK - - (Herndier, 1994)  T179  - - a 
E1 TIVE + - (An, 2006)  T200 - - a 
L1 TIVE + - (An, 2006)  T202  - - a 
     T262 - - a 
KS 101 + - b      
KS 165 + - b  HUVEC - - (Wang, 2008) 
KS 299 + - b  HMVEC - - (Wang, 2008) 
KS 310 + - b      
KS 322 + - b      
KS 336 + - b      
KS 352 + - b      
KS DOC + - c      
KS MS + - c      
                                                
a Obtained from Cooperative Human Tissue Network (CHTN) 
b Obtained from collaborators at University of Miami 
c Obtained from collaborators at Harvard University 
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Table IV.S2:  MiRNA gene loci containing genomic alterations. 
ID Accession Chromosome Start End Strand p-Value Bonferroni 
hsa-mir-26b MI0000084 2 218975613 218975689 + 1.09E-05 1.72E-03 
hsa-mir-28 MI0000086 3 189889263 189889348 + 2.66E-05 4.17E-03 
hsa-mir-30c-2 MI0000254 6 72143384 72143455 - 2.38E-05 3.73E-03 
has-mir-93 MI0000095 7 99529327 99529406 - 1.04E-07 1.63E-05 
hsa-mir-335 MI0000816 7 129923188 129923281 + 1.77E-11 2.77E-09 
hsa-mir-151 MI0000809 8 141811845 141811934 - 3.92E-06 6.15E-04 
hsa-mir-7-1 MI0000263 9 85774483 85774592 - 1.40E-06 2.20E-04 
hsa-let-7d MI0000065 9 95980937 95981023 + 5.50E-05 8.63E-03 
has-mir-23b MI0000439 9 96887311 96887407 + 5.84E-05 9.18E-03 
hsa-mir-181b-2 MI0000683 9 126495810 126495898 + 7.65E-08 1.20E-05 
hsa-mir-34b MI0000742 11 110888873 110888956 + 1.43E-09 2.25E-07 
hsa-mir-125b-1 MI0000446 11 121475675 121475762 - 3.53E-07 5.54E-05 
hsa-mir-331 MI0000812 12 94226327 94226420 + 7.69E-08 1.21E-05 
hsa-mir-337 MI0000806 14 100410583 100410675 + 3.03E-05 4.75E-03 
hsa-mir-140 MI0000456 16 68524485 68524584 + 1.21E-05 1.90E-03 
hsa-mir-324 MI0000813 17 7067340 7067422 - 1.29E-07 2.02E-05 
hsa-mir-122a MI0000442 18 54269286 54269370 + 7.55E-10 1.18E-07 
hsa-mir-181c MI0000271 19 13846513 13846622 + 9.53E-06 1.50E-03 
hsa-mir-330 MI0000803 19 50834092 50834185 - 3.38E-05 5.30E-03 
hsa-mir-133a-2 MI0000451 20 60572564 60572665 + 5.49E-08 8.62E-06 
hsa-mir-98 MI0000100 X 53599909 53600027 - 9.49E-07 1.49E-04 
hsa-mir-424 MI0001446 X 133508310 133508407 - 2.27E-06 3.56E-04 
kaposin  KSU75698 117535 118233 - 1.78E-17 2.80E-15 
kshv-mir-K12-8 MI0002478 KSU75698 119943 120012 - 4.85E-18 7.62E-16 
kshv-mir-K12-6 MI0002480 KSU75698 120761 120822 - 1.64E-20 2.58E-18 
kshv-mir-K12-5 MI0002481 KSU75698 121263 121332 - 4.11E-25 6.45E-23 
kshv-mir-K12-4 MI0002482 KSU75698 121413 121482 - 3.17E-16 4.97E-14 
kshv-mir-K12-2 MI0002476 KSU75698 121674 121764 - 2.31E-17 3.63E-15 
kshv-mir-K12-1 MI0002475 KSU75698 121847 121913 - 1.40E-21 2.20E-19 
lana  KSU75698 123010 127446 - 8.44E-23 1.33E-20 
 
 
  121 
   
 Table 4.S3:  Summary of RNA extraction method results. 
Method of Extraction Avg Conc. (ng/ul) Avg RIN miRNA Conc. (pg/ul) 
Triazol 237.5 9.7 20.5 
High Molecular Weight Depletion N/A N/A 10.5 
ABI mirVana Total RNA Isolation 222.3 9.7 10.5 
ABI mirVana Small RNA Enrichment N/A N/A 11.0 
 
   
 
 
 
CHAPTER V: DISCUSSION AND CONCLUDING REMARKS 
 
 MicroRNAs (miRNAs) are small, functional, non-coding RNAs, which bind to 
complementary mRNAs and regulate their expression post-transcriptionally; either 
through translational repression or mRNA degradation. Each miRNA may regulate 
from one to several hundred target mRNAs.  Currently, nearly 700 miRNAs have 
been recorded for the human genome. Many more have been predicted.  Profiling of 
miRNA expression has revealed distinct profiles specific to cell type, developmental 
stage, or cell cycle stage.  Additionally, miRNAs have been shown to be involved in 
a wide variety of cellular processes, including differentiation, proliferation, apoptosis, 
metabolism, infection and cancer.  Profiling of many different types of cancer, 
including lung, prostate, colon and breast, has yielded distinct profiles for each 
entity.  These miRNA profiles are important in both cancer diagnosis and cancer 
treatment.   
 MiRNA profiling can be achieved through a wide variety of methods.  
Traditionally, gel-based assays are used, such as Northern blotting.  These will 
indicate the size of the expressed RNA, as well as absolute levels.  However, this 
type of assay is extremely low-throughput and fairly insensitive.  As a result, a large 
amount of input RNA is required for the assay and miRNAs with low levels of 
expression are not detectable.  DNA microarrays have emerged as a new 
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technology that can be used in high throughput applications.  However, this method 
still requires a large amount of RNA and is less sensitive for rare targets compared 
to target specific detection methods.  Additionally, false positives are common in 
microarray analyses and further validation by a second, independent method is 
required.  A prototypical method of profiling is quantitative real-time PCR or QPCR.  
This method is high throughput and extremely sensitive.  Whereas it is often chosen 
only to validate cDNA microarrays, we demonstrated that it could function quite well 
on its own as a primary array platform.  As a result, QPCR was the method of choice 
for all of the profiling and screening described in the previous experiments.   
 Using QPCR, miRNAs can be identified at the DNA or RNA level.  SYBR 
based amplification and detection allows for genetic analysis on the DNA level to 
determine gene copy number amplifications and deletions.  The same miRNA-
specific primers can also be used at the RNA level to determine levels of the primary 
and precursor miRNA transcripts.  A Taqman™ based assay is used to look at the 
mature miRNA expression patterning.  This multi-level analysis is highly useful for 
determining the overall miRNA profile, as changes on the gene level can certainly 
have an impact on expression.  Furthermore, a certain level of expression at the 
precursor level does not guarantee similar expression at the mature miRNA level.  
Profiling of both species allows for insight into the regulation of miRNA expression 
and processing. 
 Kaposi’s Sarcoma-associated herpesvirus (KSHV) is the causative agent of 
primary effusion lymphoma (PEL), a B-cell lymphoma found in the body cavity and 
Kaposi’s sarcoma (KS) a highly vascular endothelial cancer.  KSHV itself encodes 
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12 viral miRNA genes.  These genes bear little homology to cellular miRNAs. Only 
one viral miRNA (KSHV-mir-K11) shares a conserved seed sequence to a cellular 
miRNA (hsa-mir-155).  MiRNA profiling of these two cancers, PEL and KS, 
determined many similarities and differences.  Because both cancers are infected 
with KSHV, cellular and viral miRNAs induced or repressed from the virus share an 
expression pattern common to both cancers.  At the pre-miRNA level, this mainly 
consisted of a shared expression pattern of the KSHV miRNAs.  This was a novel 
finding, as viral miRNAs were not previously detected in primary KS biopsies.  
Interestingly, the level of KSHV miRNA expression was variable both within each 
sample and between sample types.  Though the entire intergenic region containing 
the viral miRNAs is generated from a common promoter and transcript, the actual 
processing of each miRNA varies, allowing for differential expression of the viral 
miRNAs within any given sample.  Additionally, it was noted that viral miRNA 
expression, as a fraction of total RNA, was highest in PEL, intermediate in primary 
KS biopsies, and lowest in infected endothelial cell models (E1 TIVE, L1 TIVE, 
HUVEC+KSHV, and HMVEC+KSHV). The level of KSHV miRNA expression 
paralleled the level of KSHV miRNA gene copy number in each tumor class. These 
expression patterns are all novel findings for this body of work. 
 Cellular miRNAs profiling revealed a number of interesting findings.  Initially, 
nine PEL samples were profiled using a set of pre-miRNA primers and a 
corresponding set of mature miRNA primers.  Pre-miRNA profiling identified 4 
cellular miRNAs that were highly expressed in all PEL.  Mature miRNA profiling 
confirmed the expression of 3 of these miRNAs. The Taqman™ assay proved to be 
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highly reproducible with low standard deviations within repetitions.  Also, like the 
KSHV miRNAs, differential regulation of cellular miRNAs between PEL samples was 
also found.  Furthermore, this initial study showed that QPCR is far more sensitive 
than the cloning methods previously used to determine miRNA expression:  12 
additional mature miRNAs were detected in all PEL samples profiled, but were not 
previously detected by limited cloning methods. 14 others that were detected by 
real-time QPCR were described in previous publications. 
 Building on this data set, additional samples were added.  Along with 12 PEL 
cell lines, 4 primary KS biopsies and 4 KSHV infected endothelial cell lines 
(HUVEC+KSHV clone 1, HUVEC+KSHV clone 2, E1 TIVE, and L1 TIVE) were 
profiled.  While absolute expression of the mature cellular miRNAs present in all PEL 
was ascertained in the previous report, there was not enough statistical power to 
also identify miRNAs that were specifically down regulated in PEL, as compared to 
control samples.  Using the Taqman™ QPCR array, 84 mature miRNAs of interest 
were profiled.  The expression of multiple cellular miRNAs was altered in infected 
samples as compared to control. With the addition of KSHV infected cell lines, 
comparisons were also made to determine if any miRNAs were virally regulated, i.e. 
altered expression due to viral presence alone and not necessarily viral-induced 
oncogenesis.  Comparisons in expression indicated at least 5 cellular miRNAs (miR-
181b, miR-220, miR-338, miR-20a and miR-152) whose expression is regulated by 
the KSHV virus.    MiR-221 and miR-222 were down regulated in both PEL and KS.  
These miRNAs exhibit tumor suppressor phenotypes.  C-Kit, a target for these 
miRNAs, is over expressed in KS and KS models.  The let-7 family miRNAs, which 
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are co-regulated and exhibit tumor suppressor phenotypes, are down regulated in 
PEL and KS, though to a lesser extent.  Since classical tumor suppressor proteins 
(p53, p21/ARF and PTEN) are not mutant in KS and PEL, miRNA deregulation 
provides an alternate mechanism of transformation.  Finally, miR-143 and miR-145 
were identified as being highly up-regulated in expression in KS biopsies alone; their 
expression in KS defines a novel KS tumor marker. 
 Following this study, additional samples were added to do a more 
comprehensive profiling of pre-miRNA expression in PEL and KS.  A total of 14 PEL, 
13 primary KS biopsies and 5 KSHV infected endothelial cell lines (HUVEC+KSHV 
clone 1, HUVEC+KSHV clone 2, HMVEC+KSHV, E1 TIVE, and L1 TIVE) were 
profiled, along with 20 assorted control samples.  DNA profiling of the miRNA gene 
loci indicated no common deletions or amplifications, though genomic changes were 
found many KSHV positive samples.  Quality control indicated few cellular miRNAs 
are regulated by growth phase (logarithmic versus stationary), suggesting that the 
miRNA profile reflects tumor origion rather than specific culture conditions.  Though 
a number of cellular pre-miRNAs are commonly expressed in all KSHV positive 
samples (miR-220, -125b-2, -181c, -194-2, -7-1, -140, -152, -27a, and let-7a), 
deeper analysis into the endothelial lineage samples determined pre-miRNA profiles 
for progressive stages of endothelial cell transformation.  In fact, 8 cellular miRNAs 
were highly expressed in KS alone, as compared to infected and uninfected 
endothelial cell models.   
 Comparison of the cellular miRNA expression patterns between these 
different sample types led to a model of endothelial KSHV-dependent transformation 
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(see figure IV.8, p114). Immortalized endothelial cells (tertHUVEC and tertHMVEC) 
are infected with KSHV [Wang, 2008].  Both the uninfected and infected endothelial 
cells share common pre-miRNA profiles, however the infected cells express low 
levels of KSHV miRNAs as well as a distinct group of cellular miRNAs.  These 
infected cells are able to grow in reduced serum, indicating the virus has a 
transformative effect on the cells, however these cells do not form tumors in mice.   
The viral life cycle in these cells remains tightly latent. The E1 and L1 TIVE cells are 
KSHV- infected cells that have undergone a second transformative event [An et al., 
2006].  These cells are capable of forming tumors in mice.  The E1/L1 TIVE cells 
express intermediate levels of KSHV miRNAs and a distinctive group of pre-
miRNAs.   While these cells are highly transformed, similar to KS, the life cycle of 
the virus is still tightly latent.  KS expresses the highest level of KSHV miRNAs, as 
compared to other infected cell types.  It expresses a third distinctive group of pre-
miRNAs that are highly up-regulated in KS specifically and continues to express a 
second set of the same miRNAs that were highly induced upon KSHV infection in 
the HUVEC/HMVEC cells.  Unlike the previous cell culture models, KS has a 
number of infected cells undergoing spontaneous lytic reactivation.  Overall, it is 
observed that expression of KSHV miRNAs increases with disease progression 
through the model.  Each cell type profiled has a unique set of highly expressed 
cellular miRNAs, independent of the presence of virus, and a second set of 
commonly expressed miRNAs that is dependent on the presence of virus.  Given 
that the cell models are pure cultures of cells while primary KS biopsies are a 
mixture of cells, it is possible that some of these miRNA expression differences are 
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due to other infiltrating cell types.  However, given that the overall input amount of 
sample is identical in each reaction and the extremely high level of KSHV transcript 
expression in the KS biopsies, any additional cells in the biopsy are likely infected 
and therefore contributing to the tumor microenvironment. 
 The combination of these works provides great progress in cellular miRNA 
profiling of KSHV malignancies.  Firstly, these profiling experiments indicate that pre-
miRNA and mature miRNA profiling provide non-redundant information.  Several 
novel PEL and KS specific miRNAs have been identified, which can be used as 
tumor specific biomarkers.  For PEL, miR-125a, and mir-222 were repeatedly 
identified; for KS, miR-24, -143 and -145 were identified.  Finally all KSHV positive 
malignancies show altered expression of mir-221, mir-140 and the let-7 family.  
These results indicated that multiple tumor suppressor miRNAs (mir-221, mir-222, 
let-7 family) are down regulated in KSHV positive malignancies, which provides and 
alternate mechanism of transformation.  This is important, since classical tumor 
suppressor proteins are not mutant in PEL and KS.  Finally, miRNA expression 
profiling defines endothelial cell transformation upon KSHV infection. 
 Still, much can be done.  These experiments evaluated 218 miRNAs.  
Currently, close to 700 cellular miRNAs have been identified.  Further evaluation of 
the remaining cellular miRNAs may provide valuable information and additional 
biomarkers.  Given these miRNA profiles, specific miRNAs can be investigated with 
respect to possible cellular or viral targets.  With a defined set of notable miRNAs, 
relevant targets for this relatively small number of miRNAs can be identified.  As 
miRNAs serve as strict regulators of cellular functions, including oncogenesis, target 
  129 
   
discovery can lead to new insights and eventually treatment of these and other 
malignancies.  Finally, the biological relevance of the expression of specific miRNAs, 
in terms of KSHV malignancy can be determined.  By over-expressing miRNAs with 
transfections that are typically reduced in expression with KSHV malignancy, or by 
using antagomirs to knockdown over-expressed miRNAs, it can be determined 
which cellular miRNAs are biologically relevant.  This may include cellular miRNAs 
required to maintain viral latency, to aid in cell survival, to aid in immune invasion or 
are simply required hits for oncogenesis.  In the long term, all of these insights can 
be used to eventually determine new courses of diagnosis and treatment for these 
and other related diseases. 
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Abstract  
EBV-encoded microRNAs (miRNAs) have been identified and their functions are 
being studied. The expression pattern of these miRNAs in clinical samples of EBV-
associated non– Hodgkin’s lymphomas is unknown. We analyzed five primary 
‘‘endemic’’ pediatric Burkitt’s lymphomas (BL), two acquired immunodeficiency 
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syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV+ 
primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell 
lymphomas (DLBCL) for expression of EBV-encoded miRNAs. A markedly elevated 
expression of miRNA BHRF1-3 in type III relative to its parental type I BL line was 
found. Primary unmanipulated type I BLs and EBV+ PELs expressed high levels of 
BART2 miRNA, whereas DLBCLs expressed both BART2 and BHRF1-3 species. 
BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular 
target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and 
suppression of this factor was reversed by transfection of an antisense oligo to the 
EBV miRNA BHRF1-3. EBV encoded miRNAs are expressed in primary lymphomas 
classically linked to the virus and are associated with the viral latency status. 
Targeted suppression of CXCL-11/I-TAC by a viral-encoded miRNA may serve as 
an immunomodulatory mechanism in these tumors.  
 
Introduction  
 MicroRNAs (miRNA) are small noncoding RNAs of ~22 nucleotides 
processed from primary transcripts (pri-miRNAs) to short stem-loop RNA precursors 
of f60 nucleotides (pre-miRNAs) and finally to functional miRNAs. miRNAs regulate 
gene expression by base pairing with the 3’-untranslated region (UTR) of their target 
mRNAs and repress target gene translation or induce target mRNA degradation. 
miRNAs have important regulatory functions as indicated by their gene specificity 
and modulation [Du, 2005; He, 2004; Sevignani, 2006]. The absence of miRNAs in 
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all unicellular organisms studied thus far makes a case for their role in highly 
specialized cell functions [Carthew, 2006; Zamore, 2005].  
 A growing body of data indicates that viruses exploit the miRNA machinery to 
modulate and/or subvert virus-host cell interactions [Lecellier, 2005; Pfeffer, 2004; 
Cai, 2006a; Sullivan, 2005; Grundhoff, 2006]. Pfeffer et al. [Pfeffer, 2004] initially 
identified five EBV-encoded miRNAs from the B95-8 EBV laboratory strain. The 
EBV-encoded BHRF1 miRNAs cluster map to the 5’-UTR (BHRF1-1) and 3’-UTR 
(BHRF1-2 and BHRF1-3) of the BHRF1 (BamHI fragment H rightward open reading 
frame 1) gene, whereas the BART miRNAs (BART1 and BART2) cluster map to 
intronic regions of the BART (BamHI-A region rightward transcript) gene. Cai et al. 
[Cai, 2006a] identified additional BART miRNAs from an EBV-infected primary 
effusion lymphoma (PEL) cell line, and Grundhoff et al. [Grundhoff, 2006] identified 
additional EBV miRNAs in the BART and BHRF1 region, bringing the total to 22 
clustered, EBV-encoded miRNAs. The conservation of miRNAs in the 
lymphocryptoviruses indicates their importance in the viral life cycle, and the 
elucidation of their function is ongoing albeit incompletely understood.  
 The typical outcome of EBV infection is viral latency, which may eventually 
result in transformation [Wang, 1990; Zhang, 2004]. Latency patterns have been 
defined based on EBV gene expression in distinct tumor subtypes. Primary Burkitt’s 
lymphomas (BL) generally show the type I pattern of latency, whereas posttransplant 
lymphoproliferative disease, immunoblastic lymphomas [including some acquired 
immunodeficiency syndrome (AIDS)-related lymphomas], as well as in vitro–
transformed lymphoblastoid cell lines (LCL) adopt the latency type III pattern of gene 
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expression [Zhang, 2004]. Latency variation is consistent with the hypothesis that 
the more restricted the viral gene expression, the easier it is for the virally infected 
cell to escape immune surveillance. In the absence of immunologic constraints, such 
as in vitro, primary BL cell cultures tend to drift from the classic type I latency to a 
type III lymphoblastoid phenotype [Wang, 1990; Zhang, 2004]. Prior studies have 
focused exclusively on long-term culture propagated cell lines. These can 
accumulate mutations in viral miRNA loci, such as exemplified by B95-8 [Cai, 
2006a], or the host genome, which may alter miRNA transcription, processing, or 
stability. Here, we extend these studies by analyzing viral miRNA levels by two 
independent methods, RNase protection assay (RPA) and a novel quantitative PCR 
(QPCR) method, in early-passage primary BL cultures, a lymphoblastoid derivative 
of BL, and a wide variety of unmanipulated primary EBV-related lymphomas. We 
show that EBV-encoded BHRF1-3 miRNA levels are markedly elevated in the type 
III latency cell line and for the first time in primary EBV-associated AIDS-related 
diffuse large B-cell lymphomas (DLBCL). Primary BLs and PELs expressed high 
levels of BART2 but not BHRF1-3 miRNA. We further show that BHRF1-3 miRNA 
represses the expression of the IFN-inducible T-cell attracting chemokine, CXCL-
11/I-TAC, a putative cellular target of BHRF1-3 miRNA. This targeted suppression of 
CXCL-11/I-TAC by BHRF1-3 miRNA may serve as an immunomodulatory 
mechanism in EBV-related lymphomas.  
 
Materials and Methods  
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 Cell culture, collection, and histologic confirmation of primary tumors. This 
study was approved by the University of Miami and the Federal University of Bahia 
Institutional Review Boards. Informed consent was obtained from patients or their 
guardians before obtaining clinical samples, and only tissue deemed unnecessary 
for pathologic diagnosis was used. BL-5 and BL-8 cells are primary cultures derived 
from patients with AIDS-related EBV+ BL. The tumors carry the typical t8:14 c-MYC 
translocation [Kurokawa, 2005]. A lymphoblastoid derivative (BL-5R) was obtained 
after serially passaging BL-5 cells over a 4- to 5-week period. BC-1 and JSC-1 are 
PEL lines that are dually infected with human herpes virus type 8 (HHV-8) and EBV 
[Cesarman, 1995]. Cells were cultured in RPMI 1640 (Life Technologies) 
supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin, 1% 
glutamine, and 1 mM/L sodium pyruvate at 37°C in a 5% CO2- humidified 
atmosphere. The PEL cell lines were maintained in the same medium with the 
addition of 1 unit/mL human interleukin-6.  
 Primary EBV+ lymphomas were obtained from an area where an extremely 
high (~90%) association between EBV and pediatric Burkitt’s type histology has 
been reported [Hayashi, 1997; Araujo, 1996]. Pediatric BLs (BL-1, BL-2, BL-3, BL-4, 
and BL-6) and EBV+ DLBCLs from AIDS patients (DLBCL-1, DLBCL-2, and DLBCL-
3) were obtained from the residual tumor of patient biopsies. A primary PEL 
specimen (PELmo1) coinfected with EBV and HHV-8 was obtained from residual 
material from a diagnostic procedure. The EBV- primary DLBCL (DLBCL-4), the 
BJAB line, and the EBV-  PEL lines BCBL-1 and BC-3 served as controls. 
Classification of lymphomas was made by an experienced hematopathologist (I.A.) 
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and association with EBV was determined by eber staining. RNA was prepared as 
described below from tumors before any culture step or other manipulation.  
 Total RNA and miRNA extraction. RNA was extracted with the RNeasy kit 
(Qiagen, Inc.) for analyses of cellular and EBV RNAs by reverse transcription-PCR 
(RT-PCR). For RNase protection analysis of miRNAs, total RNA and miRNA-
enriched fractions were prepared with the mirVana miRNA extraction kit (Ambion, 
Inc.). For real-time QPCR analysis, total RNA was isolated by RNAzol (Sigma, Inc.) 
and residual DNA was removed using Turbo DNA-free (Ambion). RNA was 
quantitated by UV absorption at 260 nm/280 nm using an Ultrospec 1000 machine 
(Pharmacia Biotech, Inc.).  
 PCR analyses. cDNA was synthesized using Moloney murine leukemia virus 
reverse transcriptase (Promega, Inc.) according to the manufacturer’s instructions. 
cDNA (2 µL) was PCR amplified with gene-specific primers as previously described 
[Hilscher, 2005]. Real-time QPCR primers for BART1, BART2, and BHRF1-3 are 
shown in Supplementary Table S1. Reverse transcription, realtime QPCR, and data 
analysis were conducted following our established procedures [Hilscher, 2005; 
Papin, 2005]. The final PCR contained 7.5 µL primer mix (final concentration, 166 
nM/L), 15 µL of 2x SYBR PCR mix (Applied Biosystems), and a 7.5 µL sample. To 
guard against contamination and handling errors, all real-time QPCRs were 
assembled in a segregated clean room using a CAS-1200 robot (Corbett Research, 
Inc.) with 0.1 µL accuracy, liquid level sensing, and filtered pipette tips. Real-time 
PCR was performed using an Opticon 2 unit (MJ Research, Inc.) and universal cycle 
conditions.  
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 RNase protection assay. RPAs were performed using the mirVana miRNA 
detection kit in accordance with the manufacturer’s instructions (Ambion). 32P-
labeled RNA probes were generated from DNA templates corresponding to the 
miRNA target sequence using the mirVana miRNA probe construction kit (Ambion) 
according to the manufacturer’s instructions.  
 BHRF1-3 miRNA or anti-miRNA transfection. Chemically modified 
oligonucleotides corresponding to the antisense to the BHRF1-3 miRNA target 
sequence (BHRF1-3 anti-miR), the BHRF1-3 pre-miR miRNA precursor, scrambled 
sequence, and a negative control anti-miR inhibitor were obtained from Ambion. 
Oligonucleotides were delivered using the Amaxa nucleofection technology (Amaxa) 
according to the manufacturer’s protocols.  
 ELISA. CXCL-11/I-TAC protein levels in cell culture conditioned medium were 
determined with the Quantikine human CXCL-11/I-TAC ELISA kit (R&D Systems, 
Inc.) as per the manufacturer’s instructions.  
 
Results  
 To determine the expression pattern of EBV miRNAs in type I and III EBV-
related lymphomas, and to investigate their role in EBV pathogenesis, we initially 
used two BL early-passage cell lines (BL-5 and BL-8) derived from primary tumors 
that carry the typical t8:14 chromosomal translocation (Fig. 1A; [Kurokawa, 2005]). 
Serially passaged primary cultures evolved from single-cell suspension (BL-5) to 
macroscopic clumps (BL-5R), indicating a drift to lymphoblastoid phenotype (Fig. 
1B). The expression of viral-encoding proteins, EBNA3C, EBNA2, and LMP-1, is 
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associated with the lymphoblastoid phenotype [Wang, 1990; Zhang, 2004]. We 
therefore assessed the transcription of these mRNAs in BL-5 and its lymphoblastoid 
derivative BL-5R by RT-PCR. Although cultured BL-5 cells contained some 
detectable EBNA2 and EBNA3C transcripts, the BL-5R cells, by comparison, 
expressed higher levels of EBNA2 and EBNA3C (Fig. 1C). Consistent with its role in 
the lymphoblastoid phenotype, LMP-1 was exclusively expressed in BL-5R cells 
(Fig. 1C) and LMP-1 protein expression was confirmed by Western blot (data not 
shown).  
 Small RNAs (<200 nucleotides) were purified from BL-5, BL-8, and BL-5R 
cells and EBV miRNA levels were determined by RPA. We observed elevated levels 
of BART2 miRNA in the parental type I BL-5 cells and a marked expression of 
BHRF1-3 miRNA (and concomitantly low levels of BART2 miRNA) in BL-5R cells 
(Fig. 2A, lanes2 and 3). The early-passage type I BL-8 cells also expressed high 
levels of BART2 miRNA, but BHRF1-3 miRNA was not detectable in these cells (Fig. 
2A, lane 1). This finding was in agreement with recently published data on long-term 
established EBV+ cell lines that showed an increased level of BHRF1 miRNAs in 
type III latency cell lines [Cai, 2006a].  
 We also analyzed viral miRNAs from an EBV+ primary DLBCL-1 biopsy. RPA 
analysis revealed high levels of both BART2 and BHRF1-3 miRNAs in this tumor 
(Fig. 2A, lane 4), but neither miRNA was detectable in its EBV- DLBCL counterpart 
(DLBCL-4; Fig. 2A, lane 5).  
 To verify the differential expression of the BHRF1-3 and BART2 miRNAs by 
another method, we used real-time QPCR. Primers specific for the BHRF1-3, 
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BART1, and BART2 pre-miRNAs were designed. As control for RNA isolation, we 
used published primers against pre-miRNAs for cellular miRNAs, miR16, miR124, 
and miR219 [Cheng, 2005; Schmittgen, 2004]. All quantitative analyses were 
normalized to account for differences in cell number, RNA quality, and reverse 
transcription efficiency [Hilscher, 2005; Papin, 2005]. We used U6 as the common 
denominator for these studies because it was the most abundant RNA, normally 
distributed and the least variable RNA in our target set (data not shown). Control 
experiments were done to discount mRNA or DNA contamination of miRNA QPCR 
amplification (data not shown). The miRNA QPCR confirmed the marked induction 
(f21-fold) of BHRF1-3 pre-miRNA in BL-5R cells relative to BL-5 cells. BART pre-
miRNAs did not show marked differences between BL-5 and BL-5R (<2-fold) 
compared with BHRF1-3 pre-miRNA in the QPCR assay (Fig. 2B). In contrast to the 
viral pre-miRNAs, none of the three cellular pre-miRNAs showed a pattern that 
correlated with EBV status, indicating that specific viral miRNA regulation rather than 
global defects in miRNA processing accounts for the pattern of viral miRNA levels. 
We also analyzed several well characterized PEL cell lines, wherein EBV assumes a 
tight latency I phenotype based on latent EBV mRNA splicing patterns [Papin, 2005]. 
BART1, BART2, and, to a lesser degree, BHRF1-3 pre-miRNAs were detectable in 
the EBV+ PEL cell lines BC-1 and JSC-1, but not in the EBV- BCBL-1 and BC-3 cell 
lines, and the expression levels were comparable with the latency I BL-5 cells (data 
not shown).  
 As all prior studies were conducted entirely in long-term culture adopted cell 
lines, we assessed the expression of EBV miRNAs in primary B-cell lymphomas 
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classically associated with EBV. Endemictype pediatric BLs from an area of high 
incidence and DLBCLs from HIV+ patients were confirmed to be EBV+ by in situ 
analysis of constitutively expressed EBV-encoded small RNAs (EBER; Fig. 3A) and 
by RT-PCR of EBV-encoded mRNAs (data not shown). As a control, an EBV 
(EBER)-negative DLBCL (DLBCL-4) was used in these analyses (Fig. 3A). Each of 
the EBV+ DLBCLs expressed high levels of LMP-1 (Fig. 3B), confirming that they 
are associated with type III EBV latency pattern. We also analyzed a primary EBV+ 
PEL specimen (PELmo1) as well as the established EBV+ PEL line (BC-1). RPA 
analysis showed that, as was observed in the EBV associated BL lines (BL-5 and 
BL-8), endemic-type BLs (BL-1, BL-2, BL-3, BL-4, and BL-6) also expressed 
predominantly BART2 miRNA (Fig. 3C, lanes2, 3, 4, 5, and 7), whereas the EBV+ 
DLBCLs (DLBCL-1, DLBCL-2, and DLBCL-3) expressed both BART2 and BHRF1-3 
miRNAs at high levels (Fig. 3C, lanes 1, 6, 9, 11, and 12). The established PEL line 
and the primary PEL specimen both expressed predominantly BART2 miRNAs (Fig. 
3C, lanes 14 and 15), consistent with the reported type I EBV latency transcription 
pattern in PEL. In EBV- controls (DLBCL-4 and BJAB), expression of both viral 
miRNAs was not detected (Fig. 3C, lanes 8, 10, and 13). Therefore, as in the type I 
latency cell line (e.g., BL-5), both EBV-associated primary BLs and PELs express 
high levels of BART2 miRNA, whereas the expression of BHRF1-3 miRNA is 
markedly elevated in the type III latency cell line (BL-5R) as well as in primary EBV+ 
AIDS-related DLBCLs. The types of primary lymphomas and cell lines analyzed and 
their expression pattern of EBV miRNA are summarized in Table 1.  
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 The IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC is one of three 
CC chemokines, including CXCL-9/Mig and CXCL-10/ IP-10, that bind to and 
activate the chemokine receptor CXCR3, which is predominantly expressed on T 
cells [Cole, 1998; Colvin, 2004]. Although these cytokines are functionally 
redundant, CXCL-11/I-TAC is by several orders of magnitude the most potent T-cell 
chemoattractant [Cole, 1998]. Based on published in silico analysis, the 3’-UTR of 
CXCL-11/I-TAC contains a sequence that is 100% complimentary to the BHRF1-3 
miRNA sequence and therefore constitutes a putative BHRF1-3 miRNA target 
[Pfeffer, 2004]. Because of significantly differing BHRF1-3 miRNA levels, we 
hypothesized that CXCL-11/I-TAC might also be differentially expressed in BL-5 and 
BL-5R. The basal level of CXCL-11/I-TAC proteins secreted from culture 
supernatants of BL-5 and BL-5R was analyzed using ELISA. BL-5 cells expressed 
higher levels of CXCL-11/I-TAC than BL-5R cells (Fig. 4A), suggesting that the 
expression of CXCL-11/I-TAC in these cells inversely correlates with the expression 
of EBV-encoded BHRF1-3 miRNA.  
 We investigated the effect of BHRF1-3 miRNA on its putative target, CXCL-
11/I-TAC. First, we studied the high BHRF1-3 miRNA BL-5R cell line. BL-5R cells 
were transfected with increasing amounts of BHRF1-3 miRNA antisense 
oligonucleotide (BHRF1-3 anti-miR) at ~65% efficiency (Fig. 4B, top) and the CXCL-
11/I-TAC level was assessed by RT-PCR. By competing the BHRF1-3 miRNA 
targeting sequence with its antisense RNA oligonucleotide, we repeatedly elicited 
basal induction of CXCL-11/I-TAC expression in BL-5R (Fig. 4B, bottom, lanes 6–9). 
Control transfections with a scrambled RNA oligonucleotide (Fig. 4B, bottom, lanes 
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2–5), as well as mock transfection (Fig. 4B, bottom, lane 1), showed no modulation 
of CXCL-11/I-TAC expression. This result indicates that BHRF1-3 miRNA antisense 
competes out BHRF1-3 miRNA and reverses its repressive effect on CXCL-11/I-
TAC expression. We also analyzed the expression of another chemokine, CXCL-7, 
in the same set of experiments. RT-PCR showed that CXCL-7 mRNA level was not 
modulated by transfection of either BHRF1-3 anti-miR or scrambled oligonucleotides 
(Fig. 4B, bottom), which indicates that the effect of BHRF1-3 miRNA on CXCL-11/I-
TAC expression is specific. Similarly, CXCL-11/I-TAC expression was markedly 
induced in the low BHRF1-3 miRNA BL-5 cells transfected with BHRF1-3 anti-miR, 
and we also observed a much greater induction of CXCL-11/I-TAC expression in BL-
5 cells dually treated with both the antisense oligo of BHRF1-3 miRNA and IFN-g 
(data not shown). This showed that expression of CXCL-11/I-TAC is suppressed by 
the EBV-encoded BHRF1-3 miRNA.  
 We further examined the direct effect of BHRF1-3 miRNA on CXCL-11/I-TAC 
expression. CXCL-11/I-TAC was stimulated to a higher level in BL-5 cells when 
transfected with 100 nM/L BHRF1-3 anti-miR and induced with 1,000 units/mL IFN-g 
(Fig. 4C, left and right, lanes 2–5). Cells were then transfected with increasing 
amounts of BHRF1-3 miRNA sense oligos (Fig. 4C, left and right, lanes 3–5) and 
analyzed for CXCL-11/I-TAC by RT-PCR (Fig. 4C, left) and ELISA (Fig. 4C, right). 
We observed a significant reduction of CXCL-11/I-TAC at both mRNA and protein 
levels when cells were transfected with BHRF1-3 miRNA. This result further shows 
that CXCL-11/I-TAC expression is suppressed by EBV miRNA BHRF1-3, suggesting 
that cellular chemokines can be targeted by the viral miRNA.  
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Discussion  
 Following primary EBV infection, B cells undergo blast transformation during 
which they express the full spectrum of EBV genes (latency III program; [Wang, 
1990; Zhang, 2004]). Presumably, to evade host viral immune defenses, the cells 
later adopt a latency I program, in which EBV gene expression is restricted to the 
relatively nonimmunogenic EBNA1 protein, the BamHI transcripts including the 
BART miRNAs, and the noncoding EBER transcripts. It is thought that BL arises 
from a B-cell subset in which EBV naturally adopts a tight latency I program or that a 
clone with limited antigen expression is selected from an EBV-transformed latency III 
progenitor pool [Kelly, 2002]. EBV latency III lymphomas typically arise in 
immunodeficient patients, such as those infected with HIV, or following 
pharmacologic immunosuppression after organ transplantation or they arise during 
in vitro culture of latency type I cells, which underscores the importance of a robust 
immunosurveillance system to counter the expression of EBV genes [Kelly, 2002; 
Khanna, 2000].  
 Although there are distinct forms of EBV latency types in established cell 
lines, the clinical scenario is often quite different. Clinical specimens from patients 
with the diagnosis of BL have been found to express a heterogeneous latency 
program [Xue, 2002; Touitou, 2003; Niedobitek, 1995]. The heterogeneity of EBV 
latency patterns in clinical specimens may be due to variant EBV clones, the 
establishment of immunoprivileged sites in the tumor microenvironment, and the 
selection of a clone from a type III progenitor pool [Frisan, 1995; Kelly, 2002]. It may 
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also be part of an immune evasion strategy that includes EBV-mediated regulation 
of antigen processing and presentation and the downmodulation of the cytotoxic T-
cell (CTL) cytokine networks [Ploegh, 1998]. It will be important to study the biology 
of these primary EBV+ lymphomas to advance diagnosis and treatment.  
 The identification of virus-encoded miRNAs has generated new insights on 
virus transformation and immune evasion. Sullivan et al. [Sullivan, 2005] showed 
that SV40-encoded miRNAs target early viral mRNAs for cleavage, thus reducing 
the expression of viral tumor antigens, CTL recognition, and cytolysis. Recently, 
Samols et al. [Samols, 2007] identified thrombospondin 1, a strong tumor 
suppressor and antiangiogenic factor, as a potential target for HHV-8–encoded 
miRNAs, and Lo et al. [Lo, 2007] reported modulation of LMP-1 protein expression 
by EBV-encoded BART miRNAs, highlighting the role of viral miRNAs in regulating 
viral pathogenesis.  
 We analyzed for the first time a variety of primary unmanipulated EBV-
associated lymphomas (rather than established cell lines) that are representative of 
the major forms that occur in immunocompromised patients. Primary BLs expressed 
high levels of BART2 miRNA, which was expected based on the ubiquitous, high-
level transcription across the BamHI locus in all EBV+ tumors [Karran, 1992; Brooks, 
1993; Sadler, 1995]. In contrast, a lymphoblastoid derivative of a BL line derived 
from an AIDS patient as well as AIDS-related DLBCLs expressed high levels of 
BHRF1-3 miRNA. The expression pattern of these two EBV miRNAs correlated with 
that previously seen in long-term cultured cell lines [Cai, 2006a]. An induced 
expression of BHRF1 miRNAs and a putative cleavage residue have recently been 
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reported in EBV+ AKATA cells induced from type I latency to type III latency, 
indicating that the high level of BHRF1 miRNAs is a characteristic of EBV latency III 
infection [Xing, 2007]. It is interesting to note that BHRF1-3 miRNA was low or 
absent in AIDS-related BL. These tumors typically occur in relatively 
immunocompetent patients compared with EBV+ DLBCL, which arise in patients 
with more advanced immunodeficiency [Navarro, 2006]. In contrast, EBV-associated 
large cell variants may exert a previously unknown immunosuppressive effect via 
modulation of cellular chemokines. Therefore, we hypothesize that one of the 
activities of EBV BHRF1-3 miRNA is the regulation of host cell immune function. 
This article establishes that EBV miRNAs are readily detectable in primary 
unmanipulated lymphomas associated with the virus. It is also likely that BHRF1-3 
and other EBV miRNAs have additional complementary cellular targets.  
 Two recent reports have shown a potent antitumor activity for the IFN-
inducible T-cell attracting chemokine (CXCL-11/I-TAC) in laboratory animals. 
However, there is a paucity of studies on the expression of CXCL-11/I-TAC 
expression in clinical specimens [Yang, 2006; Hensbergen, 2005]. We have 
identified EBV BHRF1-3 miRNA, which is 100% identical to its target sequence in 
the 3’-UTR of CXCL-11/I-TAC mRNA, as a potential effector in the modulation of 
CTL cytokine networks [Pfeffer, 2004]. We show that CXCL-11/I-TAC mRNA and 
protein levels inversely correlate with BHRF1-3 miRNA expression levels. Changes 
in BHRF1-3 miRNA levels in a pair of isogenic type I/III BL cell lines were inversely 
correlated with CXCL-11/I-TAC levels. Furthermore, antisense delivery of the 
BHRF1-3 miRNA could relieve BHRF1-3 miRNA repression of CXCL-11/I-TAC. 
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Therefore, the activity of BHRF1-3 miRNA and other virally encoded miRNAs may 
have far-reaching implications in cancer immunosurveillance. Alternatively, 
antisense delivery of BHRF1-3 miRNA may represent a targeted immunotherapeutic 
tool that can be directed toward enhancing immunosurveillance of EBV-related 
tumors.  
 
Notes 
 This manuscript was received 8/31/2007; revised 11/27/2007; accepted 
12/23/2007 and published in Cancer Research, 1 March 2008, volume 68, number 
4, pages 1436-1442. 
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Figure AI.1. Cytogenetic and morphologic analysis of BL lines and differential 
expression of EBV genes in latency type I and III BL lines.  
 (A) cytogenetic analysis of BL lines BL-5 and BL-8 reveals the characteristic 
t8:14c-MYC translocation. Arrows point to translocated chromosomes. (B) bright-
field photomicrograph of BL-5 and BL-5R cells in culture. Magnification, x100. BL-5 
cells grow as a single-cell suspension, whereas BL-5R cells grow as macroscopic 
clumps, characteristic of LCLs. (C) RT-PCR analysis of EBV-encoded EBNA3C, 
EBNA2, and LMP-1 mRNA levels in BL-5 and BL-5R cells. b-Actin mRNA level was 
analyzed as loading control. Agarose gels were exposed under UV light in a Bio-Rad 
Gel Doc 2000 imager and inverted images of DNA bands captured.  
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Figure AI.2. Differential expression of BHRF1-3 and BART2 miRNAs in BL cell lines.  
 (A) RPA analysis of BHRF1-3 and BART2 miRNA expression in BL lines BL-8 
and BL-5, a lymphoblastoid derivative BL-5R, an EBV+ DLBCL-1(+), and an EBV  
DLBCL-4(-). Expression of a cellular miRNA, miR16, was analyzed as loading 
control. (B) Real-time QPCR analysis of EBV miRNA expression in BL-5 and BL-5R 
cells. Bars, relative level of miRNAs in percentage to U6 RNA on the vertical axis on 
a logarithmic scale. Expression of EBV miRNAs (BHRF1-3, BART1, and BART2) 
and expression of cellular miRNAs (miR16, miR124, and miR219) were analyzed.  
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Figure AI.3. Differential expression of BHRF1-3 and BART2 miRNAs in primary 
unmanipulated clinical specimens.  
 (A) representative immunohistochemical analysis in primary unmanipulated 
clinical specimens. Endemic BLs (BL-1, BL-2, and BL-3) and primary DLBCLs 
(DLBCL-1 and DLBCL-4) were stained with H&E (top row) or stained for EBER1 
(bottom row). Positive staining to EBV/EBER is visualized as dark blue spots. ( ), 
EBV negative; (+), EBV positive. (B) Western blot of LMP-1 protein in primary 
DLBCLs. EBV+ DLBCL-1, DLBCL-2, and DLBCL-3 were probed with specific 
antibody to LMP-1. An EBV  BL line, BJAB, was used as a negative control, and the 
same membrane was also probed with h-tubulin for a loading control. (C) RPA 
analysis of BHRF1-3 and BART2 miRNA expression in primary EBV+ BLs (BL-1, 
BL-2, BL-3, BL-4, and BL-6), EBV+ primary DLBCLs (DLBCL-1, DLBCL-2, and 
DLBCL-3), a primary EBV+ PEL specimen (PELmo1), and an established EBV+ 
PEL line (BC-1). EBV  DLBCL-4and BJAB were also analyzed as negative controls, 
and miR16 as a loading control. 
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Figure AI.4. Differential expression and modulation of putative BHRF1-3 miRNA 
target CXCL-11/I-TAC.  
 (A) ELISA analysis of basal level expression of CXCL-11/I-TAC proteins 
secreted from culture supernatants of BL-5 and BL-5R. (B) RT-PCR analysis of 
CXCL-11/I-TAC mRNA levels in BL-5R cells following BHRF1-3 miRNA antisense 
transfection. Top, green fluorescent protein (GFP) control to determine transfection 
efficiency; bottom, mRNA level of CXCL-11/I-TAC following BHRF1-3 antisense 
transfection in BL-5R cells. BL-5R cells were transfected with RNA oligonucleotides 
at the following dosages: control transfections with no oligo (lane 1); transfection 
with a scrambled RNA oligo at 0.25 Amol/L for 8 h (lane 2), 1.25 Amol/L for 8 h (lane 
3), 0.25 Amol/L for 16 h (lane 4), and 1.25 Amol/L for 16 h (lane 5); and transfection 
with anti-BHRF1-3 miRNA oligo at 0.25 Amol/L for 8 h (lane 6), 1.25 Amol/L for 8 h 
(lane 7), 0.25 Amol/L for 16 h (lane 8), and 1.25 Amol/L for 16 h (lane 9). CXCL-11/I-
TAC, CXCL-7, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
levels in transfected cells were also analyzed by RT-PCR. PCR products were 
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visualized under UV in a Bio-Rad Gel Doc 2000 imager and inverted images of DNA 
bands were captured. (C) effect of BHRF1-3 miRNA on induced CXCL-11/I-TAC. 
BL-5 cells were transfected with 100 nmol/L BHRF1-3 anti-miR and treated with 
1,000 units/mL IFN-g (lanes 2–5) and then transfected with BHRF1-3 miRNA sense 
oligos (lane 2, 0 nmol/L; lane 3, 10 nmol/L; lane 4, 30 nmol/L; lane 5, 100 nmol/L). 
CXCL-11/I-TAC and b-actin mRNA levels in transfected cells were then analyzed by 
RT-PCR (left ) and CXCL-11/I-TAC protein level was analyzed by ELISA (right ). 
Agarose gels were exposed under UV in a Bio-Rad Gel Doc 2000 imager and 
inverted images of DNA bands captured.  
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Table AI.1. EBV miRNA expression in primary lymphomas and cell lines. 
    Bart 2 BHRF1-3 
EBV+    
Early-passage BL lines BL-5 High Low 
 BL-8 High Low 
Primary pediatric BLs BL-1 High Low 
 BL-2 High Low 
 BL-3 High Low 
 BL-4 High Low 
 BL-6 High Low 
Type III derivative line BL-5R Low High 
Primary AIDS-related 
DLBCLs DLBCL-1 High High 
 DLBCL-2 High High 
 DLBCL-3 High High 
PELs BC-1 High Low 
 JSC-1 High Low 
 
PELmo1 
(primary) High Low 
    
EBV-    
BL line BJAB None None 
Primary AIDS-related 
DLBCL DLBCL-4 None None 
PELs BCBL-1 None None 
 BC-3 None None 
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Table AI.S1. Primer and probe sequences 
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